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Abstract 
Tripartite motif protein 22 (TRIM22) is an evolutionarily ancient interferon-induced 
protein that been shown to potently inhibit human immunodeficiency virus (HIV), 
hepatitis B virus (HBV), and influenza A virus (IAV) replication. Altered TRIM22 
expression levels have also been linked to autoimmune disease, cancer, and cellular 
proliferation. Despite its important role in a number of biological processes, the factors 
that influence TRIM22 expression and/or antiviral activity remain largely unknown. To 
identify key functional sites in TRIM22, we performed extensive evolutionary and in 
silico analyses on the TRIM22 coding region. These tools allowed us to pinpoint multiple 
sites in TRIM22 that have evolved under positive selection during mammalian evolution, 
including one site that coincides with the location of a common non-synonymous SNP 
(nsSNP) in the human TRIM22 gene (TRIM22 rs1063303:G>C). We found that the 
frequency of TRIM22 rs1063303:G>C varied considerably among different ethnic 
populations and African (AFR), American (AMR), and European (EUR) populations 
contained an excess of intermediate frequency TRIM22 rs1063303:G>C alleles when 
compared to a neutral model of evolution. The latter is typically indicative of balancing 
selection, a non-neutral selective process that maintains polymorphism in a population. 
Interestingly, we also found that the TRIM22 nsSNP rs1063303:G>C had an inverse 
impact on TRIM22 function. TRIM22 rs1063303:G>C increased TRIM22 expression 
levels, but decreased its anti-HIV activity and altered its subcellular localization pattern. 
In addition to these studies, we used a variety of in silico methods to prioritize and 
delineate other functional sites in TRIM22. We showed that the majority of positively 
selected sites in the C-terminal B30.2 domain of TRIM22 are located in one of four 
surface-exposed variable loops that are critical for the anti-HIV effects of the closely-
related TRIM5α protein. Moreover, we used six different in silico nsSNP prediction 
programs to screen all of the nsSNPs in the TRIM22 gene and identified 14 high-risk 
nsSNPs that are predicted to be highly deleterious to TRIM22 function. Finally, to 
examine the TRIM22 nsSNP rs1063303:G>C in a more isolated population, we 
genotyped this nsSNP in two Inuit populations (Canadian and Greenlandic Inuit). We 
found that the TRIM22 rs1063303:C allele is inordinately prevalent in the Inuit compared 
to non-Inuit populations and that these two populations do not contain an excess of 
  iii 
intermediate frequency TRIM22 rs1063303:G>C alleles compared to a neutral model of 
evolution, indicating that site TRIM22 rs1063303:G>C has not evolved under balancing 
selection in the Inuit. Lastly, we found an interesting association between the TRIM22 
rs1063303:C allele and serum levels of triglycerides (TG) and high-density lipoprotein 
(HDL). Taken together, the results presented here identify a number of pertinent sites in 
the TRIM22 protein that likely influence its biological and/or antiviral functions.  
 
 
Keywords 
Tripartite motif protein 22, host restriction factors, evolution, interferon, innate immune 
system, single nucleotide polymorphism, in silico analysis 
 
  iv 
Co-Authorship Statement 
Chapter 2 of this thesis was published in Human Mutation 35: 1072-1081, June 2014 
doi: 10.1002/humu.22595. I was involved in performing all of the experiments with the 
exception of those described in Fig 2.4d, which were primarily performed by M. W. 
Woods.  
Chapter 3 of this thesis was published in PLoS One 9 (7): e101436, July 2014. I was 
involved in performing all of the experiments.  
 
 
 
 
  v
Acknowledgements  
I am fortunate to have many remarkable and inspiring people in my life who have made 
the completion of this dissertation possible. I would like to thank my supervisor, Dr. 
Stephen Barr, for his guidance and support throughout my PhD studies. His positive 
attitude and encouragement helped me overcome many of the challenging situations I 
encountered during my research. I am also thankful to him for giving me the freedom to 
explore my own ideas and forge my own path as a researcher. I would like to thank my 
advisory committee members, Dr. Greg Dekaban and Dr. Joe Mymryk, for their many 
insightful comments and suggestions. Their guidance, support, and ‘open-door policy’ 
have been invaluable through both successes and difficulties. I would also like to thank 
Dr. Robert Hegele for allowing me to work in his lab and for sharing his genotyping 
expertise with me. His knowledge, guidance, and commitment to the highest research 
standards inspired and motivated me.  
I am deeply indebted to my amazing family and friends for their constant support and 
encouragement throughout my studies. I am forever grateful to my incredible parents – 
Neta & Scott Leonard and Jim & Judy Kelly – and to my siblings – Mike, Kate, Erica, 
and Tyler – for their constant love and support over the years. Without their wisdom, 
strength, and encouragement, none of this would have been possible. I am so lucky to 
have you all in my life. Thank you for always believing in me! I am also immensely 
grateful to my boyfriend, Jamie, for his love, encouragement, and patience during my 
studies. Thank you for always making me smile through the best and worst of times. I 
would also like to thank my friends and colleagues for making graduate school a truly 
unforgettable and enjoyable experience. I owe a particularly enormous ‘thank you’ to 
Stacey, Matt, and Teresa, for always being there to discuss science, life, and just about 
everything else in between. You have all been wonderful friends and I could not have 
done this without you! Sincere thanks as well to my extended family – grandparents, 
aunts, uncles, and cousins. You have all been instrumental contributors to my success.  
 
  vi 
Table of Contents 
Abstract ............................................................................................................................... ii 
Acknowledgements ............................................................................................................. v 
Table of Contents ............................................................................................................... vi 
List of Tables ..................................................................................................................... xi 
List of Figures .................................................................................................................. xiii 
List of Abbreviations........................................................................................................xiv 
1 Introduction .................................................................................................................... 1 
1.1 Host restriction factors ............................................................................................ 5 
1.1.1 Inhibition of HIV replication by host restriction factors ............................ 6 
1.1.2 Innate immune regulation by host restriction factors ............................... 11 
1.2 The TRIM family .................................................................................................. 11 
1.2.1 Evolution and classification ...................................................................... 11 
1.2.3 The SPRY and PRY/SPRY (B30.2) domains ........................................... 22 
1.1.3 Antiviral activity ....................................................................................... 23 
1.2 The TRIM22 protein ............................................................................................. 24 
1.2.1 Origins and evolution ................................................................................ 25 
1.3 Rationale and Experimental Approach ................................................................. 37 
1.4 References ............................................................................................................. 39 
Chapter 2 ........................................................................................................................... 57 
2 Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification 
of a single nucleotide polymorphism that impacts TRIM22 function  ........................ 57 
2.1 Introduction ........................................................................................................... 58 
2.2 Materials and methods .......................................................................................... 59 
  vii
2.2.1 Sequence analysis ..................................................................................... 59 
2.2.2 Cells, plasmids, and transfections ............................................................. 60 
2.2.3 RNA isolation and real-time PCR............................................................. 61 
2.2.4 Western Blotting ....................................................................................... 62 
2.2.5 Confocal immunofluorescence microscopy .............................................. 62 
2.2.6 Neutrality tests .......................................................................................... 63 
2.2.7 Statistical analysis ..................................................................................... 63 
2.3 Results 63 
2.3.1 Positive selection in multiple TRIM22 domains among mammals .......... 63 
2.3.2 Genetic Variation in the Human TRIM22 Gene ....................................... 73 
2.4 Discussion ............................................................................................................. 81 
2.5 References ............................................................................................................. 87 
Chapter 3 ........................................................................................................................... 95 
3 In silico analysis of functional single nucleotide polymorphisms in the human 
TRIM22 gene  ............................................................................................................... 95 
3.1 Introduction ........................................................................................................... 96 
3.2 Materials and methods .......................................................................................... 97 
3.2.1 Retrieval of nsSNP data ............................................................................ 97 
3.2.2 In silico nsSNP analysis ............................................................................ 98 
3.2.3 Phylogenetic analysis ................................................................................ 98 
3.2.4 Comparative molecular modeling ............................................................. 98 
3.2.5 Prediction of post-translational modification sites ................................... 99 
3.2.6 Protein stability analysis ........................................................................... 99 
3.3 Results and Discussion ....................................................................................... 100 
3.3.1 SNP dataset ............................................................................................. 100 
3.3.2 In silico nsSNP analysis .......................................................................... 100 
  viii 
3.3.3 Conservation Profile of High-Risk nsSNPs ............................................ 105 
3.3.4 Comparative Modeling of High-Risk nsSNPs ........................................ 110 
3.3.5 Prediction of Post-Translational Modification Sites in TRIM22 ............ 113 
3.4 Conclusions ......................................................................................................... 121 
3.5 References ........................................................................................................... 125 
Chapter 4 ......................................................................................................................... 134 
4.1 Introduction ......................................................................................................... 135 
4.2 Materials and methods ........................................................................................ 137 
4.2.1 Study subjects ......................................................................................... 137 
4.2.2 Clinical characteristics and biochemical analyses .................................. 138 
4.2.3 Genotype analyses .................................................................................. 138 
4.2.4 Neutrality tests ........................................................................................ 138 
4.2.5 Statistical analyses .................................................................................. 138 
4.3 Results 139 
4.3.1 Baseline phenotypic characteristics of study subjects ............................ 139 
4.3.2 TRIM22 rs1063303:G>C genotype and allele frequencies ..................... 139 
4.3.3 TRIM22 rs1063303:G>C is not evolving under balancing selection in 
the Canadian or Greenlandic Inuit .......................................................... 142 
4.3.4 Association between TRIM22 rs1063303:G>C and plasma lipoproteins 
in the Canadian Inuit ............................................................................... 142 
4.5 References ........................................................................................................... 150 
Chapter 5 ......................................................................................................................... 157 
5 Discussion .................................................................................................................. 157 
5.1 Summary of results ............................................................................................. 157 
5.1.1 Ancient and recent adaptive evolution in the antiviral TRIM22 gene: 
identification of a single nucleotide polymorphism that impacts 
TRIM22 function .................................................................................... 157 
  ix 
5.1.2 In silico analysis of functional single nucleotide polymorphisms in the 
human TRIM22 gene ............................................................................... 158 
5.1.3 The TRIM22 nsSNP rs1063303:G>C is not evolving under balancing 
selection in the Inuit and is associated with low serum TG and high 
serum HDL levels in the Canadian Inuit................................................. 159 
5.2 Multiple sites in TRIM22 have evolved under positive and/or balancing 
selection .............................................................................................................. 160 
5.2.1 Positive selection .................................................................................... 160 
5.2.2 Balancing selection ................................................................................. 163 
5.3 TRIM22 contains 14 high-risk deleterious nsSNPs and numerous putative 
PTM sites ............................................................................................................ 165 
5.3.1 High-risk deleterious nsSNPs ................................................................. 165 
5.3.2 Putative PTM sites .................................................................................. 167 
5.4 The TRIM22 nsSNP rs1063303:G>C influences diverse TRIM22-mediated 
biological functions ............................................................................................. 170 
5.4.1 The TRIM22 nsSNP rs1063303:G>C increases TRIM22 expression 
levels 170 
5.3.2 The TRIM22 nsSNP rs1063303:G>C decreases TRIM22-mediated 
antiviral activity against HIV-1 .............................................................. 171 
5.3.3 The TRIM22 nsSNP rs1063303:G>C is associated with low serum TG 
and high serum HDL levels in the Canadian Inuit .................................. 173 
5.5 Concluding remarks ............................................................................................ 173 
5.5 References ........................................................................................................... 175 
Appendix A ..................................................................................................................... 182 
A.1 Overview of serum lipoproteins.......................................................................... 182 
A.1.1  Introduction to serum lipoproteins ......................................................... 182 
A.2 Serum lipoproteins during the APR .................................................................... 189 
A.2.1 Overview of the APR .............................................................................. 189 
A.3 References ........................................................................................................... 190 
  x
Curriculum Vitae ............................................................................................................ 191 
  xi 
List of Tables 
Table 1.1: Characteristics of well-studied host restriction factors. ................................... 12 
Table 1.2: Factors that alter TRIM22 protein expression levels. ...................................... 30 
Table 2.1: Mammalian TRIM22 coding sequences used for Selecton analysis. .............. 64 
Table 2.2: Models of evolution applied to TRIM22 coding sequences. ........................... 69 
Table 2.3: Positive selection in TRIM22 protein domains. .............................................. 72 
Table 2.4: Results of Tajima’s D and Fu’s FS neutrality tests. ......................................... 78 
Table 3.1 In silico prediction results for nsSNPs in TRIM22......................................... 101 
Table 3.2 Summary of in silico prediction results for all nsSNPs in TRIM22. .............. 104 
Table 3.3: TRIM22 nsSNPs predicted to be functionally significant by four or more SNP 
prediction algorithms. ..................................................................................................... 106 
Table 3.4 Conservation profile of amino acids in TRIM22 that coincide with the location 
of high-risk nsSNPs. ....................................................................................................... 109 
Table 3.5: RMSD (Å) and TM-score for the 9 high-risk nsSNPs in the B30.2 domain of 
TRIM22........................................................................................................................... 114 
Table 3.6 Putative ubiquitylation and sumoylation sites in the TRIM22 protein. .......... 116 
Table 3.7 Putative phosphorylation sites in the TRIM22 protein. .................................. 119 
Table 3.8: I-Mutant results for selected nsSNPs in the TRIM22 protein. ...................... 122 
Table 4.1 Baseline phenotypic characteristics (mean ± SD) of Canadian Inuit, Greenland 
Inuit, and European Caucasian populations. ................................................................... 140 
Table 4.2 Genotype frequencies for TRIM22 rs1063303:G>C in the Canadian Inuit, 
Greenlandic Inuit, and European Caucasian populations. .............................................. 141 
  xii
Table 4.3: Results of Tajima’s D and Fu’s Fs neutrality tests. ....................................... 143 
Table 4.4: Summary of ANOVA results showing determinants of serum lipoproteins in 
the Canadian Inuit, Greenlandic Inuit, and European Caucasian populations. ............... 145 
Table 4.5: Significant associations between the TRIM22 rs1063303:G>C genotype and 
plasma lipoproteins in the Canadian Inuit. ..................................................................... 146 
Table A.1: Physical properties and lipid composition of serum lipoproteins ................. 183 
 
  xiii 
List of Figures 
Figure 1.1: ISG induction by type I IFN signaling. ............................................................ 4 
Figure 1.2: Stages of HIV replication targeted by host restriction factors. ........................ 8 
Figure 1.3: Subgroup classification of the TRIM family. ................................................. 16 
Figure 1.4: The RING E3 ligase-mediated ubiquitylation pathway. ................................ 20 
Figure 1.5: TRIM22 evolution, genomic organization, and protein structure. ................. 27 
Figure 2.1: Mapping positively selected sites in the TRIM22 protein. ............................ 68 
Figure 2.2: Selecton analysis of mammalian TRIM22 coding sequences. ....................... 71 
Figure 2.3: Genetic variation at amino acid site 242 in the TRIM22 protein. .................. 76 
Figure 2.4: nsSNP rs1063303:G>C alters TRIM22 expression and antiviral activity. .... 80 
Figure 3.1: ConSurf analysis of amino acid residues in the TRIM22 protein. ............... 108 
Figure 3.2: Structural models for wild type TRIM22 and high-risk nsSNPs in the B30.2 
domain............................................................................................................................. 112 
Figure 3.3: Putative sumo-interacting motifs (SIM) in TRIM22. ................................... 118 
Figure 3.4 Putative functional sites in the TRIM22 protein. .......................................... 124 
Figure A.1 General structure of serum lipoprotein. ........................................................ 185 
Figure A.2 Serum lipoprotein synthesis and transport. ................................................... 188 
 
 
 
  xiv
List of Abbreviations 
AIC   Akaike Information Content  
AP-1   Activator protein 1  
APOBEC3G  Apolipoprotein B mRNA-editing enzyme catalytic polypeptide 3G  
APR   Acute phase response 
ARF   ADP ribosylation factor-like domain 
BB   B-box domain 
BR   Bromodomain 
BST-2   Bone marrow stromal antigen 2  
CB   Cajal bodies 
CC   Coiled-coil domain 
CD4   Cluster of differentiation 4 
COS   C-terminal subgroup one signature domain 
CP   Core promoter  
Cys   Cysteine residue 
E1   Ubiquitin activating enzyme  
E2   Ubiquitin conjugating enzyme 
E3   Ubiquitin ligating enzyme 
eISRE   5’ extended IFN-stimulated response element 
EMCV   Encephalomyocarditis virus 
  xv 
FIL   Filamin-type immunoglobulin domain 
FN3   Fibronectin type 3 domain 
Fv1   Friend virus susceptibility 1 locus 
G1   Group 1 TRIM  
G2   Group 2 TRIM 
GAS   Gamma interferon activation site 
HBV   Hepatitis B virus 
HCV   Hepatitis C virus 
HDL   High density lipoprotein 
HECT   Homologous to the E6-AP carboxyl terminus 
HIV   Human immunodeficiency virus 
HIV-1   Human immunodeficiency virus type 1  
HIV-2   Human immunodeficiency virus type 2 
HOM   Hominoids 
huTRIM5α  Human TRIM5α 
IFN   Interferon 
IFNAR  Interferon alpha/beta receptor 
IL-1   Interleukin 1 
IRF-1   Interferon regulatory factor 1 
IRF-3   Interferon regulatory factor 3  
  xvi
IRF-7   Interferon regulatory factor 7 
IRF-8   Interferon regulatory factor 8 
ISG   Interferon stimulated gene 
ISG15    Interferon stimulated gene 15 
ISGF3   Interferon stimulated gene factor 3 
ISRE   Interferon stimulated response element 
JAK/STAT  Janus kinases/signal transducers and activators of transcription 
LDL   Low density lipoprotein 
LPS   Lipopolysaccharide 
LTA   Lipoteichoic acid  
LTR   Long-terminal repeat  
Lys   Lysine residue 
MATH Merpin and tumor-necrosis factor receptor-associated factor 
homology domain 
MDM   Monocyte derived macrophages 
NHL   NHL repeats 
N-MLV  N-tropic murine leukemia virus 
NB   Nuclear bodies 
NF-κB   Nuclear factor-kappa B 
NLR   Nucleotide binding oligomerization domain (NOD)-like receptor 
  xvii
NLS   Nuclear localization signal 
NP   Nucleoprotein 
nsSNP   Non-synonymous single nucleotide polymorphism (SNP) 
NWM   New world monkey 
OWM   Old world monkey 
PAMP   Pathogen-associated molecular pattern 
PHD   Plant homeodomain  
PIC    Preintegration complex 
PML   Promyelocytic leukemia protein (also called TRIM19) 
PRR   Pattern recognition receptor 
PTM   Post-translational modification 
qPCR   Quantitative polymerase chain reaction 
RBCC   RING, BB1 and/or BB2, and CC domains 
rhTRIM5α  Rhesus macaque TRIM5α 
RING   Really interesting new gene domain 
RLR   Retinoic acid inducible gene (RIG-I)-like receptor 
SAMHD1 Sterile alpha motif and histidine/aspartic acid domain-containing 
protein  
SIFT   Sorting intolerant from tolerant 
SIM   SUMO interacting motif 
  xviii
SIV   Simian immunodeficiency virus 
SLE   Systemic lupus erythematosus 
SNP   Single nucleotide polymorphism 
SPRY   SplA/ryanodine receptor domain 
SUMO   Small ubiquitin-like modifier 
TAK1   Transforming growth factor beta-activated kinase 1 
TG   Triglyceride 
TLR   Toll-like receptor 
TM   Transmembrane domain 
TNFα   Tumor necrosis factor alpha 
TRIM   Tripartite motif protein 
TRIM22  Tripartite motif protein 22 
TRIM5α  Tripartite motif protein 5 alpha  
UBE2D  Ubiquitin conjugating enzyme 2/E2 class D 
UBE2E  Ubiquitin conjugating enzyme 2/E2 class E 
v1-v4   Variable loops 1-4 
VLDL   Very low density lipoprotein 
VSV   Vesicular stomatitis virus 
 
  
1
Chapter 1 
 
1 Introduction 
The immune system has evolved over millennia to provide effective defense measures 
against invading pathogens and promote host survival. The vertebrate immune system 
can be divided into innate and adaptive arms, which together comprise both germline-
encoded and acquired immune responses. The innate immune system is evolutionarily 
more ancient than the adaptive immune system and constitutes the first line of defense 
against infectious agents. It is also essential for initiating subsequent adaptive immune 
responses, which unlike innate immune responses, are characterized by specificity and 
the generation of immunological memory 1. Innate immunity is activated upon pathogen 
recognition by a limited repertoire of germline-encoded pattern recognition receptors 
(PRR). PRRs can be grouped into several distinct families: 1) the membrane bound toll-
like receptors (TLR), 2) the cytosolic retinoic acid inducible gene (RIG-I)-like receptors 
(RLR), 3) the nucleotide binding oligomerization domain (NOD)-like receptors (NLR), 
and 4) DNA sensors 2,3. PRRs recognize conserved products of microbial metabolism 
called pathogen-associated molecular patterns (PAMP). PAMPs, which are not usually 
present in host cells, bind to specific PRRs to activate innate immunity. For example, 
specific TLR family members recognize genomic material or replication intermediates 
from viruses (i.e. TLRs 3, 7, 8, and 9), while other TLRs recognize diverse microbial 
products from parasites, fungi, and/or bacteria 4–8.  
PRR-PAMP binding triggers a complex downstream signaling cascade that induces the 
activation of multiple cytosolic transcription factors, including nuclear factor-kappa B 
(NF-κB), activator protein 1 (AP-1), and interferon regulatory factors 3 (IRF-3) and 7 
(IRF-7). Activation of NF-κB and AP-1 results in the upregulation of proinflammatory 
cytokines [e.g. interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF-α)], whereas 
activation of IRF-3 and/or IRF-7 leads to the production of type I interferons (IFN) 9. 
Type I IFNs are one of the three major classes of the IFN family, which is a group of 
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secreted cytokines that are essential for host antiviral defense and immune activation. 
Type I IFNs are produced in direct response to viral infection and comprise multiple 
subtypes of IFN-α plus IFN-β and several additional IFNs (δ, ε, κ, τ, ω) with less-
definitive roles in antiviral immunity. The other two major classes of IFNs, type II and 
type III, each contain only one subtype. IFN-γ (type II IFN) is generally produced by 
activated T lymphocytes or natural killer cells in response to cytokine secretion from 
infected cells or macrophages. Similar to type I IFNs, IFN-λ (type III IFN) is typically 
produced in direct response to viruses; however type III IFN binds to different cognate 
receptors than type I IFNs. Type III IFN receptors are found mainly on epithelial cells, 
whereas type I IFN receptors are present on all cell types 10–13. 
Canonical type I IFN production is essential for the host antiviral response to infection 
and critical for host survival. Following synthesis and secretion, type I IFNs (IFN-α/β) 
bind to the IFN-α/β receptor (IFNAR) complex on the cell surface in an autocrine and 
paracrine manner, which induces signal transduction through the janus kinases/signal 
transducers and activators of transcription (JAK/STAT) pathway. Specifically, IFN-α/β 
binding to the IFNAR complex leads to the phosphorylation of receptor-bound tyrosine 
kinases janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), which in turn leads to the 
phosphorylation of signal transducers and activators of transcription 1 (STAT1) and 2 
(STAT2). STAT1/STAT2 phosphorylation results in STAT1/STAT2 dimerization and 
recruitment of interferon regulatory factor 9 (IRF-9) to form the IFN-stimulated gene 
factor 3 (ISGF3) complex. The ISGF3 complex, which acts as a transcription factor, 
translocates to the nucleus where it upregulates a large number of IFN-stimulated genes 
(ISG) (Fig 1.1). Many ISGs have antiviral properties, especially host restriction factors, 
which directly interfere with specific stages of viral replication. Collectively, ISGs 
establish a powerful cell-intrinsic antiviral state that is essential for withstanding and 
controlling many pathogens 14,15.    
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Figure 1.1: ISG induction by type I IFN signaling.  
Type I IFNs bind to the IFNAR1/2 heterodimer complex on the surface of the cell and 
activate the JAK/STAT signaling pathway. IFN-IFNAR1/2 binding triggers JAK1 and 
TYK2 phosphorylation, which leads to the recruitment and phosphorylation of STAT1 
and STAT2. Phosphorylated STAT1 and STAT2 form a heterodimer and bind to IRF-9, 
creating the ISGF3 complex. ISGF3 translocates to the nucleus where it binds to IFN-
stimulated response elements (ISRE) in the promoters of multiple ISGs. This induces a 
powerful antiviral state in the cell that inhibits many pathogens.  
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Figure 1.1 
 
 
 
Figure 1.1: ISG induction by type I IFN signaling. 
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1.1 Host restriction factors 
Host restriction factors are IFN-induced proteins that inhibit specific steps in the viral 
replication lifecycle. Researchers first coined the term ‘restriction factor’ in the 1970’s 
following the characterization of the mouse friend virus susceptibility 1 (Fv1) locus, 
which conferred resistance to murine retroviruses 16. Since this discovery, restriction 
factors have been identified in many vertebrate species, and today the term is used to 
describe host proteins that inhibit the replication of any animal virus 17,18. Several major 
characteristics distinguish restriction factors from other host proteins. Typically, host 
restriction factors: 1) have antiviral activity as their main biological function, 2) are 
induced by IFN signaling and/or viral infection, 3) contain evolutionary signatures of 
positive selection, and 4) are antagonized by a viral protein 18,19. Characteristics for a 
number of well-known host restriction factors, including the apolipoprotein B mRNA-
editing enzyme catalytic polypeptide 3G (APOBEC3G), tripartite motif protein 5 alpha 
(TRIM5α), bone marrow stromal antigen 2 (BST-2 or tetherin), and sterile alpha motif 
and histidine/aspartic acid domain-containing protein (SAMHD1), are summarized in 
Table 1.1. at the end of this section. 
Type I IFNs have long been recognized as potent inhibitors of human immunodeficiency 
virus (HIV) replication 20. As such, HIV has been used for many years as a system to 
identify and characterize the IFN-induced host restriction factors responsible for this 
inhibition. Type I IFNs block both early and late stages of the HIV lifecycle 21–25. Early 
stages of HIV replication include HIV binding and fusion to the host cell via its CD4 
receptor, uncoating of the viral core in the cell cytoplasm, reverse transcription of the 
single-stranded RNA viral genome, and integration of the viral cDNA into the host cell 
genome. Late stages include transcription of the integrated HIV provirus from the 5’ 
long-terminal repeat (LTR) promoter, viral RNA export, translation of viral proteins, 
trafficking/assembly of new virions, virion budding/release, and maturation of virions 
into fully infectious HIV particles (Fig 1.2). Host restriction factors, which form the 
effector arm of the IFN response, target specific stages (both early and late) in the HIV 
replication life cycle. However, HIV also encodes viral antagonists to counteract host 
restriction factors. These antagonists are typically HIV accessory proteins, namely Vif, 
  
6
Nef, Vpu, and Vpr, which are only required for viral replication in the presence of host 
restriction factors 26. Whereas HIV type 1 (HIV-1) encodes only the latter accessory 
proteins, a number of strains of simian immunodeficiency virus (SIV) and HIV type 2 
(HIV-2) also encode an additional accessory protein called Vpx 27. Stages of HIV-1 
replication (and/or SIV or HIV-2 replication) targeted by the APOBEC3G, TRIM5α, 
BST-2/tetherin, and SAMHD1 host restriction factors plus their viral antagonists (if 
known) are shown in Fig 1.2 and outlined in further detail in the text below.  
 
1.1.1 Inhibition of HIV replication by host restriction factors 
Multiple host restriction factors that inhibit HIV replication have been identified within 
the last decade, some of which have been studied extensively. One such protein is the 
host restriction factor APOBEC3G, which was first identified as a HIV-1 restriction 
factor in 2002 28. APOBEC3G is targeted by the HIV-1 Vif accessory protein; however 
when Vif is not present, APOBEC3G is packaged into assembling HIV-1 virions and 
released into the cytoplasm of newly infected target cells. APOBEC3G is a cytidine 
deaminase enzyme or an enzyme that converts deoxycytidine into deoxyuridine in a 
nucleic acid sequence. When APOBEC3G is present in newly infected target cells, it 
converts deoxycytidine to deoxyuridine in the nascent viral single-stranded negative-
sense cDNA. This results in deoxyguanine to deoxyadenine hypermutation and loss of 
genetic integrity in the HIV-1 plus-strand sequence and inhibits HIV-1 replication at the 
level of reverse transcription (Fig 1.2) 29–32. When Vif is present in cells, APOBEC3G 
becomes polyubiquitylated and is targeted for proteasomal degradation. Vif facilitates 
this process by binding directly to both APOBEC3G and the Cul5 E3 ligase ubiquitin 
complex. Interestingly, Vif antagonism is not always fully efficient and hypermutated 
HIV-1 sequences are readily recovered from HIV-1 infected individuals. Moreover, 
hypermutation frequency has been shown to correlate inversely with plasma viremia in 
several sizable HIV-1 cohorts 33–37.  
Another well-studied HIV-1 restriction factor is the TRIM5α protein. Unlike other host 
restriction factors, TRIM5α typically only restricts retroviruses that have been isolated  
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Figure 1.2: Stages of HIV replication targeted by host restriction factors. 
Host restriction factors, such as APOBEC3G, TRIM5α, BST-2/tetherin, and SAMHD1, 
target multiple stages of HIV-1 (or SIV/HIV-2) replication. Post-entry, TRIM5α targets 
the assembled HIV-1 capsid protein on the viral core and facilitates its disassembly. In 
the absence of Vif, the APOBEC3G protein creates deoxycytidine to deoxyuridine 
mutations in the nascent viral cDNA, which inhibits HIV-1 replication at the level of 
reverse transcription. SAMHD1, which is countered by Vpx (SIV/HIV-2), also inhibits 
reverse transcription; however, it does so by decreasing the cellular pool of dNTPs 
required for viral cDNA synthesis. BST-2/tetherin inhibits HIV-1 replication at the 
budding/release stage by ‘tethering’ HIV-1 virions to the cell membrane. BST-2/tetherin 
is antagonized by the HIV-1 Vpu protein.  
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from a host species other than its own. For example, the human TRIM5α (huTRIM5α) 
protein strongly inhibits N-tropic murine leukemia virus (N-MLV), but has very weak 
activity against HIV-1. Similarly, rhesus monkey TRIM5α (rhTRIM5α) does not inhibit 
SIVmac (SIV strain isolated from rhesus macaques that were experimentally inoculated 
with SIV from asymptomatic sooty mangabey monkeys [SIVsmm]38). The majority of 
studies have shown that rhTRIM5α inhibits HIV-1 by targeting the assembled HIV-1 
capsid protein found on the mature viral core. Capsid is the main structural protein of 
HIV-1 and forms the inner viral protein shell that surrounds the HIV-1 genome and its 
core proteins in mature virions 39. To inhibit HIV-1 replication, rhTRIM5α binds to the 
incoming mature viral core and facilitates its premature disassembly. This leads to the 
inhibition of reverse transcription and subsequent HIV-1 replication (Fig 1.2) 40–42. Of 
interest, rhTRIM5α, which localizes in subcellular structures called cytoplasmic bodies, 
has been shown to mediate its own polyubiquitylation and proteasomal degradation 
during the HIV-1 restriction process. Self-ubiquitylation of rhTRIM5α may destabilize 
the HIV-1 capsid lattice and induce its disassembly. Notably, other studies have shown 
that proteasome inhibitors do prevent inhibition of reverse transcription by rhTRIM5α, 
but do not disrupt overall rhTRIM5α-mediated HIV-1 restriction 43–46. Thus, it has also 
been proposed that rhTRIM5α may inhibit HIV-1 replication in two or more redundant 
ways, such as by blocking the nuclear translocation of the viral preintegration complex 
(PIC). The viral PIC includes the viral cDNA plus both viral and host proteins and its 
nuclear translocation is required for proper integration of HIV-1 into the host genome 47. 
To date, there have been no HIV-1 antagonists to rhTRIM5α identified.  
Tetherin or BST-2 was only recently identified as a HIV-1 restriction factor, but since 
this time has been studied in great detail. BST-2/tetherin is antagonized by the HIV-1 
Vpu protein and targets a later stage of viral replication than APOBEC3G or TRIM5α. 
When Vpu is absent, BST-2/tetherin ‘tethers’ fully formed HIV-1 virions to the plasma 
membrane of infected cells (Fig 1.2). Captured HIV-1 virions are later internalized by 
endocytosis and accumulate in CD63+ endosomes, where they are likely degraded 48–53. 
BST-2/tetherin contains two membrane anchors, the N-terminal transmembrane domain 
and the C-terminal glycosylphosphatidylinositol domain, which are both essential for 
BST-2/tetherin-mediated virion retention and endocytosis 54–56. Although several models 
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for BST-2/tetherin configuration have been proposed, experimental evidence strongly 
supports a parallel-membrane-spanning model. This models postulates that one end of 
two BST-2/tetherin monomers (either the N-terminus or C-terminus) is anchored to the 
cell membrane and the other end of both monomers is anchored to the viral membrane. 
BST-2/tetherin is downregulated from the cell surface when Vpu is present and likely 
degraded via the proteasomal and/or lysosomal pathway. However, some studies have 
shown that Vpu may simply sequester BST-2/tetherin in the cytoplasm. These methods 
are unlikely to be mutually exclusive and may work together to counteract the BST-
2/tetherin protein. The mechanism of Vpu antagonism may also depend on the cellular 
context of HIV-1 restriction 19,57.  
SAMHD1, the most recently identified host restriction factor, restricts SIV/HIV-2 viral 
replication in non-dividing cell types, including CD4+ T cells, dendritic cells, and 
macrophages. Vpx, an accessory protein encoded by HIV-2 and certain strains of SIV, 
targets SAMHD1 and induces its proteasomal degradation. In the absence of Vpx, 
SAMHD1 inhibits SIV/HIV-2 replication by decreasing the intracellular pool of dNTPs 
to below the level required for viral cDNA synthesis. This results in early post-entry 
restriction at the level of reverse transcription (Fig 1.2) 58–61. While HIV-1 is unable to 
neutralize SAMHD1, one recent study demonstrated that a subset of Vpr proteins from 
ancestral lentiviruses without Vpx are able to disrupt SAMHD1-mediated restriction. 
Since Vpr is hypothesized to have originally given rise to Vpx via a gene duplication 
event, the ability of Vpx to antagonize SAMHD1 may have originated in Vpr before it 
was lost following Vpx acquisition. Interestingly, distinct orthologues of Vpx and Vpr 
have evolved multiple ways to recognize SAMHD1. For example, certain orthologues 
interact with the N-terminus of SAMHD1, while others interact with the C-terminus; 
however, they all target SAMHD1 for proteasomal degradation. Thus, even though the 
method of Vpx/Vpr antagonism toward SAMHD1 has remained the same, the site of 
antagonism has changed back and forth throughout viral evolution 62,63.  
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1.1.2 Innate immune regulation by host restriction factors 
In addition to their direct antiviral effects, a growing number of host restriction factors 
indirectly influence the antiviral response by regulating important innate immune 
signaling pathways. For example, TRIM5α was recently shown to function as a PRR for 
the HIV-1 capsid lattice. Upon capsid recognition, TRIM5α activates the transforming 
growth factor beta-activated kinase 1 (TAK1), AP-1 and NF-κB signaling, and the 
transcription of proinflammatory cytokines 64. This signaling is required for TRIM5α-
mediated retroviral restriction. Thus, in addition to its direct antiviral effects, TRIM5α 
also inhibits HIV-1 replication by activating innate immune signaling pathways. BST-
2/tetherin and SAMHD1 have also recently been implicated in the activation of innate 
immune and proinflammatory signaling pathways  65,66. 
 
1.2 The TRIM family 
The tripartite motif or TRIM family is a large group of evolutionarily ancient proteins 
that are involved in multiple biological processes and have been linked to a number of 
different human diseases. Many TRIM proteins are upregulated by type I and type II 
IFNs and some, such as the host restriction factor TRIM5α, have antiviral properties. 
TRIM proteins are particularly adept at targeting retroviruses and to date, ~20 TRIM 
proteins have been shown to inhibit retrovirus replication 67–70. Recent studies have also 
identified several TRIM proteins that regulate key proteins involved in innate immune 
signaling, including IRF-3, IRF-8, RIG-I, and NF-κB 71,72. In addition to their role in 
antiviral immunity, TRIM proteins have also been implicated in numerous Mendelian 
inherited disorders and autoimmune diseases, cell cycle progression, development, and 
several types of cancer 73–76.  
 
1.2.1 Evolution and classification 
TRIM proteins are conserved throughout the metazoan kingdom; however, the TRIM 
family has expanded rapidly during vertebrate evolution. For example, the invertebrate 
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Table 1.1 
Table 1.1: Characteristics of well-studied host restriction factors. 
 
Restriction factor IFN 
induced? 
Viral target Stage of life cycle inhibited Viral antagonists 1 Positive 
selection? 
Fv1 (mouse)  No Retroviruses Capsid uncoating 77 None known Yes 78 
MxA  Yes Orthomyxoviruses 
Paramyxoviruses 
Hepadnaviruses 
Rhabdoviruses 
Alphaviruses 
Bunyaviruses 
Togaviruses 
Picornaviruses 
Nucleocapsid transport or another early life cycle 
step 79 
None known Yes 80 
MxB  Yes Retroviruses Nuclear import or integration 81 None known ND 
IFITM1, IFITM2, 
IFITM3 
Yes Orthomyxoviruses 
Flaviviruses 
Coronavirus 
Rhabdoviruses 
Alphaviruses 
Bunyaviruses 
Filoviruses 
Endosomal fusion or uncoating 82,83 None known ND 
TRIM5α Yes Retroviruses 
Hepadnaviruses 
Capsid uncoating 84 None known Yes 85 
APOBEC3G No Retroviruses 
Hepadnaviruses 
Adenoviruses  
Paramyxoviruses 
Retrotransposons 
Reverse transcription 31,33,35,77,86–90 Vif (HIV-1) 
Bet (PFV) 
glycol-Gag (MLV) 
 
Yes 91 
SAMHD1 Yes Retroviruses 
Herpesviruses 
Reverse transcription 58,60,92,93 Vpx (HIV-2) 
Vpr (SIV) 
Yes 94 
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Poxviruses  
BST-2/Tetherin Yes Retroviruses 
Flaviviruses 
Herpesviruses 
Rhabdoviruses 
Paramyxoviruses 
Arenaviruses 
Filoviruses 
Budding 48,51,53,54,95–98 Vpu (HIV-1) 
Nef (SIV) 
Env (HIV-2) 
VP40 (Ebola) 
K5 (KSHV) 
NA (IAV) 
gM (Herpes) 
Yes 99 
PKR  Yes  Retroviruses 
Orthomyxoviruses 
Filoviruses 
Paramyxoviruses 
Bunyaviruses 
Herpesviruses 
Poxviruses 
Viral protein translation 100–102 NS1 (IAV, IBV) 
NSs (RVFV)  
VP35 (Ebola)  
 
 
Yes 103 
HERC5 Yes  Retroviruses 
Orthomyxoviruses 
Nuclear export, assembly 104–106  None known Yes 106 
1
 Viral antagonists: this is not an exhaustive list, particularly for PKR. Please refer to 107 for a more comprehensive list of PKR antagonists.  
Abbreviations: Myxovirus resistance (Mx) proteins A and B, Interferon induced transmembrane (IFITM) proteins 1, 2, and 3, Prototype foamy virus (PFV), 
Glycosylated (glyco) Gag, Murine leukemia virus (MLV), Kaposi's sarcoma-associated herpesvirus (KSHV), Influenza A/B virus (IAV, IBV), Rift valley fever 
virus (RVFV), HECT domain and RCC1-like domain-containing protein 5 (HERC5). ND: not determined.  
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Drosophila melanogaster and Caenorhabditis elegans genomes contain 7 and 18 TRIM 
genes, respectively. In stark contrast, the vertebrate Mus musculus genome contains 64 
TRIM genes and 100 TRIM genes have now been identified in the human genome. 
Notably, the TRIM family may still be expanding in humans. One study recently 
identified 11 TRIM genes that are specific to humans and African apes and another 7 
TRIM genes that are found only in humans. According to this study, the novel TRIM 
genes were acquired through multiple segmental duplication events, the majority of 
which originated from a single chromosomal locus. One Han Chinese woman with 12 
extra copies of these TRIM genes was also identified, documenting TRIM copy number 
variation in humans for the first time 108. 
Several classification systems have been proposed for organizing the TRIM family of 
proteins in humans. Initially, the TRIM family was divided into 9 distinct subgroups 
according to their C-terminal domains 109. This classification system was subsequently 
modified to include 2 new subgroups of TRIMs with previously mischaracterized C-
terminal domains (C-I to C-XI) 68. Another study divided the TRIM family into two 
major groups based on genomic organization, evolutionary properties, and domain 
structure. This study determined that ‘Group 1’ TRIM proteins contained two B-box 
(BB) domains, a variable C-terminal domain, and were found in both vertebrates and 
invertebrates. In contrast, ‘Group 2’ TRIM proteins had only one BB domain, a C-
terminal splA/ryanodine receptor (SPRY) domain or PRY/SPRY (B30.2) domain, and 
were found only in vertebrates 110. The most recent report, which performed a more 
stringent phylogenetic analysis of the TRIM family, divided TRIM proteins into 9 
distinct subgroups (A-I). ‘Group 2’ TRIM proteins were placed in one subgroup (G); 
however, ‘Group 1’ TRIMs were further subdivided into 8 different phylogenetic 
subgroups (A-F, H, I). Importantly, this study consolidated data from previous reports 
and compared the phylogenetic and domain-based classification systems for the TRIM 
family (Fig 1.3) 111.  
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Figure 1.3: Subgroup classification of the TRIM family.   
Subgroup classifications (A-I) are based on the most recent phylogenetic analysis of the 
TRIM family 111. Previous C-terminal domain-based TRIM classifications (C-I to C-XI) 
are shown in parentheses 68. TRIM proteins contain an N-terminal RING domain (blue 
square), one or two BB domains (dark/light pink circles), and a CC domain (orange 
rectangle). In addition, TRIM proteins contain one or more of 10 different C-terminal 
motifs (MATH, COS, FN3, PRY/SPRY, FIL [filamin], NHL, ARF, PHD, BR, and/or 
TM). Group 2 TRIM proteins (subgroup G) are labeled and encased in a red box. Other 
subgroups (A-E, H, I) are considered Group 1 TRIMs 110. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
16 
Figure 1.3 
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1.2.2 The RBCC motif  
Members of the TRIM family are defined by their N-terminal TRIM or RBCC motif, 
which is comprised of a ‘Really Interesting New Gene’ (RING) domain, one or two BB 
domains, and a predicted coiled-coil (CC) region. The entire RBCC motif is present in 
most TRIM proteins; however, in TRIM proteins that lack one of these domains, the 
other domains are conserved in both order and spacing 68,112. The C-terminal domain of 
TRIM family members is variable and contains any of 10 distinct motifs alone or in 
combination. The majority of TRIM proteins have a C-terminal SPRY or PRY/SPRY 
domain (also called a B30.2 domain). Other possible C-terminal domains include ARF 
(ADP ribosylation factor-like), the COS (C-terminal subgroup one signature) box, PHD 
(plant homeodomain), MATH (merpin and tumor-necrosis factor receptor-associated 
factor homology), FN3 (fibronectin type 3), and/or FIL (filamin-type immunoglobulin) 
(Fig 1.3) 112,113.  
The first domain in the RBCC motif, the RING domain, is characterized by a canonical 
sequence that consists of a number of conserved cysteine and histidine residues. These 
residues form a specialized zinc finger and coordinate two zinc atoms in a cross-braced 
arrangement 114,115. Studies have shown that RING finger proteins interact directly with 
ubiquitylation enzymes and often function as E3 ubiquitin ligases 116–119. Consistent with 
these studies, many RING-containing TRIM proteins have been shown to possess E3 
ubiquitin ligase activity 113,120,121. In many (but not all) cases, this E3 ubiquitin ligase 
activity is required for TRIM-mediated antiviral activity. Previous studies have also 
shown that RING-mediated E3 ligase activity is necessary for activation of antiviral 
signaling by TRIMs 1, TRIM5, TRIM13, TRIM25, TRIM32, and TRIM62 64,122–124. 
Ubiquitylation is a three-step process that involves ubiquitin-activating (E1), ubiquitin-
conjugating (E2), and ubiquitin-ligating (E3) enzymes. Ubiquitylation begins when the 
E1-activating enzyme activates ubiquitin and transfers it to an E2-conjugating enzyme. 
Following transfer, an E3 ligating enzyme facilitates ubiquitin attachment to the target 
substrate protein, which occurs via the formation of an isopeptide bond between the C-
terminal glycine residue of ubiquitin and an internal lysine (Lys) residue of the target 
protein (Fig 1.4). There are two main families of E3 ubiquitin ligases: RING and HECT 
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(homologous to the E6-AP carboxyl terminus). Unlike HECT-containing E3 ligase 
proteins, RING E3 ligases bind directly to both the E2 conjugating enzyme and the target 
protein and this increased proximity facilitates the direct transfer of ubiquitin from the E2 
enzyme to the target protein 23,29. TRIM proteins represent the largest group of RING-
containing E3 ubiquitin ligases and multiple TRIM family members were recently shown 
to interact with the UBE2D and UBE2E (ubiquitin conjugating enzymes 2/E2 class D and 
class E) classes of E2 conjugating enzymes; however, other combinations of TRIM-E2 
proteins have also been identified 64,113,120,121,126.  
Substrate proteins can be modified by a single ubiquitin moiety (monoubiquitylation) or 
can be tagged with a chain of ubiquitin (polyubiquitylation). Ubiquitin chains are linked 
together via the formation of an isopeptide bond between the C-terminal glycine residue 
of one ubiquitin and one of seven internal lysine residues of a second ubiquitin moiety. 
Notably, ubiquitin chains linked through distinct Lys residues have different cellular 
functions. Lys48 ubiquitin chains mark proteins for degradation by the 26S proteasome, 
whereas Lys63, other Lys-based ubiquitin chains, and monoubiquitylation often serve 
non-proteolytic functions. Depending on the substrate proteins and enzymes involved, 
these modifications can serve as signals for diverse cellular processes, including DNA 
repair, transcription, signal transduction, and/or intracellular trafficking 127. Thus far, 
most well-characterized TRIM proteins have been shown to facilitate either Lys48 or 
Lys63 polyubiquitylation. Many TRIM proteins can also undergo self-ubiquitylation, 
including TRIM5α (both huTRIM5α and rhTRIM5α proteins), which induces its own 
proteasomal degradation and rapid turnover. Several groups have proposed that self-
ubiquitylation of rhTRIM5α indirectly leads to the proteasomal degradation of HIV-1 
virions. While the precise mechanism of TRIM5α-mediated restriction is still not fully 
understood, some studies have shown that HIV-1 restriction is dependent on TRIM5α’s 
E3 ubiquitin ligase activity 43,45,46,128–131. 
In addition to their function as E3 ubiquitin ligases, several TRIM proteins have been 
shown to function as E3 ligases for other ubiquitin-like proteins, such as SUMO (small 
ubiquitin-like modifier) and ISG15 (interferon stimulated gene 3) 132–134. Ubiquitin-like 
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Figure 1.4: The RING E3 ligase-mediated ubiquitylation pathway.   
Ubiquitin is activated by the E1 activating enzyme to form a thioester linkage with the 
active-site cysteine of E1. Activated E1-bound ubiquitin is transferred to the active-site 
cysteine of the E2 conjugating enzyme. E2 transfer also requires the formation of a 
thioester linkage. E2-bound ubiquitin then interacts with a RING E3 ligase enzyme, but 
does not directly transfer ubiquitin to the E3. Instead, the RING E3 ligase binds to both 
the appropriate protein substrate and the E2. The increased proximity between the E2-
bound ubiquitin and the protein substrate facilitates the transfer of ubiquitin to a Lys 
residue on the substrate. The substrate can undergo monoubiquitylation (addition of one 
ubiquitin moiety) at one or more Lys residues or polyubiquitylation (addition of a chain 
of ubiquitin moieties linked together via internal Lys residues). Chains that are linked 
together by the Lys48 residue of ubiquitin typically target substrates for 26S proteasomal 
degradation.  
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Figure 1.4 
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proteins are activated and conjugated to target proteins using a distinct set of enzymes; 
however, the overall process is analogous to ubiquitylation 135. Notably, unlike other 
SUMO E3 ligase proteins, the SUMO E3 ligase activity of TRIM proteins is dependent 
on both RING and BB domains 132. Some TRIM family members have been shown to 
undergo SUMO modification themselves (self-sumoylation) and several TRIM proteins 
contain SUMO-interacting motifs (SIMs). SIMs bind to other proteins that have been 
modified with SUMO. Interestingly, two SIMs in huTRIM5α and rhTRIM5α play an 
important role in N-MLV and HIV-1 restriction 136–139.  
Following the RING finger domain, TRIM proteins contain one or two BB domains. 
Similar to the RING domain, BB domains are zinc binding motifs with a number of 
conserved cysteine and histidine residues; however, unlike the RING domain, BBs are 
found exclusively in the TRIM family. There are two types of BBs, BB1 and BB2, that 
share similar but distinct consensus motifs. When both BB are present in TRIMs, BB1 
always precedes BB2. If only one BB is present it is always BB2 68,113,120. Structural 
studies of several human TRIM proteins have revealed that TRIM BBs have a similar 
ternary structure as the RING finger domain 140–142. Studies on the BB2 domains of 
human TRIM63 (MuRF1) and TRIM5α identified two unusual conserved clusters of 
hydrophobic residues on the surface of the domain. Two hydrophobic clusters that are 
flanked by a number of charged residues were identified on the surface of the BB2 
domain of TRIM5α. A number of these residues (e.g. W115, L116, and R119) were 
required for major TRIM5α functions, including TRIM5α turnover, higher order self-
association, formation of cytoplasmic bodies, HIV-1 capsid binding, and/or HIV-1 
restriction 143. TRIM63 had a similar cluster of solvent-exposed hydrophobic residues 
located at the surface of its BB2 domain, which form a dimer interface and mediate 
TRIM63 self-association 142.  
The final component of the RBCC motif is the predicted CC region. The CC domain 
contains many predicted hyper-secondary structures and intertwined α-helices, which 
mediate homomeric and heteromeric interactions among TRIM proteins and other 
binding partners. A large number of TRIM proteins have been shown to self-associate 
through the CC domain 112. The CC domain also promotes the formation of higher-
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molecular-weight complexes that among other functions, define specific subcellular 
structures. For example, the CC domain of TRIM19 (also referred to as promyelocytic 
leukemia protein [PML]) is essential for the proper assembly and maintenance of 
macromolecular called nuclear bodies (NB). Moreover, the CC domain of TRIM5α 
facilitates TRIM5α trimerization. Mutations in CC that disrupt TRIM5α trimerization 
impair TRIM5α-mediated HIV-1 restriction 144–147. Interestingly, it has been proposed 
that the pleiotropic effects of TRIM proteins may be due to the ability of the CC to 
facilitate diverse homomeric and heteromeric interactions 120,148. 
 
1.2.3 The SPRY and PRY/SPRY (B30.2) domains 
The SPRY and PRY/SPRY (B30.2) domains are the most common C-termini found in 
TRIM family proteins. The evolutionarily ancient SPRY domain (~140 amino acids) is 
present alone or fused to a related domain called the PRY domain (~60 amino acids), 
which always precedes the SPRY domain. Unlike the SPRY-only domain, the fused 
PRY/SPRY domain is only found in vertebrates and PRY/SPRY-containing proteins 
(including TRIMs) have expanded rapidly during vertebrate evolution. The reasons for 
this expansion are still unclear; however, it has been proposed that the PRY/SPRY 
domain has been selected and maintained in vertebrates as a component of immune 
defense 68,149. Indeed, the PRY/SPRY domain in TRIM proteins is often critical for 
TRIM-mediated virus inhibition. For example, rhTRIM5α interacts with the HIV-1 
capsid protein via its PRY/SPRY domain and both PRY and SPRY portions of the 
domain are necessary for this interaction. Furthermore, the PRY/SPRY domain in the 
TRIM25 protein, which activates the RIG-I signaling cascade, is both necessary and 
sufficient for its interaction with RIG-I. These PRY/SPRY-mediated protein-protein 
interactions are required for both rhTRIM5α and TRIM25 to execute their antiviral 
functions 40,122,150–153. 
The SPRY and PRY/SPRY domain superfamily is among one of the largest families of 
protein interaction modules in humans. In addition to the TRIM family, the SPRY and 
PRY/SPRY domains are found in several other protein families, including a number of 
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families that contain proteins involved in ubiquitylation processes. As mentioned in the 
previous section, the TRIM family also contains a sizeable number of proteins that are 
involved in ubiquitylation. Thus, although SPRY and PRY/SPRY-containing proteins 
have diverse biological functions, it has been proposed in the literature that they may 
function primarily as target substrate recognition modules for E3 ubiquitin ligases 154,155. 
This is consistent with experimental evidence for some members of the TRIM family, 
such as TRIM27, which interacts with the NOD2 (nucleotide-binding oligomerization 
domain-containing protein 2) protein through its PRY/SPRY domain and subsequently 
facilitates NOD2 polyubiquitylation and degradation using its RING domain 156. 
However, in the majority of cases, the mechanistic details and/or interacting substrate 
proteins required for TRIM-mediated biological activities are unknown. 
Several SPRY and PRY/SPRY domain structures have now been resolved, including a 
limited number of structures in complex with their binding partners. These studies have 
revealed that the SPRY and PRY/SPRY domain structures are extremely versatile and 
can interact with diverse ligands 157,158. The core fold of the PRY/SPRY domain is a bent 
β-sandwich comprised of two antiparallel β sheets. The majority of conserved residues 
are located in the hydrophobic core between the antiparallel β sheets, whereas loops of 
variable length and sequence protrude from the core β-sandwich. In many PRY/SPRY-
containing proteins, these variable loops form protein binding surfaces that determine 
substrate binding specificity 154,155,159–162. For example, four variable (v) loops in the 
recently solved structure of the rhTRIM5α PRY/SPRY domain comprise the HIV-1 
capsid binding site. The binding surface is dominated by one variable loop (v1) that is 
highly flexible and interacts weakly with multiple capsid epitopes. Interestingly, the 
authors of this study suggests that capsid recognition by rhTRIM5α may function in a 
similar manner as IgM-mediated antigen recognition 163. 
 
1.1.3 Antiviral activity 
Most TRIM proteins are upregulated by type I IFNs and multiple TRIMs have been 
shown to possess antiviral activity. As mentioned previously, TRIM5α restricts the 
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replication of diverse retroviruses, including HIV-1 and N-MLV. A comprehensive 
screen for antiretroviral activity of 55 human and mouse TRIMs revealed that 19 
additional TRIM proteins inhibit the entry or release of HIV-1, MLV, and/or avian 
leucosis virus. Interestingly, unlike TRIM5α, most of the additional TRIM proteins 
inhibited late stages of the viral life cycle 69. Multiple TRIM proteins have also been 
shown to have antiviral activity against hepatitis B virus (HBV). These TRIM proteins 
have been shown to significantly reduce the HBV transcription in HepG2 cells 164,165. 
Some TRIM proteins, such as TRIM19/PML, have been implicated in the inhibition of 
additional viruses, including herpes simplex virus, human cytomegalovirus, vesicular 
stomatitis virus, and influenza A virus (IAV) 166. Recently, TRIM56 was shown to inhibit 
the replication of bovine viral diarrhea virus in vitro and mouse-specific TRIM79α was 
identified as a potent inhibitor of tick-borne encephalitis virus 167,168. In addition, 
TRIM21 was previously shown to act as an intracellular IgG receptor that neutralizes 
antibody-coated virus in the cytoplasm by targeting it for degradation by the 26S 
proteasome 169. These studies suggest that TRIM family proteins restrict evolutionarily 
diverse viruses and target a variety of stages in the viral replication life cycle.  
 
1.2 The TRIM22 protein 
TRIM22 is an evolutionarily ancient IFN-induced antiviral protein that inhibits HIV-1, 
HBV, IAV, and encephalomyocarditis virus (EMCV) replication. Similar to other host 
restriction factors, the major biological activity of TRIM22 is its antiviral activity; 
However, altered TRIM22 expression levels have also been associated with multiple 
sclerosis, several cancers, and a number of autoimmune diseases. While TRIM22 is 
clearly an important and dynamic protein, the key factors that influence its expression 
and antiviral activity remain largely unknown 170. An overview of what is currently 
known about TRIM22 evolution, structure, and function is provided below.  
 
  
25 
1.2.1 Origins and evolution 
Human TRIM22 is located on chromosome 11 within a cluster of closely-related TRIM 
genes that also includes TRIM5, TRIM6, and TRIM34 171,172. The origins of the entire 
TRIM5/6/22/34 gene cluster can be traced back to the Cretaceous period, or more 
specifically, to approximately 90-180 million years ago (Fig 1.5). Studies have shown 
that TRIM5/6/22/34 is absent in Metatherian (marsupial) mammals (e.g. opossum and 
chicken), but present in all major Eutherian (placental) groups (e.g. cow, dog, and 
human) 172. As such, the TRIM5/6/22/34 gene cluster must have emerged after the 
divergence of Metatherian and Eutherian mammals, but before the separation of major 
Eutherian groups. Of interest, several groups have proposed that TRIM5/6/22/34 likely 
arose through tandem gene duplication, as TRIM5, TRIM6, TRIM22, and TRIM34 are 
close human paralogs, and because major gene re-arrangements have been observed in 
this chromosomal region 108,172,173. Gene duplication plays an important role in evolution 
and a number of TRIM genes have been shown to undergo gene duplication in both 
primates and teleost fish 108,174. 
Within the TRIM5/6/22/34 gene cluster, TRIM22 and TRIM5 have an interesting and 
dynamic evolutionary relationship. In some Eutherian groups, such as cow, there are 
multiple copies of the TRIM5 gene but no TRIM22 gene. However, in other Eutherian 
groups, such as dog, the TRIM22 gene is present but the TRIM5 gene is not 172. In 
addition, TRIM22 and TRIM5 have evolved in a mutually exclusive manner, whereby 
positive selection has acted on either TRIM22 or TRIM5 (but not both) in different 
primate lineages. This striking anti-correlative pattern of evolution is thought to occur 
due to tight genetic linkage between the two genes 172. Both TRIM22 and TRIM5 are 
classified as Subgroup G (also Group 2) TRIM genes according to the most recent 
phylogenetic-based classification system (TRIM6 and TRIM34 are also Subgroup G, 
Group 2 TRIM genes) (Fig 1.3) 110,111.  
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Figure 1.5: TRIM22 evolution, genomic organization, and protein structure.  
An approximate timeline of Metatherian and Eutherian mammalian evolution is shown 
on the top panel. The estimated time (~90-180 million years ago) that TRIM22 (and the 
rest of the TRIM5/6/22/34 gene cluster) emerged in Eutherian mammals is indicated by 
two arrows. The middle panel shows the genomic organization of the TRIM5/6/22/34 
gene cluster on human chromosome 11. The bottom panel illustrates the TRIM22 protein 
domains (RING, BB2, CC, and PRY/SPRY or B30.2) and the approximate location of its 
E3 ligase activity and nuclear localization signal (NLS). 
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Figure 1.5 
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Figure 1.5: TRIM22 evolution, genomic organization, and protein structure. 
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1.2.2 Protein structure 
Similar to other Subgroup G (and Group 2) members, the TRIM22 protein is comprised 
of an N-terminal RBCC motif that includes RING, BB2, and CC domains and a C-
terminal B30.2 domain (Figs. 1.3 and 1.5). The RING domain of TRIM22 has been 
shown to possess both E3 ubiquitin and E3 SUMO ligase activity 132,175. TRIM22’s E3 
ubiquitin ligase activity is dependent on two catalytic cysteine (Cys) residues (i.e. Cys15 
and Cys18) in its RING domain. These Cys residues help stabilize the zinc finger motif 
and facilitate the transfer of ubiquitin to the appropriate substrate protein 113,117. TRIM22 
also mediates its own ubiquitylation and 26S proteasomal degradation when combined 
with the E2 conjugating enzyme UbcH5B (also referred to as UBC2D2) 175. TRIM22 
inhibits viral replication by both E3 ubiquitin ligase dependent and independent 
mechanisms. For example, TRIM22’s E3 ubiquitin ligase activity is required for 
TRIM22-mediated inhibition of HBV, IAV, and EMCV 164,176,177. However, HIV-1 
inhibition occurs in both the presence and absence of TRIM22’s E3 ubiquitin ligase 
activity 178,179. 
The second domain in the TRIM22 protein is the BB2 domain. Similar to the RING 
domain, the BB2 domain contains a zinc finger motif; however, the BB2 domain only 
coordinates one zinc ion (the RING domain coordinates two zinc ions) 180. While the 
function of TRIM22’s BB2 domain is still unclear, BB2 mutations in other TRIM 
proteins have been shown to affect viral recognition or inhibition. For example, in the 
TRIM5α protein, the RING and BB2 domains work together to promote TRIM5α 
dimerization, which is important for higher-order self-association of rhTRIM5α on the 
HIV-1 capsid lattice and subsequent HIV-1 restriction 181. It is unknown whether the 
TRIM22 BB2 domain is required for higher-order self-association; however, the BB2 
does play a role in TRIM22’s nuclear localization 182. The BB2 domain of TRIM22 is 
followed by the predicted CC region, which contains many putative hyper-secondary 
structures and α-helices 183. In TRIM5α, the CC region promotes TRIM5α trimerization 
and may be involved in TRIM5α cytoplasmic body formation. Similar to dimerization, 
TRIM5α trimerization drives its interaction with the HIV-1 capsid lattice 146,181. The CC 
region also promotes higher-order self-association in a number of additional TRIM 
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proteins. While TRIM22 has been shown to undergo trimerization, the biological and 
antiviral significance of TRIM22 trimerization is unknown 112.  
The TRIM22 protein contains a C-terminal B30.2 (PRY/SPRY) domain. Although the 
structure of this domain has not been resolved for TRIM22, several domain-deletion 
studies have shown that it is integral for many TRIM22 functions. For example, one 
study showed that B30.2 mutants of TRIM22 were no longer able to inhibit HBV 
replication and localized exclusively to the cytoplasm in HepG2 cells 164. Several 
additional studies have also reported the TRIM22’s B30.2 domain is necessary for its 
nuclear localization and the formation of nuclear bodies (NB), including a study that 
showed that amino acids 491-494 are critical for nuclear localization and amino acids 
493-494 are critical for NB formation 184,185. TRIM22’s B30.2 domain may also be 
required for EMCV restriction, self-ubiquitylation, and/or the ubiquitylation of other 
substrate proteins. One study that investigated TRIM22-mediated EMCV restriction 
showed that a C-terminal TRIM22 mutant lacking both CC and B30.2 domains was 
unable to inhibit EMCV replication or facilitate ubiquitylation of target proteins even 
though its RING domain was still intact and bound to the ubiquitylated E2 enzyme 176. 
An N-terminal TRIM22 mutant lacking both RING and BB2 domains lost the ability to 
undergo self-ubiquitylation, suggesting that the B30.2 domain of TRIM22 may be 
ubiquitylated by its own RING finger domain 176. While the role of TRIM22’s B30.2 
domain in HIV-1 restriction is still unclear, rhTRIM5α’s B30.2 domain is required for 
HIV-1 restriction 146. Moreover, several hyper-variable regions (v1-v4) in the B30.2 
domain of rhTRIM5α form the binding surface for HIV-1 capsid and confer virus 
specificity for TRIM5α-mediated restriction of retroviruses 186. The B30.2 domain of 
TRIM22 also contains these hyper-variable regions (v1-v4); however, it is unknown 
whether they play a role in its antiviral activity or specificity.  
 
1.2.3 Induction and expression 
Several reports have demonstrated that TRIM22 is basally expressed in multiple human 
tissues and is highly upregulated in response to type I and type II IFN (Table 1.2)  
  
30 
Table 1.2 
Table 1.2: Factors that alter TRIM22 protein expression levels. 
 
 Change Cell type and/or Tissue 1 
Cytokines 
IFN-α  Increase Primary MDM; CEM, Jurkat, THP-1, H9, HepG2, U937 U-937-4, Daudi, 
and HeLa cells 
IFN-β  Increase HOS, Daudi, and HeLa cells 
IFN-  Increase HeLa, HepG2, and MCF7 cells 
IL-1-β  Increase Coronary artery endothelium  
IL-2  Increase CD4+, CD8+, NK cells  
IL-15  Increase CD4+, CD8+, NK cells  
Progesterone  Increase ABC28 and T47D cells  
TNF-α  Increase Coronary artery endothelium  
   
Antigens/Infection   
EBV infection Increase BL41-EBV cells 
EBV LMP-1  Increase DG75 cells 
HBV infection  Increase Liver tissue 
HCV infection Increase Liver tissue 
HIV-1 infection  Increase Immature DCs, Primary MDMs 
HIV-1 Tat  Increase Immature DCs 
HPV infection  Decrease Human keratinocytes   
KSHV infection Increase KSHV lesion   
KSHV LANA Increase BJAB cells 
  
31 
LPS Increase Primary MDMs 
Rubella infection Increase ECV304 cells   
   
Activation/Differentiation/Cell 
cycle  
  
1α,25-dihydroxyvitamine D33 Increase Primary MDMs 
Anti-CD2  Increase Primary T cells 
Anti-CD2/CD28  Decrease Primary T cells 
Anti-CD2/CD28/CD3  Decrease CD4+, CD8+, NK cells 
All-trans retinoic acid  Increase Primary MDMs; HL60 and NB4 cells   
p53  Increase K562 and U-937-4 cells 
p73 Increase U-937-4 cells   
Pioglitazone  Increase Primary MDMs 
UV-irradiation Increase MCF-7 cells 
   
Disease   
Systemic Lupus Erythematosus  Increase CD4+ T cells from SLE patient  
Wilms Tumor Decrease   Primary Wilms Tumor  
Neuroblastoma Decrease Primary Neuroblastoma  
Breast Cancer  Decrease  Primary Breast cancer and 10 Breast cancer cell lines  
 
1 Please refer to 170 for comprehensive list of all references 
 
Abbreviations: Monocyte-derived macrophages (MDM), Dendritic cells (DC), Epstein-Barr virus (EBV), Human papillomavirus (HPV), Kaposi’s sarcoma-
associated herpesvirus (KSHV) 
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164,172,178,179,187–193
. TRIM22 expression is also induced by several viral antigens (e.g. 
Epstein-Barr virus [EBV], HIV-1, HBV, Kaposi’s sarcoma-associated herpes virus 
[KSHV], and Rubella), cytokines, and hormones. Studies have shown that TRIM22 
contains two IFN-stimulated response elements (ISRE-1, ISRE-2) and one IFN-γ 
activation site (GAS) in its 5’ promoter region. Notably, ISRE-1 and GAS are not 
required for IFN-γ induction of TRIM22. Instead, induction of TRIM22 by IFN-γ 
requires ISRE-2 plus six upstream nucleotides (referred to as the 5’ extended ISRE or 
eISRE) 190. This induction is dependent on the chromatin remodeling enzyme brahma-
related gene 1, which recruits IFN regulatory factor 1 (IRF-1) to the eISRE, and histone 
deacetylase activity, which prevents the proteasomal degradation of IRF-1 192,194. JAK, 
phosphatidylcholine-phospholipase C, and protein kinase C are also required for 
induction of TRIM22 by IFN-γ. p300 enhances IFN-γ induced expression of TRIM22 
and is also required for the recruitment of RNA polymerase II to the 5’ TRIM22 
promoter. IRF-1 binding to eISRE appears to also be required for IFN-α induced and 
basal TRIM22 expression 195. 
 
1.2.4 Sub-cellular localization 
Conflicting reports have been published on the sub-cellular localization of TRIM22. 
Some reports show that TRIM22 localizes predominantly in the cytoplasm or in the 
nucleus, whereas others show that TRIM22 localizes in both the cytoplasm and the 
nucleus 112,164,175,182,184,196–198. These studies also report different TRIM22 localization 
patterns (i.e. diffuse, speckled, and/or aggregated). Although the reasons for these 
inconsistencies are unclear, several possible explanations have been given in the 
literature. These include whether TRIM22 was expressed endogenously (e.g. IFN 
treatment of cells) or exogenously (e.g. overexpression of TRIM22), the method of 
fixation, and the epitope tag. Other potential explanations include cell-type specific 
factors or induction by different cellular signals. Consistent with the latter, TRIM22 
localizes in NBs in progesterone-treated, but not IFN-γ-treated, MCF7 and HeLa cell 
lines 197.  
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Several determinants of TRIM22 sub-cellular localization have been identified. The 
TRIM22 protein contains a bipartite nuclear localization signal (NLS) in the Spacer 2 
domain (SP2), which was previously shown to be necessary, but not sufficient, for 
nuclear localization 197. Although the B30.2 domain does not contain a known NLS, 
multiple groups have shown that it is required for nuclear localization 164,184,196,197. One 
group in particular showed that the amino acids 491-494 are essential for TRIM22 
nuclear localization and that the amino acids 493-494 are critical for the formation of 
TRIM22 NBs in MCF7 cells 197. Another group reported that the amino acids 395, 396, 
and 400 are required for the cytoplasmic localization of TRIM22 in COS-7 (African 
green monkey) cells 196. However, this group did not investigate how these amino acids 
influence TRIM22 localization in human cells. Notably, some studies that observed 
cytoplasmic TRIM22 localization used a shorter form of TRIM22 (442 instead of 498 
amino acids) that is translated from a 1329 mRNA coding sequence. As such, in these 
studies the lack of amino acids 491-494 likely contribute to the cytoplasmic localization 
of TRIM22. 
In many cell types, TRIM22 localizes in punctate NBs, which have been shown to 
partially co-localize with Cajal bodies (CB) 197. CBs are distinct nuclear organelles that 
are involved in RNA processing and modification, assembly/modification of splicing 
machinery, and cell cycle progression 199. TRIM22 interacts with p80-coilin, which is a 
major component of CBs, in stably-transfected MCF7 cells and progesterone-treated 
ABC28 cells 197. Similar to CBs, TRIM22 localization may change throughout the cell 
cycle. One report showed that during G0/G1 TRIM22 localizes in NBs, in S-phase it 
localizes diffusely in the nucleus, and in mitosis it assumes a diffuse pattern in the 
nucleus and cytoplasm (exogenous TRIM22 expression in HeLa cells) 197. However, a 
second study reported that TRIM22 co-localizes with the centrosome independently of 
the cell cycle (exogenous TRIM22 expression in U2OS cells as well as endogenous 
TRIM22 expression in peripheral blood mononuclear cells) 198. Notably, these two 
localization patterns may not be mutually exclusive because TRIM22 did not localize 
exclusively to centrosomes. These data suggest that multiple factors influence the sub-
cellular localization of TRIM22, indicating that TRIM22 may have several biological 
roles.   
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1.2.5 Antiviral function 
Human TRIM22 was first identified in 1995 during a search for IFN-induced genes in 
Daudi cells. Following sequence analysis, which revealed that TRIM22 was highly 
homologous to the mouse Rpt-1 gene, exogenous TRIM22 expression was shown to 
downregulate transcription from the HIV-1 LTR 187,200. Although this experiment was 
performed using a luciferase reporter gene instead of the entire HIV-1 genome, it was 
first to report an antiviral (and anti-HIV-1) function for TRIM22. In 2006, another 
independent study showed that TRIM22 was highly up-regulated in primary monocyte-
derived macrophages (MDM) in response to HIV-1 infection, IFN-α treatment, or 
stimulation with lipopolysaccharide (LPS). In addition, they showed that exogenous 
TRIM22 expression inhibited HIV-1 infection by 50-90% in 293T cells and primary 
MDMs 189. In 2008, Barr and colleagues showed that TRIM22 was a key mediator of 
type I IFN-induced inhibition of HIV-1 replication 178. Two different methods of HIV-1 
inhibition were observed. In HOS and HeLa cell lines, TRIM22 expression inhibited 
HIV-1 particle production by preventing the trafficking of the Gag polyprotein to the 
plasma membrane. This effect was dependent on the E3 ligase activity of TRIM22. 
Because TRIM22 was also shown to interact with Gag it was thought that TRIM22-
mediated post-translational modification of Gag may be responsible for altered Gag 
trafficking. However, to date, TRIM22 has never been shown to modify Gag post-
translationally. Unlike in HOS and HeLa cells, in U2OS and 143B cells, TRIM22 
inhibited the accumulation of intracellular Gag protein. Although the mechanism of 
restriction was not identified in these cell lines, several potential explanations were 
suggested, including inhibition of LTR-driven transcription or degradation of the Gag 
RNA and/or polyprotein 178. Notably, these experiments provided the first mechanistic 
data for restriction of HIV-1 replication by TRIM22.  
It has since been confirmed that TRIM22 can restrict HIV-1 transcription 179. In 2011, 
TRIM22 was identified as the sole factor expressed in clones of U937 cells that were 
non-permissive to HIV-1 replication, but absent in permissive U937 clones. Using a 
luciferase reporter plasmid, the authors tested LTR-driven transcription in the non-
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permissive and permissive clones. LTR transcription levels in non-permissive clones 
were decreased 7-10 fold compared to permissive clones; however, non-permissive 
transcription levels were increased when shRNA was used to knockdown TRIM22. 
Moreover, when TRIM22 was expressed in permissive clones transcription levels 
decreased to those observed in non-permissive clones. Further examination of these 
clones revealed that TRIM22 inhibited basal LTR-driven HIV-1 transcription and that 
these effects were independent of NF-κB binding sites in the LTR, Tat-mediated LTR 
transactivation, and TRIM22 E3 ligase activity 179.  
In addition to these in vitro studies, there is also in vivo evidence to support a role for 
TRIM22 as an anti-HIV-1 effector. A 2011 study demonstrated that increased TRIM22 
expression was associated with significantly lower viral loads and significantly higher 
CD4+ T-cell counts in HIV-1 positive individuals in the primary phase of infection 201. 
Recently, a follow-up study showed that TRIM22 expression was also associated with 
significantly lower viral loads in HIV-1 positive individuals in the chronic phase of 
infection 202. These data suggest that TRIM22 expression contributes to HIV-1 disease 
progression in infected individuals.  
TRIM22’s antiviral activity is not limited to HIV-1. Exogenous expression of TRIM22 
has also been shown to inhibit the replication of EMCV, IAV, and HBV. For EMCV 
restriction, TRIM22 was shown to interact with the 3C viral protease and mediate its 
ubiquitylation and subsequent degradation 176. The 3C protease has a number of 
important roles, including processing the viral polyprotein, and is essential for successful 
EMCV replication176. A similar mechanism of restriction was reported for IAV 
inhibition. Specifically, TRIM22 was shown to interact with IAV’s viral nucleoprotein 
(NP), which plays a critical structural function and is required for IAV replication. 
Following TRIM22-NP interaction, TRIM22’s E3 ubiquitin ligase activity facilitates 
ubiquitylation and subsequent proteasomal degradation of NP 177. Several studies have 
recently shown that TRIM22 may be an important antiviral factor in the liver. In 2009, 
one study demonstrated that TRIM22 expression inhibited HBV gene expression and 
replication in cultured cells and mice 164. Further experiments revealed that TRIM22 
inhibited the activity of the HBV core promoter (CP), which plays a key role in HBV 
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replication. HBV CP inhibition was dependent on TRIM22’s B30.2 domain and its E3 
ligase activity, even though a ubiquitylation target was not identified 164. Interestingly, 
TRIM22 expression is also significantly upregulated during clearance of HBV and 
hepatitis C virus (HCV) in chimpanzees 203,204. In human HCV infection, TRIM22 is 
significantly upregulated in the cirrhotic liver of HCV positive individuals and 
individuals with mild chronic HCV with no fibrosis 205.  
 
1.2.6 Other functions 
Several reports have implicated TRIM22 in other biological processes, including cell 
cycle regulation and cell proliferation/differentiation. One study identified a functional 
p53 response element in intron 1 of the TRIM22 gene and demonstrated that upon p53 
binding this element activates TRIM22 expression. Moreover, the same study showed 
that overexpression of TRIM22 in U937 cells led to decreased clonogenic growth and 
that endogenous TRIM22 was upregulated during induced differentiation in NB4 cells 
188
. A later study investigating TRIM22 expression during hematopoietic differentiation 
showed that TRIM22 is highly expressed in CD34+ bone marrow progenitor cells, but 
declines in mature populations. Notably, although TRIM22 expression was inversely 
correlated with differentiation in both lineages, its expression pattern differed during 
erythroid versus granulocytic differentiation. Decreased TRIM22 expression was more 
pronounced and lasting during erythroid differentiation and undetectable in nucleated 
erythroid populations 193.  
TRIM22 has also been linked to other human diseases, including certain cancers and 
autoimmune diseases. Two studies have shown that decreased TRIM22 expression is 
associated with increased progression, relapse, and mortality in cases of Wilms tumor 
206,207
. In addition, a recent study reported that TRIM22 expression is significantly 
decreased in both a panel of 10 breast cancer cell lines and breast tumors compared to 
three non-malignant cell lines and normal breast tissue. Interestingly, TRIM22 protein 
levels correlated with p53 protein levels in the normal breast tissue, but not in breast 
cancer tissue. Additional experiments showed that TRIM22 expression was no longer 
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p53-inducible in breast cancer cells, suggesting that a defect in p53-mediated TRIM22 
regulation was responsible for TRIM22 downregulation in breast cancer 208. Two gene 
profiling studies have also implicated TRIM22 in the pathogenesis of systemic lupus 
erythematosus (SLE). The first study showed that TRIM22 was overexpressed in the 
CD4+ T cells of individuals with active SLE compared to individuals with non-active 
SLE. The second study also reported that TRIM22 was upregulated in SLE-positive 
CD4+ T cells and that, along with a number of other IFN-induced genes, TRIM22 was 
significantly hypomethylated in SLE cells compared to healthy controls 209,210. 
 
1.3 Rationale and Experimental Approach 
Genetic variation in immune genes plays an integral role in host susceptibility to and 
progression of infection and disease. Much of this variation is due to single nucleotide 
polymorphisms (SNPs), which are defined as single base changes in a DNA sequence. 
While many SNPs are phenotypically neutral, non-synonymous or amino acid altering 
SNPs (nsSNP) often have deleterious effects on protein structure and/or function 211–218. 
Previous studies have shown that nsSNPs do not appear randomly in the genome, but 
emerge based on genomic location and selective pressures. Since innate immune genes 
are located at the interface of the microbial environment, they tend to be exposed to a 
wide range of selective pressures. As such, innate immune genes often contain genetic 
signatures of positive (directional) and/or balancing selection, whereas most other host 
genes are dominated by negative (purifying) selection 219–221.  
Multiple host restriction factors, including APOBEC3G, TRIM5α, BST-2/tetherin, and 
SAMHD1, have evolved under positive and/or balancing selection 18. Host restriction 
factors often interact directly with viral antagonists and/or other viral proteins and as a 
result, they tend to be subjected to intense pathogenic pressures. In order to effectively 
adapt to an ever-changing pathogenic environment, host restriction factors must evolve 
new advantageous mutations and/or maintain genetic flexibility to counteract emerging 
pathogenic threats. Since new beneficial mutations and/or sites of genetic diversity are 
typically located at critical functional sites, performing evolutionary analyses on host 
restriction factors can be a powerful way to delineate integral sites in these proteins. It 
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follows that a number of studies on host restriction factors have used an evolutionary 
approach to identify essential residues in these proteins 62,85,91,99,106,222. In addition, other 
studies have used in silico nsSNP prediction programs to identify functionally and/or 
clinically relevant polymorphisms in innate immune genes 19–24. Further, in silico 
methods have also been used to identify important functional regions in these genes (e.g. 
post-translational modifications) and support evolutionary analyses 229–232. One of the 
major advantages of performing in silico analyses is that it allows for the systematic 
analysis and prioritization of specific functional sites. This is becoming increasingly 
important given the tremendous number of SNPs in the human genome and the vast 
amount of genetic data that is generated on a daily basis. Collectively, evolutionary and 
in silico analyses provide valuable insight into protein function and are powerful tools 
that can help identify key structural and/or functional sites in a protein.  
Given the important role played by TRIM22 in multiple biological processes, including 
the host antiviral response, and the paucity of information about key functional sites in 
the TRIM22 protein, we conducted an extensive evolutionary and in silico analysis to 
identify critical amino acid residues that mediate TRIM22 function. This approach has 
previously been used to pinpoint specific amino acid residues that are essential for the 
activities of other host restriction factors, including the APOBEC3G, TRIM5α, BST-
2/tetherin, and SAMHD1 proteins. We hypothesized that evolutionary forces have been 
acting on TRIM22 and have selected for specific amino acids that impact TRIM22 
function. To address this hypothesis, we characterized the evolutionary forces acting on 
TRIM22 and used a number of in silico methods to delineate and prioritize potential 
functional sites in human TRIM22 that may be relevant to its overall antiviral and/or 
biological functions. We then investigated how various TRIM22 nsSNPs may affect 
human infection and disease and identified a functional nsSNP (rs1063303:G>C) that 
influences two diverse TRIM22-mediated biological activities.  
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Chapter 2 
 
2 Ancient and recent adaptive evolution in the antiviral 
TRIM22 gene: identification of a single nucleotide 
polymorphism that impacts TRIM22 function 1 
TRIM22 is a novel IFN-induced protein that potently inhibits the replication of 
evolutionarily diverse viruses, including HIV-1, HBV, and IAV. Altered TRIM22 
expression is also associated with diseases such as multiple sclerosis, cancer, and 
autoimmunity. To date, the factors that influence TRIM22 expression and antiviral 
activity are largely unknown. Here, we used an evolutionary approach to identify 
potential genetic determinants of TRIM22 function. Evolutionary analysis using 29 
mammalian TRIM22 sequences revealed that TRIM22 evolution has been shaped by 
ancient and variable selective forces. Positive selection has operated on a number of 
TRIM22 sites, many of which cluster together in putative protein-protein interaction 
motifs. Interestingly, we found that the second most prevalent nsSNP in the human 
TRIM22 gene (rs1063303:G>C) is located at one of these positively selected sites. In 
addition, the frequency of this nsSNP varied up to 10-fold between different ethnic 
populations. We found that nsSNP rs1063303:G>C had an inverse functional impact, 
whereby it increased TRIM22 expression and decreased TRIM22 antiviral activity. 
Taken together, our data describes the extensive genetic variation in TRIM22 and 
identifies nsSNP rs1063303:G>C as a highly prevalent nsSNP that impacts TRIM22 
function.  
 
 
                                                 
1
 The material contained in this chapter was published in: Kelly, J.N., Woods, M.W., Xhiku, S., and Barr, 
S.D. Ancient and recent adaptive evolution in the antiviral TRIM22 gene: identification of a single 
nucleotide polymorphism that impacts TRIM22 function. Hum Mutat. (2014). 
Copyright 2014.  
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2.1 Introduction 
The TRIM family is a large group of proteins involved in diverse cellular processes. 
TRIM proteins are increasingly becoming recognized as key regulators of the innate 
immune response and a number of TRIM proteins have been shown to possess antiviral 
activity 1–6. According to a recent evolutionary study, TRIM proteins can be divided into 
two main groups based on genomic organization, evolutionary properties, and domain 
structure. Group 1 TRIM proteins (G1) are present in both invertebrate and vertebrate 
species and have variable C-terminal domains, while Group 2 TRIM proteins (G2) are 
only found in vertebrates and have a C-terminal B30.2 domain 7. All TRIM proteins (G1 
and G2) have a conserved N-terminal RBCC motif, which consists of a RING domain, 
one or two BB domains, and a predicted CC region. The RING domain often has E3 
ligase activity, allowing some TRIMs to modify other proteins (including viral proteins) 
with ubiquitin or ubiquitin-like molecules 8–10.  
In the human genome, four G2 TRIM genes cluster together on chromosome 11: TRIM6, 
TRIM34, TRIM5, and TRIM22 (Online Mendelian Inheritance in Man #606559). 
Evolutionary analysis of this gene cluster has shown that TRIM6 and TRIM34 have 
evolved under purifying selection in primates, and that TRIM5 and TRIM22 have a 
dynamic evolutionary relationship in primates that includes episodes of gene expansion 
and gene loss 11,12. It was previously shown that TRIM5 and TRIM22 sequences have 
undergone positive selection in primates, with primate lineages showing positive 
selection in either TRIM5 or TRIM22, but not both 12–15. Moreover, the TRIM5 and 
TRIM22 genes of Haplorhini primates have evolved species-specific differences in 
transcriptional regulation, mediated by transposable element sequences in their non-
coding regions 16. Both TRIM5 and TRIM22 encode proteins with antiviral activity 
against retroviruses. TRIM5α inhibits HIV-1 replication in non-human primate cells; 
however, this activity is weak to absent in human cells 17–19. Conversely, TRIM22 
inhibits HIV-1 replication in several human cell lines and primary MDMs 20–23. The 
TRIM22 protein also inhibits the replication of EMCV, HBV, and IAV 24–26.  
Genetic conflict between host and viral genomes can lead to the rapid accumulation of 
amino acid replacement changes (dN) relative to synonymous changes (dS). This 
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phenomenon of positive selection (i.e. dN/dS >1) is one hallmark of the evolutionary 
‘battle’ that occurs between host antiviral factors and their pathogen antagonists 27,28. 
Although positive selection is not typically observed in other host genes, multiple 
antiviral factors contain genetic signatures of positive selection 29,30. For example, well-
known host restriction factors, including APOBEC3G, BST2/tetherin, and TRIM5α all 
contain positively selected sites that play key roles in their antiviral activities 13–15. 
A previous evolutionary study of TRIM22 in primates spanning ~33 million years of 
primate divergence identified a strong signature of positive selection for TRIM22 in 
hominoids and old world monkeys (OWM) 12. The positions of amino acid residues 
found to be under positive selection were located predominantly in the β2-β3 surface 
loop of B30.2 domain. In the present study, we analyzed TRIM22 sequences from 
evolutionarily diverse mammals spanning ~100 million years and used an evolution-
guided functional approach to identify residues that may dictate TRIM22-mediated 
antiviral activity. Using three paired evolutionary models, we identified residues in 
several TRIM22 domains that are predicted to be under strong positive selection in 
mammals. We demonstrated that the human TRIM22 gene exhibits remarkable genetic 
diversity and characterized one highly prevalent nsSNP (rs1063303:G>C) that is located 
at a site evolving under strong positive selection. Notably, we showed that nsSNP 
rs1063303:G>C has an inverse functional impact on TRIM22, whereby it increased 
TRIM22 expression levels and decreased TRIM22 antiviral activity. Our findings in this 
study indicate that genetic variation in the TRIM22 gene is both prevalent and ancient, 
and that positively selected sites in TRIM22 may influence its antiviral activity.  
 
2.2 Materials and methods 
2.2.1 Sequence analysis 
TRIM22 sequences were aligned in COBALT and a phylogenetic tree was generated 
using EvolView software 31,32. Positive selection was evaluated using the Selecton 
program, as previously described 33,34. Briefly, sequences were analyzed using three 
paired models, two nested (M8a and M8; M7 and M8) and one non-nested (M8a and 
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MEC). The models that allowed positive selection to occur (M8 and MEC) fit the data 
better than models that did not allow positive selection to occur (M8a and M7). The non-
synonymous (Ka) to synonymous (Ks) ratio (i.e. Ka/Ks) was also calculated for each 
codon using Selection. Codons with a Ka/Ks ratio >1.5 exhibited high probabilities of 
having evolved under positive selection and were highlighted in Fig 2.1b. Primate 
TRIM22 sequences in Fig 2.2c were also aligned in COBALT. Frequency data for the 
rs1063303:G>C nsSNP was extracted from the 1000 Genomes database and includes 
individuals from the following regions: African (AFN) population includes Nigeria, 
Kenya, The Gambia, Sierra Leone, Americans of African ancestry in southwestern 
United States, African Caribbean in Barbados; American (AMR) population includes 
Puerto Rico, Colombia, Peru, Mexican ancestry from Los Angeles, United States; 
European (EUR) population includes Italy, United Kingdom, Finland, Spain, Northern 
and Western European ancestry from Utah, United States; Asian (ASN) population 
includes China, Vietnam, and Japan 35.  
2.2.2 Cells, plasmids, and transfections 
Cells were maintained at 37°C with 5% CO2 in standard DMEM growth medium 
(Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, 100 
U/ml penicillin, and 100 µg/ml streptomycin). 293T and HeLa cell lines were obtained 
from the ATCC. HOS-CD4+ cell line was obtained from NIH AIDS Reagents. The 
empty vector plasmid (pGL3) was purchased from Promega and the pR9 plasmid 
encoding replication-competent HIV-1 was kindly provided by Dr. F. Bushman 
(University of Pennsylvania, USA). The coding region of the wild type TRIM22 gene 
(GenBank Accession NM_006074.4) was subcloned into p3xFLAG-CMV-10 (Sigma) 
using HindIII and XbaI restriction sites to generate pWT-T22. The flag-tagged nsSNP 
rs1063303:G>C plasmid (pSNP-T22) was created using PCR mutagenesis. pSNP-T22 
contains C in place of the ancestral allele G at nucleotide position 725 of the TRIM22 
coding region (GenBank Accession NM_006074). The following primers were used to 
amplify pWT-T22 and generate PCR fragment 1: “Forward WT” (5’ ACG TAA GCT 
TAT GGA TTT CTC AGT AAA GG 3’) and “Reverse SNP” (5’ GAC GAT CCC GTC 
AAC CTC CGC TGG AGA 3’). Similarly, PCR fragment 2 was generated using the 
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primers: “Forward SNP” (5’ TCT CCA GCG GAG GTT GAC GGG ATC GTC 3’) and 
“Reverse WT” (5’ ACG TTC TAG ATC AGG AGC TCG GTG GGC ACA CAG 3’). 
Following amplification, a 1:25 dilution of PCR fragment 1 and PCR fragment 2 was 
added with “Forward WT” and “Reverse WT” primers together in a PCR reaction. The 
amplified TRIM22 coding region containing the nsSNP was subcloned into p3xFLAG-
CMV-10 (Sigma) using HindIII and XbaI to generate pSNP-T22. The entire coding 
region of pSNP-T22 was sequenced and no other PCR-introduced variations were 
detected. 293T and HeLa cells were seeded in 12-well or 6-well plates and transfected 
using Lipofectamine 2000 (Invitrogen) with 2 µg or 5 µg of plasmid DNA (pEV, pWT-
T22, or pSNP-T22), respectively. As a control for transfection efficiency, a plasmid 
encoding enhanced green fluorescent protein (peGFP) (Clontech) was included in the 
transfections at a concentration of one tenth the total amount of transfected DNA. The 
percent GFP+ cells were measured using standard flow cytometry. Unless otherwise 
stated, all co-transfections of pR9 with pEV, pWT-T22, and pSNP-T22 were performed 
at a ratio of 10:1. 
2.2.3 RNA isolation and real-time PCR 
Total RNA was extracted from cells using the R&A-BLUE Total RNA Extraction kit 
(Frogga Bio). To ensure that no detectable genomic or plasmid DNA was carried over 
during the RNA purification, 0.1µg of each RNA sample was subjected to PCR (35 
cycles) and real-time PCR using primers within the TRIM22 coding region or primers 
specific to the TRIM22 3’ untranslated region. 1µg of DNase-treated RNA was then 
reverse transcribed to cDNA using the M-MLV reverse transcriptase and Oligo(dT) 
primers (Invitrogen). Prior to real-time PCR, cDNA samples were diluted 1:10 with 
water. Each PCR reaction consisted of 10µl of SYBR Green Master Mix, 2µl of the 
appropriate primers (1µl of 10µM forward primer (5’ CAT CTG CCT GGA GCT CCT 
GAC 3’) and 1µl of 10µM reverse primer (5’ AGA TGA TCA CTG ACT CCT TGA 
TCT TTG C 3’), 1µl of diluted cDNA, and water to a total volume of 20µl. Real-time 
PCR was run on the Rotor-Gene 6000 real-time PCR machine (Corbett Life Science) 
under the following cycling conditions: 10 min at 95°C and 40 cycles of 10 sec at 95°C, 
15 sec at 60°C, and 20 sec at 72°C. The Rotor-Gene 6000 series software (version 1.7) 
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was used to determine the CT for each PCR reaction. All samples were amplified in 
triplicate with no template controls and the mean was used for further analysis. 
2.2.4 Western Blotting 
Cells were pelleted by centrifugation (350 x g for 10 minutes), washed twice with PBS, 
and lysed in 1X RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1x 
Complete Protease Inhibitor (Roche), 1% Triton X-100, 0.1% SDS). Virus released into 
the supernatant was clarified by centrifugation, pelleted by centrifugation (21,000 x g for 
2 hours) over a cushion of 20% sucrose and lysed with 1X RIPA buffer. Protein was 
separated on a 12% SDS-PAGE gel and then transferred to a FluorTransW membrane 
(Pall) by semi-dry transfer. Following transfer, the membrane was blocked for 1 hour in 
LI-COR Blocking Buffer (LI-COR Biosciences) and incubated overnight with primary 
antibody at 4°C (1:1000 dilution with LI-COR Blocking Buffer). Detection was carried 
out using an IRDye-labeled secondary antibody (1:20,000 dilution with LI-COR 
Blocking Buffer for 30 minutes) and the LI-COR Odyssey Detection System (LI-COR 
Biosciences).    
2.2.5 Confocal immunofluorescence microscopy 
Cells were seeded in 12-well plates on 18mm coverslips. 24 hours post-transfection, cells 
were washed with PF buffer (1x PBS + 1% FBS), fixed (1x PBS + 5% formaldehyde + 
2% sucrose for 10 minutes), and permeabilized (1x PBS, 5% NP-40, 10% sucrose for 10 
minutes). Cells were incubated with primary antibodies for 1 hour (1:1000 dilution of 
mouse anti-Flag antibody in PF buffer), washed thoroughly with PF buffer, and then 
incubated with secondary antibodies for 1 hour (1:1000 dilution of AlexaFluor 546 anti-
mouse antibody in PF buffer). Coverslips containing the cells were mounted on glass 
slides with Vectashield mounting media (Vector laboratories) and slides were examined 
using a Zeiss LSM 510 confocal fluorescence microscope. DAPI staining was used to 
visualize the nuclei (blue). Images shown represent optical slices taken through the center 
of cells from a series of z-stack images with a 63x Plan-Apochromat oil immersion 
objective lens (Numerical Aperture = 1.4).  
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2.2.6 Neutrality tests 
Tajima’s D and Fu’s FS neutrality tests were performed to distinguish between neutrally 
evolving sequences under mutation-drift equilibrium and sequences evolving under non-
neutral processes such as balancing selection 36–38. These two tests are based on the 
principle that a recent population expansion associated with a non-neutral process will 
detect a shift in the allele frequency spectrum compared to a neutral Wright-Fisher 
model. A negative Tajima’s D signifies an excess of low frequency variants relative to 
expectation, indicating population size expansion (e.g. after a bottleneck or selective 
sweep) and/or purifying selection. A positive Tajima’s D signifies low levels of both low 
and high frequency (i.e. an excess of intermediate frequency) variants, indicating a 
decrease in population size and/or balancing selection. A negative value of Fu’s FS is 
evidence for an excess number of rare alleles, as would be expected from a recent 
population expansion or from genetic hitchhiking. A positive value of FS is evidence for a 
deficiency of alleles, as would be expected from a recent population bottleneck or from 
overdominant selection. The FS statistic was considered significant at the 5% level if its P 
value was below 0.02 38. The analyses were performed using the software Arlequin 
3.5.1.3 39. Simulated P values were generated using 10,000 simulations under a model of 
selective neutrality.  
2.2.7 Statistical analysis 
Unless stated otherwise, statistical analyses were performed using GraphPad Prism 
(Version 6.0). P values of less than 0.05 were considered statistically significant. 
 
2.3 Results  
2.3.1 Positive selection in multiple TRIM22 domains among 
mammals 
To better understand the evolution of TRIM22, and to examine how selective pressures 
have shaped its antiviral properties, we obtained the TRIM22 coding sequence from 29 
evolutionarily diverse mammalian species (Table 2.1). We aligned these sequences and 
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Table 2.1 
Table 2.1: Mammalian TRIM22 coding sequences used for Selecton analysis. 
 
Common name Scientific name Type 1 NCBI Reference  Verified 2 
Human Homo sapiens HOM NP_006065.2  Yes  
Chimpanzee Pan troglodytes HOM NP_001106867.1 Yes  
Bonobo Pan paniscus HOM XP_003819095.1  Yes  
Gorilla Gorilla gorilla HOM XP_004050610.1   Yes  
Sumatran Orangutan Pongo abelii HOM NP_001153280.1   No 
Bornean Orangutan Pongo pygmaeus HOM EU124707 Yes  
Island Siamang Hylobates syndactylus HOM EU124708 Yes  
White-Cheeked Gibbon Nomascus leucogenys  HOM NP_001267028.1  Yes  
African Green  Cercopithecus aethiops OWM EU124709 Yes  
Patas  Erythrocebus patas OWM EU124696 Yes  
Sooty Mangabey Cercocebus atys OWM EU124695 Yes  
Baboon Papio anubis OWM NP_001162333.1  No 
Rhesus Macaque Macaca mulatta OWM NP_001106830.1  Yes  
Kikuyu Colobus Colobus guereza kikuyuensis OWM EU124712 Yes  
Red-Shanked Douc Pygathrix nemaeus OWM EU124710 Yes  
Bolivian Squirrel  Saimiri boliviensis NWM XM_003923356.1 No 
Common Squirrel  Saimiri sciureus sciureus NWM EU124716 Yes  
White-Faced Saki Pithecia pithecia pithecia NWM EU124715 Yes  
Dusky Titi Callicebus moloch NWM EU124692 Yes  
Common Marmoset Callithrix jacchus NWM XM_002754905.2 No 
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Pygmy Marmoset Callithrix pygmaea NWM EU124714 Yes 
Bolivian Red Howler Alouatta sara NWM EU124713  Yes  
Southern White Rhinoceros  Ceratotherium simum simum OM XM_004418316.1 No 
Cat Felis catus OM XM_003992898.1  No 
Pacific Walrus Odobenus rosmarus divergens OM XM_004407583.1 No 
Giant Panda Ailuropoda melanoleuca OM XM_002926071.1 No 
Dog Canis lupus familiaris OM XM_542402.4 No 
Florida Manatee Trichechus manatus latirostris OM XM_004389072.1 No 
African Elephant Loxodonta Africana OM NW_003573536.1 No 
1 Mammals are classified as hominoids (HOM), old world monkeys (OWM), new world monkeys (NWM) or other mammals (OM).  
2 Sequences were independently verified in 12 
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generated a phylogenetic tree, representing ~100 million years of evolution (Fig 2.1a). 
Our primate phylogeny was consistent with previously published studies and only 
orthologous non-primate sequences were included in our analysis (Table 2.1) 12. Using 
this dataset, we employed the software program Selecton to evaluate TRIM22 evolution 
among mammals. Selecton uses several standard evolutionary models, including two 
nested paired models (M8a and M8; M7 and M8) and one non-nested paired model (M8a 
and MEC) 33,34. We compared the nested pairs using the likelihood ratio test and found 
that in both cases, the model that allowed sites to evolve under positive selection (M8) fit 
the data significantly better than the models that did not (M8a and M7) (Table 2.2). The 
non-nested MEC model differs from the nested model in that it accounts for differences 
in amino acid replacement rates. A position with radical amino acid replacements will 
obtain a higher Ka value than a position with more moderate replacements. Akaike 
Information Content (AICc) scores are compared between the MEC and the M8a models. 
The lower the AICc score, the better the fit of the model to the data, and hence the model 
is considered more justified 33. Comparison of the AICc scores of the MEC and M8a 
models were indicative of positive selection (M8a: 25211.8, MEC: 25079.2) and that the 
data was more congruent with the model that allowed for positive selection (MEC) than 
the one that did not (M8a) (Table 2.2).  
The Selecton analysis identified several codons with high probabilities of having evolved 
under positive selection (Fig 2.2). Eleven of the 28 codons predicted to be evolving under 
positive selection were located in the B30.2 domain (Fig 2.1b Table 2.3). Six of these 
eleven codons (K324, R327, T330, K332, S334, C337) clustered together in the one 
region, whereas the other five (S377, S395, G471, L488, V489) were more dispersed. 
The codon numbering uses the translation initiation codon as codon 1. Interestingly, 
many of the positively selected codons corresponded in location and spacing to 
previously identified positively selected codons in the TRIM5α protein (K324, P325, 
G330, R332, R335, Q337, F339, V340, K389, Q471, G483) (Fig 2.1c) 15. In TRIM5α, 
most positively selected codons are located in one of four variable regions (v1-v4) in the 
B30.2 domain. These variable regions are also found in a number of other TRIM 
proteins, including TRIM22 15,19. The v1 region of TRIM5α (or the ‘antiviral patch’
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Figure 2.1: Mapping positively selected sites in the TRIM22 protein. 
(a) Phylogenetic tree showing the evolutionary relationship among 29 mammalian 
species for the TRIM22 protein. Tree was created using COBALT and EvolView 
software. Numbers shown represent arbitrary distances from each branch point on the 
tree. Hominoids (HOM) are highlighted in red, old world monkeys (OWM) in purple, 
new world monkeys (NWM) in blue, and additional mammals in green. (b) Bayesian 
analysis of mammalian TRIM22 coding sequences. Ka/Ks values for each codon are 
plotted on y-axis. Ka/Ks ratio >1 indicates positive selection, Ka/Ks ratio <1 indicates 
purifying selection, and Ka/Ks ratio of 1 indicates neutral selection. Asterisks show 
approximate location of codons under strong positive selection. TRIM22 domains are 
shown above the graph, along with the approximate location of functional motifs 
(C15/18: two cysteine residues required for E3 ligase activity; C97, H100: zinc finger 
motif in the BB2 domain; predicted CC region; NLS). The ‘antiviral patch’ refers to 
several residues previously shown to be a major specificity determinant for TRIM5α-
mediated anti-HIV activity. (c) Comparative model showing the putative B30.2 3D 
structures for both TRIM5α and TRIM22. The blue and red colored regions represent 
structurally conserved regions (blue) or regions with no correspondence in structural 
proximities (red) after structural alignment. The QH value is a metric for structural 
homology (an adaptation of the Q value that measures structural conservation). Q=1 
implies that two structures are identical. When Q has a low score (0.1-0.3), structures are 
not aligned well (i.e. only a small fraction of the Cα atoms superimpose). Colored balls 
correspond to residues (van der Waals radii) predicted to evolve under strong positive 
selection (colored yellow for TRIM5α and green for TRIM22). (d) Molecular model of 
TRIM22’s B30.2 domain. The colored regions in the image on the left show the four 
variable regions (v1: red, v2: blue, v3: magenta, and v4: green). The image on the right 
shows only the variable regions (v1-v4) plus the location of sites predicted to evolve 
under strong positive selection (yellow). Molecular models were created with Visual 
Molecular Dynamics (VMD) software (v1.9.1) support. VMD is developed with NIH 
support by the Theoretical and Computational Biophysics group at the Beckman Institute, 
University of Illinois at Urbana-Champaign. 
  
68 
Figure 2.1 
 
Figure 2.1: Mapping positively selected sites in the TRIM22 protein. 
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Table 2.2 
Table 2.2: Models of evolution applied to TRIM22 coding sequences. 
 
Nested Log-likelihood 2(Ln1-Ln0) Degrees of Freedom Χ2 
M8a, M8 -12601.9, -12599.1 5.6 1 <0.001 
M7, M8 -12608.1, -12599.1 18 2 <0.001 
Non-nested  Log-likelihood AICc Score∆ 1 Parameters 
M8a, MEC -12601.9, -12534.6 25211.8, 25079.2 4, 5 
1
 AICc Score∆ = -2*logL+2p*(N/N-p-1), where L is the likelihood of the model given the data, p is the 
number of free parameters, and N is the sequence length. The lower the AICC score, the better the fit of the 
model to the data, and hence the model is considered more justified.  
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Figure 2.2: Selecton analysis of mammalian TRIM22 coding sequences. 
Selecton results for 29 mammalian TRIM22 coding sequences using the MEC model. 
Positively selected sites are colored orange or yellow (Ka/Ks > 1), whereas sites 
undergoing purifying selection are colored shades of purple (Ka/Ks <1). Sites colored 
white have a Ka/Ks ratio = 1.  
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Figure 2.2 
 
 
Figure 2.2: Selecton analysis of mammalian TRIM22 coding sequences. 
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Table 2.3 
Table 2.3: Positive selection in TRIM22 protein domains. 
 
Domain (AA 1) Percent PS 2 Ka/Ks 3 Positively selected codons 
RING (1-59) 1.00 1.86 D2, F3, S4, S50, S54 
SP1 (60-96) 0.60 1.97 T61, N76, V96 
BB2 (97-129) 0.40 2.30 Q105, I106 
CC (130-233) 0.60 1.83 A171, V192, T220 
SP2 (234-296) 0.80 1.90 L241, R242, K257, R279 
B30.2 (297-498) 2.21 1.90 K324, R327, T330, K332, S334, 
C337, S377, S395, G471, L488, V489 
1 AA: Amino acids included in each domain 
2 Percent PS: Percent of positively selected sites in each domain compared to the total number of sites 
3 Ka/Ks: Number of non-synonymous substitutions per non-synonymous site (Ka) to the number  
of synonymous substitutions per synonymous site (Ks) 
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region) was previously shown to be a major determinant for species-specific HIV-1 
restriction in primates 18. Mutations in other variable regions (v2-v4) of TRIM5α have 
also been shown to alter HIV-1, SIV, and N-MLV restriction 40–44. Remarkably, all of the 
positively selected codons in TRIM22’s B30.2 domain (except G471) were located in one 
of its v1-v4 regions. Six positively selected codons were found in the v1 region, two in 
the v2 region, and two in the v4 region. Unlike TRIM5α, there were no positively 
selected codons in TRIM22’s v3 region (Fig 2.1d).  
Outside of the B30.2 domain, we also found evidence for positively selected codons in 
each of TRIM22’s other domains (Table 2.3). Many of these codons clustered together 
around putative functional motifs in the TRIM22 protein. For example, three positively 
selected codons (V96, Q105, I106) surrounded a zinc finger motif in the BB2 domain 
(Fig 2.1b, Table 2.3). Zinc finger motifs are critical for proper domain folding and often 
contribute to protein-protein interactions 45. We also identified four positively selected 
codons (L241, R242, K257, R279) that flanked the nuclear localization signal (NLS) in 
TRIM22’s SP2 domain (Fig 2.1b, Table 2.3). Along with amino acids 491-494 in the 
B30.2 domain, TRIM22’s NLS was previously shown to be required for its nuclear 
localization 46,47. Notably, we also identified two positively selected codons (L488, V489) 
in the B30.2 domain that are located directly upstream of amino acids 491-494 (Fig 2.1b 
Table 2.3).  
 
2.3.2 Genetic Variation in the Human TRIM22 Gene 
Since TRIM22 is an integral component of the host antiviral response, and since it has 
been linked to a number of diseases, we also had an interest in its evolutionary pattern 
among humans. To examine genetic variation in the human TRIM22 gene, we compiled a 
list of known nsSNPs in the TRIM22 coding region using the National Center for 
Biotechnology Information (NCBI) dbSNP database. To date, 64 nsSNPs and 2 indels 
have been identified in the exons of human TRIM22, most of which are found in its 
B30.2 domain. The majority of these nsSNPs result in missense variations; however, 
several generate truncated versions of the TRIM22 protein (nonsense and frameshift 
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variations). To identify nsSNPs that may play important roles in the activity of human 
TRIM22, we used a program called Sorting Intolerant From Tolerant (SIFT) to predict 
their functional effects 48. SIFT analysis predicted that 23 nsSNPs were deleterious to 
TRIM22 function and 33 nsSNPs were tolerated. Paradoxically, two of the potentially 
deleterious nsSNPs (rs192306924:C>A, rs1063303:G>C) were located at amino acid 
sites evolving under strong positive selection in mammals (Table 2.2). Due to its high 
prevalence in the human population, we selected nsSNP rs1063303:G>C for further 
analysis and characterization.     
The guanine (G) to cytosine (C) nucleotide change in nsSNP rs1063303:G>C results in 
an arginine (R) to threonine (T) amino acid change at position 242 in the TRIM22 protein 
(Fig 2.3a). To determine its prevalence in the human population, we obtained frequency 
data from four different ethnic populations using the 1000 Genomes database 35. 
Interestingly, we observed large differences in the frequency of nsSNP rs1063303:G>C 
among various ethnic groups. For example, 31% of European (EUR) individuals were 
homozygous for the nsSNP (C/C) genotype; however, only 3% of Asian (ASN) 
individuals were homozygous for C/C. African (AFN) and American (AMR) populations 
had intermediate nsSNP frequencies, with 15% and 19% of individuals who were 
homozygous for the C/C genotype, respectively (Fig 2.3b). An alignment of amino acid 
site 242 in mammals revealed that the ancestral allele (G) was highly conserved in 
hominoids (HOM) and Old World monkeys (OWM), but variable in New World 
monkeys (NWM) and other mammals (Fig 2.3c). The reason for these frequency 
differences among humans for nsSNP rs1063303:G>C is unknown.  
Tests for Selective Neutrality 
A recent genome-wide scan of two ethnic populations identified TRIM22 as one of 60 
‘extreme’ genes undergoing balancing selection in humans 49. To distinguish between a 
neutrally evolving site under mutation-drift equilibrium and a site evolving under non-
neutral processes such as balancing selection, we performed both the Tajima’s D and 
Fu’s FS tests for neutrality on the TRIM22 rs1063303 variant. These two tests are based 
on the principle that a recent population expansion associated with a non-neutral process  
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Figure 2.3: Genetic variation at amino acid site 242 in the TRIM22 protein.  
(a) Schematic showing the approximate location of nsSNP rs1063303:G>C in the human 
TRIM22 protein. Inset shows the nucleotide (red) and amino acid changes for nsSNP 
rs1063303:G>C. C15/18: two cysteine residues required for E3 ligase activity; C97, 
H100: zinc finger motif in the BB2 domain; predicted CC region; NLS. The ‘antiviral 
patch’ refers to several residues previously shown to be a major specificity determinant 
for TRIM5α-mediated anti-HIV activity 18. (b) Genotype frequency data for nsSNP 
rs1063303:G>C in African (AFR) (n= 246), American (AMR) (n= 181), Asian (ASN) 
(n= 286), and European (EUR) (n= 379) 1000 Genomes populations 35. For each 
population, the percentage of wild type homozygotes (GG), heterozygotes (GC), and 
nsSNP homozygotes (CC) are colored green, red, or blue, respectively. (c) Sequence 
alignment of nsSNP rs1063303:G>C in HOM and OWM (left) as well as NWM and 
additional mammals (right). Amino acid changes at site 242 (location of nsSNP 
rs1063303:G>C in human TRIM22) are denoted by an asterisk and highlighted in bold.  
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Figure 2.3 
 
Figure 2.3: Genetic variation at amino acid site 242 in the TRIM22 protein. 
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will detect a shift in the allele frequency spectrum compared to a neutral Wright-Fisher 
model. As shown in Table 2.4, Tajima’s D values were positive for all populations, 
indicating an excess of intermediate frequency nucleotide site variants compared to the 
expectation under a neutral model of evolution. These deviations from neutrality were 
significant (P <0.05) for the AFR, AMR and EUR populations, but not for the ASN 
population. Similarly, the results of Fu’s FS test also showed largely positive values for 
AFR, AMR and EUR populations, indicating an excess of intermediate haplotypes over 
that expected under neutrality. None of the FS coefficients were considered significant at 
the 5% level (P <0.02); however, the FS coefficients for AFR, AMR and EUR 
populations approached significance.  
 
2.3.3 Functional Analysis of the rs1063303:G>C Polymorphism 
To investigate whether nsSNP rs1063303:G>C was deleterious to TRIM22 function, we 
transfected human cells with an empty vector control plasmid (pEV), a plasmid encoding 
flag-tagged wild type TRIM22 (pWT-T22), or a plasmid encoding flag-tagged TRIM22 
with the R242T variation (pSNP-T22). Total RNA was isolated 24 hours post-
transfection, reverse-transcribed into cDNA and subjected to quantitative polymerase 
chain reaction (qPCR). Surprisingly, cells transfected with pSNP-T22 exhibited an 
average 40-fold increase in TRIM22 mRNA compared to cells transfected with pWT-T22 
(p= 0.0001, unpaired Student’s t test) (Fig 2.4a). Whole cell lysates from similarly 
transfected cells were subjected to Western blot analysis using anti-flag to analyze 
TRIM22 levels. Densitometric analysis of Western blots after normalization to β-actin 
levels and transfection efficiency revealed that TRIM22 protein levels were 10.3 fold 
higher in cells transfected with pSNP-T22 compared to cells transfected with pWT-T22 
(Fig 2.4b). We also examined the effect of nsSNP rs1063303:G>C on the sub-cellular 
localization of TRIM22 using confocal microscopy. Consistent with previous reports, 
WT-T22 protein localized predominantly in the nucleus and formed punctate bodies 
25,50,51
 (Fig 2.4c). In contrast, SNP-T22 protein localized diffusely in both the cytoplasm 
and the nucleus.  
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Table 2.4 
Table 2.4: Results of Tajima’s D and Fu’s FS neutrality tests. 
 
Population Tajima’s D p-value Fu’s FS p-value 
African (AFR) 2.56 0.028 2.06 0.050 
Asian (ASN) 0.82 0.251 0.29 0.439 
American (AMR) 2.49 0.031 1.83 0.065 
European (EUR) 2.79 0.017 2.51 0.028 
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Figure 2.4: nsSNP rs1063303:G>C alters TRIM22 expression and antiviral activity.  
(a) Total RNA was harvested from HeLa cells transfected with empty vector control 
plasmid (pEV), plasmid expressing wild type TRIM22 (pWT-T22) (rs1063303:G), or 
TRIM22 plasmid containing nsSNP rs1063303:G>C (pSNP-T22). RNA was reverse 
transcribed into cDNA and quantified using qPCR. Data shown as the fold change 
relative to wild type TRIM22 mRNA levels after normalization to β-actin levels. P= 
0.0001 unpaired Student’s t test. (b) HeLa or HOS cells were transfected with equivalent 
amounts of one of the following plasmids: pEV, flag-tagged pWT-T22, or flag-tagged 
pSNP-T22. TRIM22 protein was detected via Western blotting using an anti-flag 
antibody. β-actin was used as a loading control. (c) Confocal immunofluorescence 
microscopy of HeLa cells transiently transfected with pEV, pWT-T22 or pSNP-T22. 
HeLa cells were fixed 24 hours post-transfection and TRIM22 localization was detected 
using an anti-flag antibody (green). Images shown represent optical slices taken through 
the center of cells from a series of z-stack images with a 63x Plan-Apochromat oil 
immersion objective lens (Numerical Aperture = 1.4). DAPI staining was used to 
visualize the nuclei (blue). Scale bars = 10 µm. (d) Lysates from HeLa cells co-
expressing the full-length replication-competent HIV-1 plasmid (pR9) and increasing 
concentrations of either pWT-T22 or pSNP-T22 were resolved by SDS-PAGE and 
subjected to Western blotting using anti-p24CA or anti-β-actin (β-actin was used as a 
loading control. Data shown are representative of at least three independent experiments.  
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Figure 2.4 
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Figure 2.4: nsSNP rs1063303:G>C alters TRIM22 expression and antiviral activity. 
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Previous studies have demonstrated that TRIM22 can inhibit HIV-1 particle production 
in human cells 20–23. To assess the impact of nsSNP rs1063303:G>C on TRIM22’s 
antiviral activity, human osteosarcoma (HOS) cells or HeLa cells were co-transfected 
with a plasmid encoding replication-competent proviral HIV-1 (pR9) and either pWT-
T22 or pSNP-T22. HIV-1 Gag is expressed as the Pr55Gag polyprotein, which includes 
the matrix (p17MA), capsid (p24CA) and nucleocapsid (p7NC) proteins. Pr55Gag is 
proteolytically cleaved into MA, CA and NC proteins during the assembly/budding 
process. Intracellular Gag protein levels were measured by quantitative Western blotting 
using anti-p24CA. Cells expressing increasing concentrations of WT-T22 exhibited 
decreasing levels of intracellular HIV-1 Gag protein expression. Cells expressing 
increasing concentrations of SNP-T22 did not exhibit a substantial reduction in 
intracellular Gag protein production (Fig 2.4d). Collectively, these data show that the 
rs1063303:G>C variant had an inverse functional impact where it increased TRIM22 
expression and decreased the antiviral activity of TRIM22. 
 
2.4 Discussion 
Recent studies on host restriction factors have used an evolutionary approach to identify 
amino acid residues that are required for their antiviral activity. These studies exploit the 
evolutionary ‘arms race’ that occurs between host restriction factors and viruses as they 
compete to gain an evolutionary advantage over each other. As a result of this 
evolutionary ‘battle’, many host restriction factors contain genetic signatures of positive 
selection, particularly at amino acid sites that interact with viral antagonists 13–15. Here, 
we used a similar evolutionary approach to analyze TRIM22 sequences spanning >100 
million years of evolution. In addition to the positively selected residues previously 
identified in the coiled-coil and B30.2 domains 12, we identified positively selected 
residues in several other domains of TRIM22. We also showed that the human TRIM22 
gene contains multiple nsSNPs with the potential to alter TRIM22 function and identified 
a highly prevalent nsSNP in TRIM22 that alters its expression and antiviral activity 
against HIV-1 replication.  
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Positively selected residues are often located near protein binding sites and tend to be 
solvent-exposed. In addition, these residues typically occur in clusters with other 
positively selected residues 52. Although the tertiary structure of TRIM22 has not yet 
been resolved, its primary amino acid sequence contains a number of putative protein 
binding motifs. For example, RING domains with E3 ligase activity bind E2 conjugating 
enzymes via their zinc finger motifs to mediate ubiquitin transfer to a substrate protein 45. 
TRIM22 contains a zinc finger motif in its RING domain that facilitates E3 ligase activity 
in combination with the E2 enzyme UbcH5b 9. TRIM22 also contains a second zinc 
finger motif in its BB2 domain, a bipartite nuclear localization signal in its Spacer 2 
domain, and a short sequence in its B30.2 domain that is required for its nuclear 
localization (amino acids 491-494) 46,47. Remarkably, 13 of the 28 positively selected 
residues that we identified in TRIM22 are located within 15 amino acids of one of these 
motifs (Figure 2.1c). Most are not located directly within the motifs, but instead cluster 
around them in groups of three or four. Although in TRIM22 none of these motifs have 
been explicitly shown to interact with other proteins, this type of evolutionary pattern 
suggests that they may indeed function as protein binding sites.  
We identified a number of positively selected residues in the B30.2 domain of TRIM22 
that correspond in location and spacing to positively selected residues in TRIM5α. In 
addition, similar to TRIM5α, we showed that the majority of these residues are located in 
one of four variable regions (v1-v4). In rhesus monkey TRIM5α, v1-v4 form flexible 
loops that map to the structurally divergent face of the protein 53. Multiple residues within 
TRIM5α v1-v4 regions are critical for virus restriction, including several positively 
selected sites. For example, residues 324 and 332 in the v1 region and residues 385 and 
389 in the v2 region are required for TRIM5α-mediated inhibition of HIV-1 and/or SIV 
in hominoids 18,41,42. Moreover, in the v3 region, residues 409 and 410 are required for N-
MLV restriction by human TRIM5α 43. Unlike TRIM5α, there are no residues evolving 
under positive selection in the v3 region of TRIM22. Thus, it is possible that this region 
of TRIM22 is not subject to strong evolutionary pressures (e.g. from viral antagonists). 
Consistent with this, TRIM22 does not inhibit N-MLV replication in human cells 23. 
Similar to TRIM5α, TRIM22 has been shown to interact with the HIV-1 Gag and/or 
capsid protein 23,54,55. Because the v1-v4 regions of rhesus monkey TRIM5α form an 
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extensive HIV-1 capsid binding interface, it is possible that these regions are also 
important for TRIM22 and HIV-1 Gag/capsid binding. It will be interesting to learn 
whether the v1, v2, and v4 regions of TRIM22 are targeted by an HIV-1 antagonist, 
thereby placing evolutionary pressure on TRIM22 to, for example, maintain its 
interaction with the HIV-1 Gag protein.  
Genes that evolve under positive selection during interspecies evolution also tend to be 
highly polymorphic in humans 56. We demonstrate here that the human TRIM22 gene 
contains multiple nsSNPs and that many of these nsSNPs are predicted to be deleterious 
to protein function. We characterized one potentially deleterious nsSNP 
(rs1063303:G>C) that is highly prevalent in the human population and show that it is 
located at an amino acid site in TRIM22 that has undergone strong positive selection in 
mammals. Of interest, the frequency of nsSNP rs1063303:G>C varies considerably 
among different ethnic populations. Ethnic differences in nsSNP frequencies have been 
reported for many genes, including several nsSNPs in toll-like receptor genes and a 
number nsSNPs associated with autoimmune disease 57,58. It is possible that the 
differences in nsSNP rs1063303:G>C frequency are due to differential prevalence of 
certain diseases in different geographic locations. For example, one nsSNP in the β-
globin gene is highly prevalent in regions that are endemic for malaria, but not in non-
endemic regions. This nsSNP produces an abnormal version of the β-globin protein 
called hemoglobin S (HbS), which causes sickle-cell disease in homozygotes (HbSS), but 
affords protection from malaria in heterozygotes (HbAS) 59. As such, the ‘deleterious’ 
HbS allele is maintained at higher than expected frequencies in certain populations. This 
type of evolution, whereby polymorphism is maintained in a population because it 
confers a selective advantage, is referred to as balancing selection 30.  
Several host restriction factors have been shown to undergo balancing selection in 
primates, including human TRIM5α and primate OAS1 60–62. Moreover, a recent genome-
wide scan of two ethnic populations identified TRIM22 as one of 60 ‘extreme’ genes 
undergoing balancing selection in humans 49. Given its high frequency in certain human 
populations and history of positive selection in mammals, it is possible that nsSNP 
rs1063303 confers some selective advantage in heterozygotes and is maintained by 
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balancing selection in these populations. For example, the nsSNP allele may be more 
advantageous against a virus other than HIV-1 that is particularly prevalent in certain 
geographic locations. The overall positive values resulting from the Tajima’s D and Fu’s 
FS tests suggest that there is an excess of intermediate frequency of the TRIM22 
rs1063303 alleles, which can imply a decrease in population size and/or balancing 
selection. Together, our analyses reveal a complex and multifaceted scenario for the 
evolution of nsSNP rs1063303 and the TRIM22 gene.   
Other retroviral restriction factors, such as APOBEC3G and TRIM5α, contain nsSNPs 
that alter their antiviral activity against HIV-1. For example, the H186R variant in 
APOBEC3G is strongly associated with CD4+ T-cell decline and accelerated disease 
progression in African Americans. Interestingly, this association is not present in 
Caucasian individuals or Europeans 63–65. A number of TRIM5α nsSNPs, including 
H43Y, R136Q, and G249D, also correlate with notable differences in HIV-1 acquisition 
and disease progression 66,67. We showed here that a TRIM22 clone containing the 
ancestral allele rs1063303:G potently inhibited particle production of full-length 
replication-competent HIV-1; whereas a TRIM22 clone containing the derived allele 
rs1063303:C drastically increased the amount of TRIM22 mRNA and protein in human 
cells, altered its sub-cellular localization, and failed to inhibit HIV-1 particle production. 
This finding contrasts a previous study by Ghezzi and colleagues 68 who showed that a 
TRIM22 clone containing the derived allele rs1063303:C inhibited expression of 
luciferase from a reporter construct containing luciferase under control from the HIV-1 
long terminal repeat (LTR) promoter. A likely reason for this difference could be 
attributed to differences between the two systems where we used full-length HIV-1 and 
they used only the HIV-1 LTR, implying that other HIV-1 proteins (e.g. antagonists) may 
affect the antiviral activity of TRIM22. In addition, Ghezzi and colleagues 68 showed that 
SNP rs1063303 alone was not associated with disease progression, however a TRIM22 
haplotype involving specific SNP alleles of rs1063303 and rs7935564 was found more 
frequently in advanced progressors than in long-term non-progressors. Together, these 
findings highlight the importance of function-altering TRIM22 SNPs and haplotypes, 
warranting further investigation into their clinical significance. 
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It remains unclear how TRIM22 rs1063303:G>C increases TRIM22 mRNA and protein 
levels. Non-synonymous SNPs in the gene coding region are typically expected to alter 
protein function, expression, conformation or stability. It is possible that the amino acid 
change associated with rs1063303 may affect TRIM22 protein stability or its ability to 
undergo self-ubiquitination and proteasomal degradation. TRIM22 has been shown to 
inhibit expression from the promoters of HIV-1 and hepatitis B virus 20,22,25. The different 
TRIM22 SNP rs1063303 variants may exhibit reduced or enhanced TRIM22 activity, 
thereby affecting gene expression from TRIM22 target promoters such as the HIV-1 LTR 
and/or the promoter controlling expression of TRIM22 itself. Other explanations for the 
observed difference in TRIM22 RNA and protein levels include, among others, structural 
changes in the RNA transcript that can in turn influence splicing, stability or translational 
regulation. Further studies are required to determine precisely how TRIM22 
rs1063303:G>C affects TRIM22 mRNA and protein levels.   
Interestingly, TRIM22 mRNA expression levels have previously been shown to influence 
HIV infection in vivo. In the Centre for the AIDS Programme of Research in South 
Africa (CAPRISA) study cohort, expression of TRIM22 mRNA was positively correlated 
with CD4+ T-cell count and negatively correlated with viral load 69. Conversely, a study 
in the Swiss HIV study cohort found that expression of TRIM22 mRNA was positively 
correlated with HIV-1 RNA levels at the viral set point 70. Given the differences in 
nsSNP rs1063303 frequency among different ethnic populations, it is interesting to note 
that the CAPRISA cohort is comprised entirely of black African females, whereas the 
Swiss cohort is comprised entirely of Caucasian individuals. It is tempting to speculate 
that the high prevalence of nsSNP rs1063303:G>C in Caucasians is at least partially 
responsible for the increased viral load in these individuals. Further studies that include 
populations from different geographic regions are needed to determine if and how nsSNP 
rs1063303 influences HIV-1 infection in these different groups and if other SNPs are 
involved.  
Previous studies on host restriction factors have shown that they are rapidly evolving 
genes that must remain genetically ‘flexible’ to adapt to changing pathogenic landscapes. 
Although their flexibility is integral to host survival, it can also be detrimental to protein 
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function. Our study characterizes the effects of nsSNP rs1063303:G>C on TRIM22 
protein function and provides insight into the ancient and extensive genetic variation 
within the TRIM22 gene.  
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Chapter 3 
 
3 In silico analysis of functional single nucleotide 
polymorphisms in the human TRIM22 gene 2 
TRIM22 is an evolutionarily ancient protein that plays an integral role in the host innate 
immune response to viruses. The antiviral TRIM22 protein has been shown to inhibit the 
replication of a number of viruses, including HIV-1, HBV and IAV. TRIM22 expression 
has also been associated with multiple sclerosis, cancer, and autoimmune disease. In this 
study, multiple in silico computational methods were used to identify nsSNPs that are 
deleterious to TRIM22 structure and/or function. A sequence homology-based approach 
was adopted for screening nsSNPs in TRIM22, including six different in silico prediction 
algorithms and evolutionary conservation data from the ConSurf web server. In total, 14 
high-risk deleterious nsSNPs were identified in TRIM22, most of which are located in a 
protein-protein interaction module called the B30.2 domain. Additionally, 9 of the top 
high-risk deleterious nsSNPs altered the putative structure of TRIM22’s B30.2 domain, 
particularly in the surface-exposed v2 and v3 regions. These same regions are critical for 
retroviral restriction by the closely-related TRIM5α protein. A number of putative 
structural and functional residues, including several sites that undergo post-translational 
modification (PTM), were also identified in TRIM22. This study is the first extensive in 
silico analysis of the highly polymorphic TRIM22 gene and will be a valuable resource 
for future targeted mechanistic and population-based studies.  
 
                                                 
2
 The material contained in this chapter was published in: Kelly, JN and Barr, SD. In silico analysis of 
functional single nucleotide polymorphisms in the human TRIM22 gene. PLoS One. 9 (7): e101436 (2014). 
Copyright 2014. Open-Access License  
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3.1 Introduction 
SNPs, defined as single base changes in a DNA sequence, are responsible for the 
majority of genetic variation in the human population. Although many SNPs are 
phenotypically neutral, nsSNPs often have deleterious effects on protein structure or 
function. nsSNPs are located in protein coding regions and generate an amino acid 
substitution in their corresponding protein product. As such, nsSNPs can alter the 
structure, stability, and/or function of proteins, and are often associated with human 
disease. Indeed, previous studies have shown that approximately 50% of the mutations 
involved in inherited genetic disorders are due to nsSNPs 1–3. Recently, a number of 
genetic studies have focused on nsSNPs in innate immune genes. These studies have 
identified multiple nsSNPs that influence susceptibility to infection, as well as the 
development of inflammatory disorders and autoimmune diseases 4–9. Nonetheless, 
because innate immune genes are often highly polymorphic, many nsSNPs in these genes 
remain uncharacterized.  
Members of the TRIM protein family are involved in a wide range of biological 
processes related to innate immunity 10–12. TRIM proteins are defined by their RBCC 
motif, which consists of a RING domain, one or two BB domains, and a predicted CC 
region. Most TRIM proteins also contain a protein-protein interaction module called a 
B30.2 domain at their C-terminus 13–15. Many TRIM proteins are induced by IFN 
signaling and several possess antiviral activity, in particular against the Retroviridae 
family of viruses. Recent studies have implicated TRIM proteins in the regulation of 
pathogen-recognition and important immune signaling pathways, a finding that has 
sparked considerable interest in understanding how TRIM family proteins contribute to 
the innate immune response 16–21.  
One well-studied member of the TRIM family, TRIM5α, is required for the species-
specific block against HIV-1 replication in primate cells 22–24. Recently, TRIM5α was 
also shown to promote innate immune signaling and to function as an innate immune 
sensor for the retrovirus capsid lattice in vitro. Previous studies have established that 
TRIM5α binds to the HIV-1 capsid protein in the mature viral core via four variable 
regions (v1-v4) in its B30.2 domain 25,26. The v1 or ‘antiviral patch’ region was 
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previously shown to be the major determinant for species-specific HIV-1 restriction by 
TRIM5α. Mutations in the other variable regions (v2-v4) have also been shown to 
interfere with TRIM5α-mediated restriction of HIV-1, SIV, and/or N-MLV 22,26–29. 
Notably, analogous variable regions are found in several other B30.2-containing TRIM 
proteins 30–32.  
Human TRIM5 is located on chromosome 11 within a cluster of four closely-related 
TRIM genes that also includes TRIM6, TRIM22, and TRIM34. TRIM5 and TRIM22 have 
an ancient and dynamic evolutionary relationship, whereby both genes have evolved 
under positive selection for millions of years in a mutually exclusive manner 33. Similar 
to TRIM5α, TRIM22 has also been shown to inhibit HIV-1 replication in a number of 
human cell lines and primary monocyte-derived macrophages 34–37. TRIM22 expression 
levels have also been shown to influence HIV-1 infection in vivo 38–40. Interestingly, 
nsSNPs in TRIM5α, including H43Y, R136Q, and G249D, significantly alter HIV-1 
acquisition and disease progression in humans 41–44. Despite TRIM22’s highly 
polymorphic nature, it is unknown how nsSNPs affect its biological and/or antiviral 
functions. Here, multiple in silico computational methods were used to identify nsSNPs 
in the TRIM22 gene that are predicted to be highly deleterious to TRIM22 structure 
and/or function. A total of 14 high-risk deleterious nsSNPs were identified, including 9 
that altered the putative structure of TRIM22’s B30.2 domain. A number of sites 
predicted to undergo PTM (ubiquitylation, sumoylation, phosphorylation) were also 
identified. This is the first extensive in silico analysis of the TRIM22 gene and will 
establish a strong foundation for future structure-function and population-based studies.  
 
3.2 Materials and methods 
3.2.1 Retrieval of nsSNP data 
Polymorphism data for the TRIM22 gene was retrieved from the following databases: 
UniProt (http://www.uniprot.org), NCBI dbSNP (https://www.ncbi.nlm.nih.gov/SNP/), 
1000 Genomes (http://www.1000genomes.org/), and the Ensembl genome browser 
(http://www.ensembl.org/index.html) 45–47.  
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3.2.2 In silico nsSNP analysis 
Functional effects of nsSNPs were predicted using the following in silico algorithms: 
Polymorphism Phenotyping v 2 (PolyPhen-2) (http://genetics.bwh.harvard.edu/pp2) 48, 
Sorting Intolerant From Tolerant (SIFT) (http://sift.jcvi.org/) 49, nsSNP Analyzer 
(http://snpanalyzer.uthsc.edu/) 50, Predictor of Human Deleterious Single Nucleotide 
Polymorphisms (PhD-SNP) (http://snps.biofold.org/phd-snp/phd-snp.html) 51, SNPs and 
Gene Ontology v 3 (SNPs&GO) (http://snps-and-go.biocomp.unibo.it/snps-and-go/) 52, 
and PMut (mmb2.pcb.ub.es:8080/PMut ) 53. nsSNPs predicted to be deleterious by at least 
4 in silico algorithms were categorized as high-risk nsSNPs and were selected for further 
analysis.  
3.2.3 Phylogenetic analysis  
Evolutionary conservation of amino acid residues in TRIM22 was determined using the 
ConSurf web server (consurf.tau.ac.il/) 54. In ConSurf, 14 TRIM22 homologues were 
aligned and position-specific conservation scores were calculated using an empirical 
Bayesian algorithm (Conservation Scores: 1-4 Variable, 5-6 Intermediate, and 7-9 
Conserved). Putative functional and structural residues were also predicted using 
ConSurf by combining evolutionary conservation scores with solvent accessibility 
predictions (Fig 3.1). Highly conserved amino acids that were located at high-risk nsSNP 
sites were selected for further analysis.   
3.2.4 Comparative molecular modeling  
3D-Jigsaw (v 2.0) was used to generate 3D structural models for the B30.2 domain of 
wild type TRIM22 (UniProtKB Q8IYM9) and the 9 high-risk nsSNPs. For each model, 
only the B30.2 domain sequence was submitted. 3D-Jigsaw searches multiple sequence 
databases (e.g. PFAM and PDB) and builds structures based on homologues of known 
structure 55. Models were viewed using the Swiss-PdbViewer (v 4.1) 56. Tm-Align was 
used to calculate Tm-scores and root mean square deviation (RMSD) 57. The total energy 
after minimization (TEM) was calculated via the L-BFGF method using the NOMAD-
Ref Gromacs server (http://lorentz.immstr.pasteur.fr/nomad-ref.php) 58. 
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3.2.5 Prediction of post-translational modification sites 
Putative ubiquitylation sites were predicted using the UbPred (www.ubpred.org) and 
BDM-PUB (bdmpub.biocuckoo.org) programs 2. For UbPred, lysine residues with a 
score of ≥ 0.62 were considered ubiquitylated. For BDM-PUB, the balanced cut-off 
option was selected. Putative sumoylation sites were predicted using the SUMOplot 
(http://www.abgent.com/sumoplot) and SUMOsp v 2.0 (http://sumosp.biocuckoo.org/) 
programs 59. For SUMOplot, only high probability motifs with a score > 0.5 were 
considered sumoylated. Medium level threshold with a 2.64 cut-off value was selected 
for SUMOsp 2.0 analysis. Putative phosphorylation sites were predicted using GPS 2.1 
(http://gps.biocuckoo.org/) and NetPhos 2.0 (http://www.cbs.dtu.dk/services/NetPhos/) 
60,61
. For GPS 2.1 analysis, high level threshold with cut-off values ranging from 0.776-
11 were selected. For NetPhos 2.0, serine, threonine, and tyrosine residues with a score of 
> 0.5 were considered phosphorylated. Sumo-interacting motifs (SIM) were identified 
manually and compared to experimentally verified SIMs in the scientific literature 62,63.  
3.2.6 Protein stability analysis 
I-Mutant version 2.0, an online support vector machine tool based on the ProTherm 
database, was used to evaluate nsSNP-induced changes in protein stability 64. nsSNP 
protein-coding sequences were submitted to I-Mutant 2.0 for 2 high-risk nsSNPs that 
coincide with putative PTM sites, 5 low-risk nsSNPs that coincide with putative PTM 
sites, and 12 additional high-risk nsSNPs that do not coincide with predicted PTM sites. 
I-Mutant 2.0 estimates the free energy change value (DDG) by calculating the unfolding 
Gibbs free energy value (∆G) for the wild type protein and subtracting it from that of the 
mutant protein (DDG or ∆∆G = ∆G mutant – ∆G wild type). It also predicts the sign 
(increase or decrease) of the free energy change value (DDG), along with a reliability 
index for the results (RI: 0-10, where 0 is the lowest reliability and 10 is the highest 
reliability). A DDG < 0 corresponds to a decrease in protein stability, whereas a DDG > 0 
corresponds to an increase in protein stability. However, according to the ternary 
classification system (SVM3), a large decrease in protein stability corresponds to a DDG 
< -0.5 and a large increase in protein stability corresponds to a DDG > 0.5. In contrast, 
DDG values that fall between -0.5 and 0.5 correspond to relatively neutral protein 
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stability 64,65. The pH was set to 7 and the temperature was set to 25°C for all 
submissions.   
 
3.3 Results and Discussion 
3.3.1 SNP dataset 
SNP data for the TRIM22 gene was retrieved from the NCBI dbSNP database, the 
Ensembl genome browser, and the UniProt database 45–47. According to these databases, 
the TRIM22 gene contains a total of 64 nsSNPs plus 8 SNPs in its 5’ UTR and 32 SNPs 
in its 3’ UTR. Of the 64 nsSNPs, 10 generate truncated versions of the TRIM22 protein 
(nonsense and frameshift mutations), whereas 54 introduce single amino acid changes 
(missense mutations) into TRIM22 (Table 3.1). To determine whether a given missense 
mutation affected TRIM22 function, we subjected the latter 54 nsSNPs to multiple in 
silico SNP prediction algorithms. The results, which are summarized in Table 3.2, 
identified a number of nsSNPs with a high probability of being deleterious to TRIM22 
structure and/or function.   
3.3.2 In silico nsSNP analysis 
Our analyses included the following six in silico SNP prediction algorithms: Polyphen-2, 
SIFT, nsSNP Analyzer, PhD-SNP, PMUT, and SNPs&GO 48–52,66. According to our 
Polyphen-2 results, 13 nsSNPs (23%) are damaging to TRIM22 function, whereas 33 
nsSNPs (59%) are benign. An additional 10 nsSNPs (18%) are predicted to be ‘possibly 
damaging’ by Polyphen-2 (Table 3.2). Our SIFT analysis predicted that 19 nsSNPs (34%) 
are deleterious to TRIM22 function and 37 nsSNPs (66%) are tolerated. On the contrary, 
the nsSNP Analyzer predicted that 21 nsSNPs (38%) cause disease and 35 nsSNPs (62%) 
are neutral (Table 3.2). Both PhD-SNP and PMUT predicted that 25 (45%) nsSNPs are 
pathological and 31 (55%) nsSNPs are neutral (Table 3.2). SNPs&GO analysis, which  
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Table 3.1 
Table 3.1 In silico prediction results for nsSNPs in TRIM22. 
 
nsSNP ID Mutation 1 Polyphen-2 SIFT nsSNP Analyzer PhD-SNP PMUT SNPs&Go # Del 2 
rs368531868 D2E Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs200816458 V7A Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs372487646 E10D Benign  Deleterious  Neutral Neutral Neutral Neutral  1 
rs375540431 I43M Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs11541920 V47E Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs192306924 T61N Benign  Deleterious  Neutral Neutral Neutral Neutral  1 
rs201847190 L68R Probably damaging  Deleterious  Disease Disease Neutral Disease  5 
rs182619286 R69Q Possibly damaging  Tolerated  Neutral Disease Pathological Neutral  2.5 
rs199625192 H73R Probably damaging  Deleterious  Disease Disease Pathological Neutral  5 
rs200668710 E83K Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs141180305 E90K Benign  Tolerated  Neutral Neutral Pathological Neutral  1 
rs370446835 D95A Possibly damaging  Tolerated  Neutral Neutral Pathological Neutral  1.5 
rs373103298 H99Y Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs371543745 L104F Probably damaging  Deleterious  Disease Neutral Neutral Neutral  3 
rs187628129 Q105K Benign  Tolerated  Neutral Neutral Pathological  Neutral  1 
rs368058642 E135K Possibly damaging  Tolerated  Disease Disease Pathological  Disease  4.5 
rs200924168 R150K Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs375795798 I152K Benign  Tolerated  Neutral Disease Pathological  Neutral  2 
rs7935564 D155N Benign  Deleterious  Disease Neutral Neutral Neutral  2 
rs201531661 K185Q Benign  Tolerated  Neutral Neutral  Pathological  Neutral  1 
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rs368924880 N196S Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs2291843 T232A Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs374292901 I234N Probably damaging  Deleterious  Disease Disease Pathological Neutral  5 
rs201523218 R239Q Benign  Tolerated  Neutral Disease Pathological Neutral  2 
rs1063303 R242T Benign  Tolerated  Disease Neutral  Pathological Neutral  2 
rs61735273 S244L Probably damaging  Deleterious  Disease Disease Neutral Disease  5 
rs370736499 I253T Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs143605305 V255I Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs112606816 L264M Possibly damaging  Tolerated  Neutral Neutral Neutral Neutral  0.5 
rs181298463 R279Q Benign  Tolerated  Neutral Neutral Pathological Neutral  1 
rs73404240 T294K Benign  Tolerated  Disease Neutral Pathological Neutral  2 
rs368682946 A315V Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs12364019 R321K Possibly damaging  Deleterious  Neutral Neutral Neutral Neutral  1.5 
rs372042006 R327C Benign  Tolerated  Neutral Disease Pathological Neutral  2 
rs75023388 R327H Benign  Tolerated  Neutral Neutral Pathological Neutral  1 
rs201494620 T330I Benign  Tolerated  Neutral Disease Neutral Neutral  1 
rs368220166 K332N Benign  Tolerated  Neutral Disease Neutral Neutral  1 
rs199987600 A341T Benign  Tolerated  Neutral Neutral Neutral Neutral  0 
rs371728648 G346S Probably damaging  Deleterious  Disease Disease Pathological Neutral  5 
rs200243523 V359I Possibly damaging  Tolerated  Disease Disease Neutral Disease  3.5 
rs191847788 K364N Possibly damaging  Deleterious  Disease Disease Neutral Disease  4.5 
rs375595000 P403T Probably damaging  Deleterious  Disease Disease Pathological Disease  6 
rs369734227 I410V Possibly damaging  Tolerated  Disease Neutral Neutral Neutral  1.5 
rs150095329 T415I Benign  Tolerated  Disease Neutral Neutral Neutral  1 
rs370495523 L432W Probably damaging  Deleterious  Disease Neutral Pathological Neutral  4 
rs200915295 F435C Benign  Deleterious  Neutral Disease Neutral Neutral  2 
rs187416296 R442C Probably damaging  Tolerated  Disease Disease Pathological Disease  5 
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rs370420711 A451V Possibly damaging  Deleterious  Neutral Disease Pathological Neutral  3.5 
rs377529439 F456I Probably damaging  Deleterious  Disease Disease Neutral Disease  5 
rs371028900 T460I Probably damaging  Deleterious  Disease Disease Pathological Disease  6 
rs371139090 G471E Benign  Tolerated  Neutral Disease Neutral Neutral  1 
rs138529937 C472S Probably damaging  Tolerated  Neutral Neutral Pathological Neutral  2 
rs368256788 R473H Benign  Tolerated  Neutral Disease Neutral Neutral  1 
rs267603016 P480S Probably damaging  Deleterious  Disease Disease Pathological Disease  6 
rs200638791 P484S Possibly damaging  Deleterious  Neutral Disease Pathological Disease  4.5 
rs61735327 M491I Benign  Tolerated  Disease Disease Pathological Neutral  3 
rs200148337 C494F Probably damaging  Deleterious  Disease Disease Pathological Disease  6 
1
 Mutation: Wild type residue/amino acid position/nsSNP residue. 
2
 # Del: Total number of deleterious predictions; A score of 0.5 was assigned to amino acids that were predicted to be ‘possibly damaging’ by Polyphen-2. 
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Table 3.2 
Table 3.2 Summary of in silico prediction results for all nsSNPs in TRIM22. 
 
Prediction Total number of nsSNPs (%) 1 
 Polyphen-2 SIFT nsSNP 
Analyzer 
PhD-SNP PMUT SNPs&GO 
Deleterious 13 (23) 19 (34) - - - - 
PD 2 10 (18) - - - - - 
Benign 33 (59) 37 (66) - - - - 
Disease - - 21 (38) 25 (45) 25 (45) 11 (20) 
Neutral - - 35 (62) 31 (55) 31 (55) 45 (80) 
1 Percentage of total nsSNPs (56) are shown in parentheses for each prediction program.  
2
 PD: nsSNPs predicted to be ‘possibly deleterious’ by Polyphen-2 
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includes information from the Gene Ontology annotation, predicted that 11 nsSNPs 
(20%) cause disease and 45 nsSNPs (80%) are neutral (Table 3.2). Interestingly, we 
found that the majority of potentially deleterious nsSNPs were located in the B30.2 
domain, including 3 nsSNPs that were predicted to be damaging by all six SNP 
prediction algorithms (P403T, T460I, and C494F). Because each algorithm uses different 
parameters to evaluate the nsSNPs, nsSNPs with more positive results are more likely to 
be truly deleterious. Here, we classified nsSNPs as high-risk if they were predicted to be 
deleterious by four or more SNP prediction algorithms. 14 nsSNPs met this criteria and 
were selected for further analysis (Table 3.3).   
3.3.3 Conservation Profile of High-Risk nsSNPs 
Amino acids that are involved in important biological processes, such as those located in 
enzymatic sites or required for protein-protein interactions, tend to be more conserved 
than other residues. As such, nsSNPs that are located at highly conserved amino acid 
positions tend to be more deleterious than nsSNPs that are located at non-conversed sites 
3,67
. To further investigate the potential effects of the 14 high-risk nsSNPs in Table 3.3, 
we calculated the degree of evolutionary conservation at all amino acid sites in the 
TRIM22 protein using the ConSurf web server. ConSurf employs an empirical Bayesian 
method to determine evolutionary conservation and identify putative structural and 
functional residues 54. For the purpose of this study, we focused on amino acid sites that 
coincide in location with the 14 high-risk nsSNPs; however, ConSurf also identified a 
number of other residues that may be functionally relevant (Fig 3.1).   
ConSurf analysis revealed that residues L68, H73, E135, I234, S244, G346, K364, P403, 
L432, R442, F456, T460, and C494 are highly conserved (Conservation Score of 7-9). In 
addition, ConSurf predicted that T460 was an important structural residue (highly 
conserved and buried) and that L68, K364, and P403 were important functional residues 
(highly conserved and exposed) (Table 3.4). To identify putative structural and functional 
sites, ConSurf combines evolutionary conservation data with solvent accessibility 
predictions. Highly conserved residues are predicted to be either structural or functional 
based on their location relative to the protein surface or protein core 68. Remarkably, two 
of the three high-risk nsSNPs that were predicted to be deleterious by all six SNP  
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Table 3.3 
Table 3.3: TRIM22 nsSNPs predicted to be functionally significant by four or more 
SNP prediction algorithms. 
 
nsSNP ID Mutation Domain MAF # Del 1 
rs201847190 L68R Spacer 1 N/A 5 
rs199625192 H73R Spacer 1 0.0005 5 
rs368058642 E135K Coiled-coil 0.0001 4.5 
rs374292901 I234N Spacer 2 0.0001 5 
rs61735273 S244L Spacer 2 0.0354 5 
rs371728648 G346S B30.2  0.0001 5 
rs191847788 K364N B30.2 0.0005 4.5 
rs375595000 P403T B30.2 0.0001 6 
rs370495523 L432W B30.2 0.0001 4 
rs187416296 R442C B30.2 0.0041 5 
rs377529439 F456I B30.2 0.0001 5 
rs371028900 T460I B30.2 0.0003 6 
rs200638791 P484S B30.2 0.0008 4.5 
rs200148337 C494F B30.2 N/A 6 
1 # Del: number of deleterious predictions. 
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Figure 3.1: ConSurf analysis of amino acid residues in the TRIM22 protein.  
Schematic showing ConSurf results for the human TRIM22 protein. Amino acids were 
ranked on a conservation scale of 1-9 and are highlighted as follows: blue residues (1-4) 
are variable, white residues (5) are average, and purple residues (6-9) are conserved. 
Residues predicted to be exposed to the surface of the protein are indicated via an orange 
letter ‘e’, while residues predicted to be buried are indicated via a green letter ‘b’. 
Putative structural residues are demarcated with a blue letter ‘s’ (highly conserved and 
buried), whereas putative functional residues are demarcated with a red letter ‘f’ (highly 
conserved and exposed).  
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Figure 3.1: ConSurf analysis of amino acid residues in the TRIM22 protein. 
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Table 3.4 
Table 3.4 Conservation profile of amino acids in TRIM22 that coincide with the 
location of high-risk nsSNPs. 
 
nsSNP ID Amino Acid CS 1 ConSurf prediction 
rs201847190 L68 8 Highly conserved and exposed (f 2) 
rs199625192 H73 7 Exposed 
rs368058642 E135 7 Exposed 
rs374292901 I234 7 Buried 
rs61735273 S244 8 Buried 
rs371728648 G346 8 Buried 
rs191847788 K364 9 Highly conserved and exposed (f 2) 
rs375595000 P403 8 Highly conserved and exposed (f 2) 
rs370495523 L432 8 Buried 
rs187416296 R442 7 Exposed 
rs377529439 F456 8 Buried 
rs371028900 T460 9 Highly conserved and buried (s 3) 
rs200638791 P484 6 Exposed 
rs200148337 C494 8 Buried 
1 CS: Conservation score (1-4= variable, 5-6= intermediate, 7-9= conserved). 
2 f: predicted functional residue 
3 s: predicted structural residue 
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prediction algorithms (P403T and T460I) were also identified as important structural or 
functional residues by ConSurf (Table 3.1, Table 3.3). Taken together, our data strongly 
suggest that the nsSNPs P403T and T460I are deleterious to TRIM22 structure and/or 
function.   
3.3.4 Comparative Modeling of High-Risk nsSNPs 
To examine whether P403T and T460I altered the 3D structure of TRIM22’s B30.2 
domain, we individually substituted each nsSNP into the wild type TRIM22 sequence 
and submitted the sequences to 3D-Jigsaw for structural analysis. We also submitted 
sequences for the remaining 7 high-risk nsSNPs in the B30.2 domain (i.e. G346S, 
K364N, L432W, R442C, F456I, P484S, and C494F) since our in silico and ConSurf 
results indicated that these nsSNPs were also highly likely to be deleterious. Theoretical 
structural models were generated for each nsSNP using the 3D-Jigsaw program, which 
constructs 3D models for proteins based on homologues of known structure 55. We then 
used Swiss-PdbViewer to compare each nsSNP model to the predicted 3D-Jigsaw model 
of wild type TRIM22 56. All of the nsSNPs altered the putative 3D structure of wild type 
TRIM22’s B30.2 domain. G346S, P403T, L432W, F456I, and C494F introduced an 
alpha helix into the v2 region, whereas the other 4 nsSNPs introduced beta strands into 
the v2 region (Fig 3.2). With the exception of P484S, which introduced an alpha helix 
into the v3 region, all of the nsSNP models contained elongated and/or additional beta 
strands in the v3 region. Only G346S and F456I altered the v1 region (both introduced an 
alpha helix); however, all 9 nsSNPs altered the length and/or number of beta strands in 
non-variable regions of the B30.2 domain. Notably, P484S was the only nsSNP model 
that contained fewer beta strands than wild type TRIM22 in certain regions (Fig 3.2). The 
majority of nsSNP models contained a greater number of beta strands than wild type 
TRIM22, resulting in overall net increase in beta strand formation. 
To extend our structural analysis, we used Tm-Align to calculate the Tm-score and root 
mean square deviation (RMSD) for each nsSNP model. Tm-score is used to assess 
topological similarity between wild type and mutant models, whereas RMSD is used to 
measure average distance between the α-carbon backbones of wild type and mutant  
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Figure 3.2: Structural models for wild type TRIM22 and high-risk nsSNPs in the 
B30.2 domain.  
Putative structural models for the B30.2 domains of wild type TRIM22 and the 9 high-
risk nsSNPs located in the B30.2 domain. Variable regions (v1-v4) are highlighted as 
follows: v1 blue, v2 orange, v3 magenta, and v4 green. Non-variable regions are shown 
in white and mutated amino acids are shown in yellow. Left image: Enlarged reference 
image that illustrates the color and location of each variable region and the color of 
mutated amino acids (image shown is the v1-v4 regions of wild type TRIM22 and the 
P403 amino acid). Each of the 9 nsSNP images (small images on the right) show the 
putative 3D structure of wild type TRIM22’s B30.2 domain on the left and the putative 
3D structure of TRIM22’s B30.2 domain with the mutated amino acid (nsSNP) on the 
right. The location of the amino acid in question is shown (yellow) on both wild type and 
nsSNP structures. All models were generated using the 3D-JigSaw protein comparative 
modeling server and SPDBV (v4.1).  
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Figure 3.2 
 
 
Figure 3.2: Structural models for wild type TRIM22 and high-risk nsSNPs in the B30.2 domain.
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models 57,69. A higher RMSD typically indicates greater deviation between wild type and 
mutant structures. The Tm-score and RMSD for each nsSNP model is listed in Table 3.4. 
The maximum RMSD was 3.04 (R442C), followed by 3.03 (F456I), 3.00 (L432W), 2.96 
(G346S), and 2.80 (P484S). RMSD for nsSNPs K364N, P403T, T460I, and C494F 
ranged from 1.58 to 1.99 Å. These results indicate that 9 high-risk nsSNPs markedly alter 
the putative structure of TRIM22’s B30.2 domain, in particular the surface-exposed v2 
and v3 regions, and that they likely induce severe structural changes in the TRIM22 
protein.  
Importantly, these nsSNPs may decrease flexibility in the v2 and v3 regions of TRIM22. 
The v2/v3 regions of wild type TRIM22 are predicted to form relaxed loop segments, 
similar to the loops in the recently solved 3D structure of rhesus monkey TRIM5α’s 
B30.2 domain 26. In contrast, the v2 and v3 regions of the nsSNP models contain more 
rigid secondary structures, such as alpha helices or beta strands (Fig 3.2). Since loop 
flexibility in rhesus monkey TRIM5α is thought to facilitate restriction of divergent 
retroviruses and to increase resistance to mutations in the HIV-1 capsid protein, it is 
possible that these nsSNPs may impair the antiviral activity and/or breadth of TRIM22. 
Further experiments, such as the resolution of wild type TRIM22’s tertiary structure, are 
required to address these possibilities.   
3.3.5 Prediction of Post-Translational Modification Sites in TRIM22    
To investigate how nsSNPs may influence the post-translational modification (PTM) of 
TRIM22, we used a variety of in silico prediction tools to identify putative PTM sites in 
the TRIM22 protein. PTMs are involved in many biological processes, including a 
number of canonical innate immune pathways, and are essential for the regulation of 
protein structure and function 59,70–72. To analyze residues in TRIM22 that may undergo 
ubiquitylation or sumoylation, we used the UbPred, BDM-PUB, SUMO-plot, and 
SUMOsp 2.0 programs. The GPS 2.1 and NetPhos 2.0 servers were used to predict 
serine, threonine, and tyrosine phosphorylation sites in the TRIM22 protein 2,60,61,73.  
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Table 3.5 
Table 3.5: RMSD (Å) and TM-score for the 9 high-risk nsSNPs in the B30.2 domain 
of TRIM22. 
 
nsSNP ID Mutation RMSD (Å) TM-Score 
rs371728648 G346S 2.96 0.75184 
rs191847788 K364N 1.72 0.93911 
rs375595000 P403T  1.99 0.85389 
rs370495523 L432W 3.00 0.70821 
rs187416296 R442C 3.04 0.68305 
rs377529439 F456I 3.03 0.73743 
rs371028900 T460I  1.76 0.94873 
rs200638791 P484S 2.80 0.75981 
rs200148337 C494F  1.58 0.95645 
RMSD and Tm-scores were calculated using Tm-Align. 
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UbPred predicted that 6 lysine residues in TRIM22 undergo ubiquitylation. In contrast, 
BDM-PUB predicted that 19 lysine residues undergo ubiquitylation. Both UbPred and 
BDM-PUB predicted that residues K63, K160, and K173 undergo ubiquitylation (Table 
3.5). According to ConSurf, these 3 lysine residues are highly conserved and exposed to 
the protein surface. ConSurf also predicted that K173 was a functional residue (Fig 3.1). 
SUMOplot predicted that 4 lysine residues in TRIM22 undergo sumoylation, whereas 
SUMOsp 2.0 predicted that 2 lysine residues undergo sumoylation. Both programs 
predicted that K153 undergoes sumoylation (Table 3.5). Similar to K173, ConSurf 
showed that K153 is highly conserved and exposed to the protein surface. ConSurf also 
predicted that K153 was a functional residue (Fig 3.1). 
In addition to putative sumoylation sites, we also identified 7 potential sumo-interacting 
motifs (SIM) (Fig 3.3a). SIMs are short hydrophobic motifs that interact non-covalently 
with other sumoylated proteins. The best characterized SIMs have the consensus 
sequence V/I/L-x-V/I/L-V/I/L or V/I/L-V/I/L-x-V/I/L 63. Notably, 5 of the putative SIMs 
are highly conserved in multiple TRIM22 orthologues and 3 are also present in the 
human and rhesus monkey TRIM5α proteins (Fig 3.3b). In addition, 2 TRIM5α SIMs 
(ILGV and VIGL) were previously shown to be required for TRIM5α-mediated antiviral 
activity. SIM mutations in the rhesus monkey TRIM5α protein abolished HIV-1 
restriction and disrupted TRIM5α trafficking to SUMO-1 nuclear bodies. Moreover, SIM 
mutations in the human TRIM5α protein abrogated N-MLV restriction by preventing 
TRIM5α binding to the sumoylated N-MLV capsid protein 62,74. More studies are needed 
to determine the role that SIMs play in TRIM22-mediated antiviral activity.   
To identify putative phosphorylation sites in TRIM22, we used GPS 2.1 and NetPhos 2.0 
servers. The GPS 2.1 server predicted that there were 31 serine-specific phosphorylation 
sites, 13 threonine-specific sites, and 11 tyrosine-specific sites in the TRIM22 protein. 
Conversely, NetPhos 2.0 predicted that there were 19 serine-specific phosphorylation 
sites, 4 threonine-specific sites, and 2 tyrosine-specific sites (Table 3.6). 16 serine 
residues, 3 threonine residues, and 2 tyrosine residues were predicted to be 
phosphorylated by both GPS 2.1 and NetPhos 2.0 servers. Many of these putative 
phosphorylation sites are highly conserved among multiple TRIM22 orthologues and  
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Table 3.6 
Table 3.6 Putative ubiquitylation and sumoylation sites in the TRIM22 protein. 
 
Ubiquitylation Sumoylation 
UbPred BDM-PUB SUMOplot SUMOsp 2.0 
93 (7e)* 6 (3e) 6 (3e) 85 (2e) 
160 (7e)* 44 (1e) 153 (9e)* 153 (9e)* 
173 (9e)* 85 (2e) 185 (4e)  
204 (6e) 93 (7e)* 265 (6e)  
257 (1e) 103 (6e)   
430 (6e) 109 (9e)   
 160 (7e)*   
 173 (9e)*   
 265 (6e)   
 266 (9e)   
 268 (2e)   
 272 (6e)   
 273 (9e)   
 275 (7e)   
 324 (1e)   
 332 (2e)#   
 374 (1e)   
 380 (3e)   
 382 (1e)   
Conservation scores are shown in parentheses following amino acid site; Putative functional residues are 
indicated with bold text, whereas putative structural residues are indicated with italicized text (ConSurf 
results Fig 3.1); Residues predicted to undergo ubiquitylation or sumoylation by both programs are 
indicated with an asterisk; Residues predicted to undergo ubiquitylation or sumoylation that also coincide 
with the location of nsSNPs are indicated with a hashtag.  
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Figure 3.3: Putative sumo-interacting motifs (SIM) in TRIM22.  
(a) List of putative SIMs in the TRIM22 protein, including the sequence and domain 
location for each SIM (amino acids are indicated in parentheses); Red and blue amino 
acids are predicted functional and structural residues, respectively (ConSurf analysis Fig 
3.1); Asterisk: SIMs that are conserved in all mammalian TRIM22 orthologues except 
elephant; Double asterisk: SIMs that are not found in TRIM5α, but are replaced by a 
different SIM (e.g. VLTL, IVPL). (b) Alignment of mammalian TRIM22, human 
TRIM5α, and rhesus monkey TRIM5α amino acid sequences (amino acids 350-444 of 
the B30.2 domain are shown). Conserved SIMs are highlighted in magenta and other 
SIMs are highlighted in light blue. Conserved amino acids are indicated with an asterisk. 
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Figure 3.3 
 
Figure 3.3: Putative sumo-interacting motifs (SIM) in TRIM22. 
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Table 3.7 
Table 3.7 Putative phosphorylation sites in the TRIM22 protein. 
 
GPS 2.1 NetPhos 2.0 
Serine Threonine Tyrosine Serine Threonine Tyrosine 
4 (1e) 23 (7e) 175 (1b) 46 (7e)* 130 (7b) 356 (8b)* 
27 (9e) 61 (1b)# 298 (1e) 50 (1e) 263 (3e)* 479 (5b)* 
46 (7e)* 170 (1e) 299 (6b) 54 (3e)* 325 (1e)*  
54 (3e)* 220 (1e) 355 (5b) 87 (4e)* 330 (1e)*#  
87 (4e)* 232 (1e)# 356 (8b)* 244 (8b)*#   
122 (9e) 263 (3e)* 394 (1b) 245 (8b)*   
231 (4e) 294 (7e)# 398 (7b) 259 (9e)*   
235 (9e) 311 (2b) 418 (8b) 261 (2e)*   
244 (8b)*# 325 (1e)* 467 (8b) 269 (1e)*   
245 (8b)* 330 (1e)*# 479 (5b)* 271 (8e)*   
259 (9e)* 433 (7b) 481 (8e) 276 (5e)*   
261 (2e)* 460 (9b)#  284 (5e)*   
269 (1e)* 492 (6e)  373 (8b)*   
271 (8e)*   383 (3e)*   
276 (5e)*   384 (9e)*   
284 (5e)*   399 (7b)   
309 (8e)   425 (6e)*   
312 (6e)   426 (4e)*   
317 (9b)   475 (8e)   
373 (8b)*      
376 (2e)*      
377 (1e)      
383 (3e)*      
384 (9e)*      
391 (3e)      
424 (7e)      
425 (6e)*      
426 (4e)*      
455 (9b)      
497 (9e)      
498 (7e)      
Conservation scores are shown in parentheses following amino acid site; Putative functional residues are 
indicated with bold text, whereas putative structural residues are indicated with italicized text (ConSurf 
results Fig 3.1); Residues predicted to undergo phosphorylation by both programs are indicated with an 
asterisk; Residues predicted to undergo phosphorylation that also coincide with the location of nsSNPs are 
indicated with a hashtag.  
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several were predicted to be important structural or functional residues by ConSurf 
(Table 3.6, Fig 3.1). Although TRIM22 phosphorylation has never been demonstrated 
experimentally, our results suggest that it may undergo phosphorylation at a number of 
sites. Of interest, other TRIM proteins have been shown to undergo phosphorylation, 
including the antiviral TRIM19 and TRIM21 proteins 75–79.  
Several putative PTMs coincide in location with nsSNPs in the TRIM22 gene (T61, T232, 
S244, T294, T330, K332, and T460). S244 and T460 are particularly interesting because 
both sites are highly conserved among TRIM22 orthologues and S244L and T460I were 
predicted to be deleterious by 5 and 6 in silico algorithms, respectively (Table 3.2, Table 
3.3). In addition, T460 was predicted to be a critical structural residue by ConSurf. 
Although the consequences of TRIM22 phosphorylation are currently unknown, the 
mutation of phosphorylation sites in other proteins has been shown to profoundly alter 
protein function by, for example, altering protein stability, localization, or protein-protein 
interactions. To this end, we used I-Mutant to predict whether S244L and T460I altered 
the stability of the TRIM22 protein. I-Mutant is a support vector machine-based tool that 
predicts changes in protein stability following single site mutations by estimating free 
energy changes as well as the direction of the change (increase or decrease) 64. Both 
S244L and T460I were predicted to be less stable than the wild type protein, with free 
energy change values of -0.83 and -1.38, respectively (Table 3.7). The I-Mutant results 
for the 12 high-risk nsSNPs that do not coincide with putative PTM sites, plus the results 
for the 5 low-risk nsSNPs that do coincide with putative PTM sites, are also shown in 
Table 3.7.   
It is possible that the phosphorylation of TRIM22 at sites S244 and/or T460 is required 
for some integral TRIM22 function and that the nsSNPs S244L and T460I impair this 
function; however, these nsSNPs may also impair protein stability, which would likely 
amplify any detrimental of PTM impairment. Many additional high-risk nsSNPs, plus 
several low-risk nsSNPs located at putative PTM sites, also decreased TRIM22 protein 
stability (Table 3.7). A number of studies have shown that decreased protein stability 
leads to increased protein misfolding, aggregation, and degradation. Accordingly, 
decreased stability typically results in decreased net function 80–83. Future in-depth studies 
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are required to investigate the effects of these nsSNPs on the structure and function of 
TRIM22’s B30.2 domain. Pertinent TRIM22 sites that are predicted to be highly 
deleterious and/or undergo PTMs are depicted in Figure 3.4. 
 
3.4 Conclusions 
Our results demonstrate that multiple nsSNPs in the antiviral TRIM22 gene may be 
deleterious to TRIM22 structure and/or function. Most of these high-risk nsSNPs are 
located at highly conserved amino acid sites in a protein-protein interaction module 
called the B30.2 domain. In this study, we show that 9 of the top high-risk nsSNPs 
disrupt the putative structure of TRIM22’s B30.2 domain, particularly the surface-
exposed v2 and v3 regions. In the closely-related TRIM5α protein, these same regions 
were previously shown to play a key role in retroviral restriction. In addition to these 
findings, we also identify several TRIM22 sites that may undergo post-translational 
modification, including sites that coincide with the location of high-risk nsSNPs. This 
study is the first systematic and extensive in silico analysis of functional SNPs in the 
TRIM22 gene.  
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Table 3.8 
Table 3.8: I-Mutant results for selected nsSNPs in the TRIM22 protein. 
 
nsSNP ID Mutation # Del. Pred. DDG Sign of DDG PTM ConSurf 
rs192306924 T61N 1 0.56 Decrease (1) Yes 1b 
rs201847190 L68R 5 -1.02 Decrease (7)* No 8e 
rs199625192 H73R 5 0.23 Decrease (3) No 7e 
rs368058642 E135K 4.5 -1.00 Decrease (9)* No 7e (9b) 
rs2291843 T232A 0 -0.53 Decrease (5) Yes 1e 
rs374292901 I234N 5 -0.80 Decrease (1) No 7b (9e) 
rs61735273 S244L 5 -0.83 Decrease (2) Yes 8b 
rs73404240 T294K 2 -0.63 Decrease (5) Yes 7e 
rs201494620 T330I 1 -2.14 Decrease (7)* Yes 1e 
rs368220166 K332N 1 -0.42 Decrease (2) Yes 2e 
rs371728648 G346S 5 -0.27 Decrease (7) No 8b 
rs191847788 K364N 4.5 -1.09 Decrease (4) No 9e 
rs375595000 P403T 6 -2.64 Decrease (8) No 8e 
rs370495523 L432W 4 0.08 Decrease (6) No 8b 
rs187416296 R442C 5 -1.23 Decrease (6)* No 7e 
rs377529439 F456I 5 -1.59 Decrease (8)* No 8b (9b) 
rs371028900 T460I 6 -1.38 Decrease (5)* Yes 9b 
rs200638791 P484S 4.5 -2.97 Decrease (9)* No 6e (9b) 
rs200148337 C494F 6 -0.21 Decrease (4) No 8b 
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Figure 3.4: Putative functional sites in the TRIM22 protein.  
Schematic depicting the approximate location of the top predicted PTM sites 
(ubiquitylation, sumoylation, and phosphorylation), the 14 high-risk nsSNPs in TRIM22, 
the 3 sumo-interacting motifs (SIMs), and the 2 high-risk nsSNP sites (S244L and T460I) 
predicted to undergo phosphorylation in the wild type TRIM22 protein. Several sites of 
known functional importance are marked on the TRIM22 protein (top image), including 
the C15/C18 residues (required for TRIM22 E3 ligase activity), the C97/H100 residues 
(part of the zinc-binding motif in BB2), and the nuclear localization signal (NLS) 84–86. 
The ‘antiviral patch’ region, which was previously shown to be integral for the antiviral 
activity of TRIM5α, is shown in the B30.2 domain, as well as the approximate location of 
each variable region (v1-v4, bright blue areas) 29,33. Amino acids 491-494 were 
previously shown to be required for the nuclear localization of TRIM22 87. RING, B-box 
2 (BB2), coiled-coil (CC), and B30.2 (PRY/SPRY) domains are listed. 
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Figure 3.4 
 
Figure 3.4 Putative functional sites in the TRIM22 protein.
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Chapter 4 
 
4 The TRIM22 nsSNP rs1063303:G>C is not evolving 
under balancing selection in the Inuit and is associated 
with low serum TG and high serum HDL levels in the 
Canadian Inuit 
TRIM22 is an IFN-induced antiviral protein that plays a key role in the host antiviral 
response and inhibits the replication of diverse viruses, such as HIV-1, HBV, and IAV. 
Altered TRIM22 expression has also been linked to cancer, autoimmune disease, and 
cellular proliferation/differentiation. We previously identified a nsSNP in the TRIM22 
gene (rs1063303:G>C) that had an inverse impact on TRIM22 function. The TRIM22 
rs1063303:C allele increased TRIM22 expression, but decreased its anti-HIV activity. 
Interestingly, we found that the frequency of rs1063303:G>C varied markedly among 
ethnic populations and that the AFR, AMR, and EUR cohorts from the 1000 Genomes 
project contained an excess of intermediate frequency TRIM22 rs1063303:G>C alleles. 
The latter is typically indicative of balancing selection, a non-neutral selective force that 
maintains polymorphism in a population. In this study, we determined the frequency of 
the TRIM22 nsSNP rs1063303:G>C in two different Inuit populations and one non-Inuit 
population and calculated the selective forces acting on this site. Interestingly, we found 
that the TRIM22 rs1063303:C allele is significantly more prevalent in Inuit compared to 
non-Inuit populations and that unlike AFR, AMR, and EUR cohorts, the Inuit do not 
contain an excess of intermediate frequency TRIM22 rs1063303:G>C alleles, indicating 
that TRIM22 rs1063303:G>C has not evolved under balancing selection in these Inuit 
populations. Surprisingly, we also found that TRIM22 rs1063303:G>C was associated 
with significantly lower serum triglycerides (TG) levels and significantly higher high-
density lipoprotein (HDL) levels in the Canadian Inuit population. TRIM22’s effect on 
TG and HDL is unprecedented in the TRIM protein family and may represent an exciting 
new research avenue for TRIM22 and other TRIM proteins.  
 
135 
 
4.1 Introduction 
Infection and inflammation induce the acute-phase response (APR), an early, complex 
host reaction to injurious stimuli, that leads to specific changes in lipid and lipoprotein 
metabolism 1. During the APR in humans and other primates, serum triglyceride (TG) 
levels are markedly increased, a phenomenon that is largely due to increased levels of 
circulating very-low-density lipoprotein (VLDL). Conversely, both serum low-density 
lipoprotein (LDL) and serum high-density lipoprotein (HDL) levels, along with serum 
total cholesterol levels, are decreased (Appendix A). These changes are mediated by a 
number of proinflammatory cytokines, including TNF, IL-1, IL-2, IL-6, and IFN 2–8. 
Accordingly, SNPs in these cytokines and the genes they induce have been associated 
with altered levels of serum lipoproteins, a modified APR to infection, and multiple 
inflammatory and metabolic disorders 9–15.  
Interestingly, in addition to their well-documented role in lipid transport, an increasing 
body of evidence suggests that lipoproteins participate in host defense as agents of the 
innate immune response. For example, lipoproteins bind to and neutralize a variety of 
DNA and RNA viruses, such as Vesicular stomatitis virus (VSV), Rubella virus, HIV, 
SIV, Herpes simplex virus, Vaccinia virus, Japanese encephalitis virus, Poliovirus, and 
Epstein-Barr virus 16–21. Moreover, during the IFN response to viral infection a soluble 
antiviral form of the LDL receptor is produced that inhibits the replication of VSV and 
rhinovirus 22–24. Multiple lipoproteins also bind to and neutralize the bacterial cell wall 
components lipopolysaccharide (LPS) and lipoteichoic acid (LTA) 25–29. Thus, the APR 
and its cytokine-induced lipoprotein changes are initially beneficial to the host because 
they help resolve infection and inflammation; however, they can also promote disease 
pathogenesis if they are prolonged (e.g. during chronic infection, metabolic syndrome, 
inflammatory disorders, diabetes, obesity, or heart failure) 11–13,30–38. 
TRIM family proteins have been implicated in a wide range of biological processes, 
including the innate immune response to viral infection. Multiple TRIM proteins are 
upregulated by type I and type II IFNs and recent studies have identified a number of 
TRIMs that can: 1) restrict viral replication directly by targeting specific viral proteins 
(e.g. TRIM5α inhibits HIV replication by targeting the HIV capsid protein), and/or 2) 
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restrict viral replication indirectly by augmenting innate immune signaling pathways (e.g. 
TRIM5α activates the TAK1 kinase complex, which induces downstream NF-κB and 
AP-1 signaling and the transcription of inflammatory cytokines) 39–44. TRIM proteins 
contain a conserved N-terminal RBCC motif, which consists of RING, BB, and CC 
domains, and a variable C-terminal domain 45. The RING domain typically confers E3 
ligase activity and this activity is often critical for TRIM protein function. Multiple 
TRIMs have been shown to function as E3 ubiquitin and/or E3 sumo ligases and can 
post-translationally modify specific host/viral proteins with ubiquitin and/or sumo 
moieties 46,47. Most TRIM proteins contain a C-terminal B30.2 domain, which is a 
flexible, highly plastic structure that typically functions as a protein-protein interaction 
module 48,49.  
The TRIM22 protein is a B30.2-containing member of the TRIM family that plays an 
integral role in the host antiviral response. TRIM22 is upregulated by type I and type II 
IFNs, several proinflammatory cytokines, and a number of different viral infections 50. 
Studies have shown that TRIM22 inhibits the replication of multiple viruses, including 
HIV-1, HBV, and IAV 51–54. TRIM22 has also been linked to cancer, autoimmune 
disease, and cellular proliferation/differentiation 55–63. We previously identified a 
common nsSNP in the TRIM22 gene (rs1063303:G>C) that had an inverse impact on 
TRIM22 function 64. rs1063303:G>C increased TRIM22 expression, but decreased its 
anti-HIV activity and altered its sub-cellular localization pattern. Interestingly, the 
frequency of rs1063303:G>C varied markedly among different ethnic groups (1000 
Genomes AFN, AMR, ASN, and EUR populations) and we found an excess of 
intermediate frequency rs1063303:G>C alleles in AFN, AMR, and EUR cohorts. An 
excess of intermediate frequency alleles is often indicative of balancing selection, an 
evolutionary process whereby polymorphism is maintained in a population because it 
confers some selective advantage 65.  
Although it is rare in other host genes, balancing selection has been described in many 
immune genes and may be beneficial when, for example, different alleles are effective 
against distinct pathogens 66. Selecting for multiple alleles at a single site (maintaining 
heterozygosity) may also make it more difficult for pathogens to evolve suitable escape 
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mutants against immune genes 67. Here, we genotyped TRIM22 nsSNP rs1063303:G>C 
in two distinct Inuit populations (Canadian and Greenlandic Inuit) as well as one non-
Inuit population (Canadian population of European descent). In contrast to some ethnic 
groups (including the AFR, AMR, and EUR cohorts mentioned above), the Inuit have 
been geographically isolated for many years. As such, they have likely evolved against 
unique selective pressures and distinct pathogenic landscapes 68,69. We determined the 
frequency of a functionally important TRIM22 nsSNP (rs1063303:G>C) in these Inuit 
populations and examined the selective forces acting on this site. Of interest, we found 
that rs1063303:G>C is significantly more prevalent in the Inuit compared to non-Inuit 
populations, and that unlike AFR, AMR, and EUR cohorts, there is not an excess of 
intermediate frequency rs1063303:G>C alleles in the two Inuit populations, suggesting 
that this site has not evolved under balancing selection in these groups. We also found an 
unexpected, but striking, association between the TRIM22 nsSNP rs1063303:G>C and 
serum levels of TG and HDL. The TRIM22 rs1063303:C allele was associated with 
significantly lower serum TG levels and significantly higher serum HDL levels in the 
Canadian Inuit population. The effect of TRIM22 on serum TG and HDL levels is 
unprecedented in the TRIM family.  
 
4.2 Materials and methods 
4.2.1 Study subjects 
Study subjects included Inuit individuals from Canada (Kivalliq region, Nunavut) and 
Greenland (Nuuk, Sisimiut, Qasigiannguit, and four villages in Uummannaq region), as 
well as Canadians of European descent (European Caucasian population). 42 subjects in 
the Canadian Inuit population self-reported as being of European background and were 
included in the analysis as a regional Caucasian control group 70. All study subjects had 
previously been participants in one of the following population studies: 1) the Keewatin 
Health Assessment Study 71; 2) the Greenland Population Study 72; and 3) the Study of 
Health Assessment and Risk in Ethnic Groups 73. The details of these studies have been 
described previously 71–73. Signed informed consent was obtained from all participants 
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and the studies were approved by the Universities of Manitoba and Toronto, and from 
Western University.  
4.2.2 Clinical characteristics and biochemical analyses 
Body weight, height, and plasma lipoprotein analyses [fasting plasma concentrations of 
total cholesterol (TChol), TG, HDL-cholesterol, LDL-cholesterol, and apolipoproteins 
(Apo) A-I and B] were determined as previously described 71–73.  
4.2.3 Genotype analyses 
Detection of nsSNP rs1063303:G>C was carried out using a custom designed TaqMan 
genotyping assay (Applied Biosystems, Foster City, CA). The nsSNP genotyping was 
performed using an allelic discrimination assay with the 7900HT Fast Real-time PCR 
system and read using automated software (SDS 2.3 Applied Biosystems, Foster City, 
CA). PCR reactions were run in 5 µL volumes using an amplification protocol of 95°C 
for 10 minutes, followed by 50 cycles of 95°C for 15 sec, then 60°C for 1.3 minutes. 
4.2.4 Neutrality tests 
Tajima’s D and Fu’s FS neutrality tests were performed to detect signals of selection at 
site rs1063303:G>C in the Canadian Inuit, Greenlandic Inuit, and European Caucasian 
populations. These tests differentiate between neutrally evolving sites under mutation-
drift equilibrium and sites evolving under non-neutral processes such as balancing 
selection. Negative Tajima’s D and/or Fu’s FS values are evidence of an excess of low 
frequency variants relative to expectation, whereas positive Tajima’s D and/or Fu’s FS 
values are indicative of an excess of intermediate frequency variants. A P value of less 
than 0.02 was considered significant for the FS statistic 74–76. Statistical significance was 
assessed by coalescent simulations using Arlequin software (v 3.5.1.3) with 10,000 
iterations 77. 
4.2.5 Statistical analyses 
Statistical analyses were performed using the SAS version 9.2 software (SAS Institute, 
Cary, NC). A χ2 test was used to examine deviation in genotype frequency from the 
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Hardy-Weinberg equilibrium. ANOVA was used to determine sources of variation for 
study subjects’ levels of TChol, TG, HDL-cholesterol, LDL-cholesterol, Apo-AI, and 
Apo-B. TRIM22 rs1063303:G>C was used as the independent class variable, while sex 
and body mass index (BMI) were entered as covariates. P values less than 0.05 were 
considered statistically significant.  
 
4.3 Results 
4.3.1 Baseline phenotypic characteristics of study subjects 
Baseline phenotypic characteristics for the Canadian Inuit, Greenlandic Inuit, and 
European Caucasian populations whose TRIM22 rs1063303:G>C genotype and serum 
lipoprotein levels were determined are summarized in Table 4.1, including the baseline 
levels of total cholesterol (TChol), TG, HDL-cholesterol, LDL-cholesterol, Apo-AI, and 
Apo-B. Mean age, body mass index (BMI), and percentage of female study subjects are 
also shown in Table 4.1.  
 
4.3.2 TRIM22 rs1063303:G>C genotype and allele frequencies 
TRIM22 rs1063303:G>C genotype and allele frequencies were calculated for the three 
populations (Canadian Inuit, Greenlandic Inuit, and European Caucasian) and are shown 
in Table 4.2. There were 21 G/G homozygotes (0.091), 62 heterozygotes (0.267), and 147 
C/C homozygotes (0.634) in the Canadian Inuit population. Similarly, there were 20 G/G 
homozygotes (0.078), 104 heterozygotes (0.408), and 131 C/C homozygotes (0.514) in 
the Greenlandic Inuit population. Thus, rs1063303:C was the major allele in both the 
Canadian and Greenlandic Inuit populations, which had allele frequencies of 0.84 and 
0.72, respectively. In contrast, the rs1063303:C allele was much less prevalent in the 
European Caucasian population as well as in a small subset of European Caucasian 
individuals within the Canadian Inuit (Table 4.2). Similar low rs1063303:C allele 
frequencies were reported previously for the European Caucasian population from the 
1000 Genomes project (EUR) 64. Moreover, rs1063303:C was even less prevalent in  
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Table 4.1 
Table 4.1 Baseline phenotypic characteristics (mean ± SD) of Canadian Inuit, 
Greenland Inuit, and European Caucasian populations. 
 
 Canadian Inuit Greenland Inuit European Caucasian  
Number 232 254 67 
Percent female (%) 50.4 62.9 59.7 
Age (years) 38.1 ± 14.8 48.6 ± 13.3 57.7 ± 18.1 
BMI (kg/m2) 26.9 ± 4.84 27.1 ± 5.18 27.6 ± 5.26 
Total cholesterol (mmol/L) 5.06 ± 1.01 6.35 ± 1.03 5.29 ± 0.86 
Triglycerides (mmol/L) 1.17 ± 0.77 1.14 ± 0.68 1.20 ± 0.40 
HDL cholesterol (mmol/L) 1.37 ± 0.39 1.67 ± 0.47 1.21 ± 0.33 
LDL cholesterol (mmol/L) 3.16 ± 0.92 4.15 ± 1.04 3.73 ± 0.79 
Apo-AI (g/L) N/A 1.81 ± 0.30 1.41 ± 0.25 
Apo-B (g/L) N/A 0.99 ± 0.24 1.07 ± 0.21 
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Table 4.2 
Table 4.2 Genotype frequencies for TRIM22 rs1063303:G>C in the Canadian Inuit, 
Greenlandic Inuit, and European Caucasian populations. 
 
Population n G/G G/C C/C 
Canadian Inuit 232 0.091 0.267 0.634 
     Inuit 188 0.053 0.208 0.734 
     Caucasian  44 0.273 0.523 0.205 
Greenland Inuit 255 0.078 0.408 0.514 
European Caucasian  67 0.397 0.397 0.206 
European (1000 Genomes*)  193 0.228 0.507 0.265 
African (1000 Genomes*) 133 0.329 0.541 0.130 
American (1000 Genomes*) 84 0.365 0.464 0.171 
Asian (1000 Genomes*) 66 0.745 0.231 0.024 
* 1000 Genomes populations: European (EUR) cohort includes British individuals from Scotland and 
England, Iberian individuals from Spain, Finnish individuals and Italian individuals; African (AFR) cohort 
includes Yoruba individuals from Nigeria, Luhya individuals from Kenya, and African Americans from the 
southwestern United States; American (AMR) cohort includes Colombian individuals, Puerto Rican 
individuals, and Mexican Americans from Los Angeles, United States; Asian (ASN) cohort includes 
Japanese individuals, Han Chinese individuals from Beijing, and Southern Han Chinese.  
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AFR, AMR, and ASN populations from the 1000 Genomes project 64. Genotype 
frequencies determined for the Canadian Inuit, Greenlandic Inuit, and European 
Caucasian populations did not show significant deviation from expectations based on 
Hardy-Weinberg equilibrium (P > 0.05). 
 
4.3.3 TRIM22 rs1063303:G>C is not evolving under balancing 
selection in the Canadian or Greenlandic Inuit 
Since the Inuit have lived in isolation for many years, we hypothesized that within the 
Inuit, TRIM22 rs1063303 may contain a unique evolutionary signature. We previously 
identified an excess of intermediate frequency rs1063303:C alleles in the AFR, AMR, 
and EUR, but not ASN, cohorts from the 1000 Genomes project. This excess differed 
significantly from what was expected under a neutral model of evolution (P < 0.05) 64. 
We performed the Tajima’s D and Fu’s FS neutrality tests to establish whether TRIM22 
rs1063303:G>C has evolved under neutral or non-neutral processes in the Inuit. As 
shown in Table 4.3, the Tajima’s D values for both the Canadian and Greenlandic Inuit 
populations did not differ significantly (P > 0.05) from what was expected under a 
neutral model of evolution, suggesting that rs1063303:G>C has not evolved under 
balancing selection in these populations. While the Tajima’s D value was higher in the 
European Caucasian population (1.61) compared to the Canadian and Greenlandic Inuit 
populations (1.20 and 1.29), it did not reach statistical significance. Within the Canadian 
Inuit, a smaller Tajima’s D value (0.60) was achieved when the small subset of European 
Caucasian individuals was removed from the population. Similarly, the results of Fu’s FS 
test also showed non-significant values for the Canadian Inuit, Greenlandic Inuit, and 
European Caucasian populations (Table 4.3).  
 
4.3.4 Association between TRIM22 rs1063303:G>C and plasma 
lipoproteins in the Canadian Inuit 
We previously demonstrated that the TRIM22 rs1063303:C allele is associated with a 
significant increase in TRIM22 expression levels and a significant reduction in antiviral  
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Table 4.3 
Table 4.3: Results of Tajima’s D and Fu’s Fs neutrality tests. 
 
Population Tajima’s D p-value Fu’s Fs p-value 
Canadian Inuit 1.20 0.179 1.83 0.126 
     Inuit 0.60 0.272 1.05 0.294 
     Caucasian  1.11 0.19 1.17 0.167 
Greenland Inuit 1.29 0.150 1.96 0.111 
European Caucasian  1.61 0.114 1.78 0.092 
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activity 64. Since TRIM22 has been implicated in a plethora of diverse biological roles, 
we hypothesized that a significant increase in TRIM22 expression due to the TRIM22 
rs1063303:C allele may contribute to other biological functions. We took advantage of 
the extensive clinical data associated with the Canadian and Greenlandic Inuit 
populations used in this study to determine if the TRIM22 rs1063303:C allele was 
associated with a particular clinical phenotype. ANOVA was used to determine sources 
of variation for various serum lipoproteins, including TChol, TG, HDL, LDL, Apo-AI, 
and Apo-B, in Canadian Inuit, Greenlandic Inuit, and European Caucasian populations. 
The ANOVA results for the three populations are summarized in Table 4.4. Significant 
associations were found in the Canadian Inuit population between the TRIM22 
rs1063303:C allele and serum levels of both TG (P < 0.0008) and HDL (P < 0.05). TG 
and HDL associations were not found in the Greenlandic Inuit or the European Caucasian 
populations. Sex was found to significantly associate with HDL in all populations (P < 
0.005), while BMI was significantly associated with most lipoproteins in all three 
populations. Sex was also significantly associated with Apo-AI (P < 0.05) and LDL (P < 
0.05) in the Greenlandic Inuit population (Table 4.4).  
TRIM22 rs1063303:G>C genotypes and their corresponding TG and HDL levels are 
shown in Table 4.5 for the Canadian Inuit population. A significant association between 
the presence of the rs1063303:C allele and decreased serum TG levels was detected, with 
C/C homozygotes having lower serum TG levels than heterozygotes and heterozygotes 
having lower serum TG levels than G/G homozygotes. This pattern suggests that the 
rs1063303:C allele shows incomplete dominance. A similar significant association was 
found between the rs1063303:C allele and elevated levels of plasma HDL (Table 4.5).  
 
4.4 Discussion 
Here, we showed that the TRIM22 nsSNP rs1063303:G>C is inordinately prevalent in 
two Inuit populations (Canadian and Greenlandic) and that the rs1063303:C allele is 
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Table 4.4 
Table 4.4: ANOVA results  
 
Table 4.4: Summary of ANOVA results showing determinants of serum lipoproteins in the Canadian Inuit, Greenlandic Inuit, 
and European Caucasian populations. 
 TChol TG HDL LDL Apo-A1 Apo-B 
Source of Variation df F P F P F P F P F P F P 
Canadian Inuit              
Sex 1 0.76 n.s. 0.51 n.s. 23.42 <0.0001 0.07 n.s. 1.19 n.s. 0.16 n.s. 
BMI 1 3.89 0.0454 26.48 <0.0001 8.34 0.0043 0.75 n.s. 19.29 <0.0001 6.78 0.0031 
TRIM22 rs1063303:C  2 2.21 n.s. 7.31 0.0008 3.49 0.0323 1.43 n.s. 0.67 n.s. 0.33 n.s. 
Greenlandic Inuit              
Sex 1 0.07 n.s. 0.04 n.s. 36.37 <0.0001 11.93 0.0006 4.96 0.0268 0.44 n.s. 
BMI 1 4.95 0.0271 51.94 <0.0001 2.97 n.s. 0.08 n.s. 10.42 0.0014 9.26 0.0026 
TRIM22 rs1063303:C  2 0.65 n.s. 0.07 n.s. 0.18 n.s. 0.69 n.s. 0.24 n.s. 0.13 n.s. 
European Caucasian               
Sex 1 0.47 n.s. 0.27 n.s. 8.76 0.0043 0.95 n.s. 0.17 n.s. 1.09 n.s. 
BMI 1 5.11 0.0112 71.42 <0.0001 6.54 0.0012 1.22 n.s. 10.21 0.0005 2.32 n.s. 
TRIM22 rs1063303:C  2 0.89 n.s. 0.54 n.s. 2.90 n.s. 1.79 n.s. 0.34 n.s. 0.71 n.s. 
P value indicates probability of a greater between-group F value using ANOVA; n.s. indicates not significant (i.e. P > 0.05)
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Table 4.5 
Table 4.5: Significant associations between the TRIM22 rs1063303:G>C genotype 
and plasma lipoproteins in the Canadian Inuit. 
 
Genotype TG (LSM ± SEM) (mmol/L) HDL (LSM ± SEM) (mmol/L) 
G/G 1.72 ± 0.09 1.18 ± 0.08 
G/C 1.15 ± 0.08 1.34 ± 0.05 
C/C 1.07 ± 0.06 1.41 ± 0.03 
* LSM:  least squares means, SEM: standard error of the mean 
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associated with significantly lower levels of serum TG and significantly higher levels of 
serum HDL in the Canadian Inuit. Unlike in several non-Inuit populations (i.e. AFR, 
AMR, and EUR cohorts from the 1000 Genomes project 64), the two Inuit populations 
(Canadian and Greenlandic Inuit) did not contain a significant excess of intermediate 
frequency TRIM22 rs1063303:G>C alleles when compared to a neutral evolutionary 
model. The latter, which is not indicative of balancing selection, suggests that this site 
(TRIM22 rs1063303:G>C) has evolved in response to distinct evolutionary pressures in 
the Canadian and Greenlandic Inuit.   
One possible explanation for this disparate evolutionary footprint in the Inuit is lack of 
exposure to certain pathogens. We previously showed that TRIM22 rs1063303:G>C is 
located at site in TRIM22 that has been subject to strong positive selection during the 
evolution of mammals. Moreover, certain human populations (AFR, AMR, and EUR) 
contained an excess of intermediate frequency TRIM22 rs1063303:G>C alleles, which 
indicates a decrease in population size and/or balancing selection 64. In innate immune 
genes, amino acid sites that are subject to positive and/or balancing selection are often 
functionally relevant, typically because they are located at the host-pathogen interface 
where they are exposed to diverse pathogenic pressures 66. Indeed, we demonstrated in 
our previous study that TRIM22 rs1063303:G>C increased the expression of TRIM22, 
but disrupted its ability to restrict HIV-1 replication 64. While the reason for this effect is 
currently unclear, these results combined with the fact that this site has evolved under 
multiple non-neutral evolutionary forces, strongly suggests that its evolution has been 
driven by HIV-1 and/or other pathogens. Canadian and Greenlandic Inuit populations, 
who have lived in isolation for many years with little exposure to ‘modern’ infectious 
diseases, may not have been subjected to the same pathogenic pressures at this site as 
other populations.  
Despite advances in other non-Inuit populations, relatively few innate immune nsSNPs 
have been documented in the Inuit. Notably, there is evidence that the Inuit (and other 
indigenous populations) suffer disproportionately from infectious diseases and have a 
much higher rate of infection when compared to their non-indigenous counterparts 68. 
While several socio-economic factors certainly contribute to this increased prevalence, 
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differences in their immune response may also play a role. Interestingly, the Inuit have 
been shown to possess a unique distribution of human leukocyte antigen (HLA) alleles 
when compared to non-Inuit populations 78–81. Because specific HLA alleles have been 
linked with susceptibility to a number of viral infections, it has been suggested that the 
Inuit’s unique distribution of HLA alleles may make them more vulnerable to certain 
infections 82–85. Since TRIM22 and other important antiviral genes, such as TRIM5α, 
APOBEC3G, BST-2/tetherin, and SAMHD1, are located at the host-pathogen interface 
where they often interact directly with viral pathogens, it is possible that the Inuit also 
contain a unique distribution of alleles in these genes and that this affects their antiviral 
response. It would be interesting to clone several of these antiviral genes from the Inuit 
population and test their antiviral activity against the spectrum of viruses known to be 
inhibited by these proteins. One could also compare various innate immune responses 
among the Inuit and other non-Inuit populations.  
Surprisingly, we found an association between TRIM22 rs1063303:G>C and the serum 
levels of specific lipoproteins. In the Canadian Inuit population, the rs1063303:C allele 
was associated with significantly lower serum TG levels and significantly higher serum 
HDL levels. These TG and HDL associations were not found in the Greenlandic Inuit or 
the European Caucasian populations. The effect of TRIM22 on serum lipoprotein levels 
is unprecedented in the TRIM protein family. The molecular details underlying this effect 
are currently unexplored and may be explained by a number of diverse factors given the 
wide ranging functions of TRIM22. It is possible, for example, that TRIM22 modulates 
serum lipoprotein levels indirectly by influencing innate immune and/or inflammatory 
signaling pathways. Recent studies have implicated multiple TRIM proteins in the 
regulation of key innate signaling pathways, particularly pathways that control NF-κB 
signaling, the IFN response, and cytokine production following PRR activation 40,42,44. 
PRRs, which include the membrane-bound TLRs and cytoplasmic receptors such as 
RLRs, are activated by diverse microbial products termed PAMPs. TRIM proteins have 
been shown to regulate NF-κB activation, either positively or negatively, by targeting 
various stages of the NF-κB signaling pathway. For example, TRIM19/PML sequesters 
NF-κB in PML nuclear bodies to prevent it from activating downstream transcription, 
whereas TRIM30α and TRIM27 repress NF-κB signaling by targeting TAB2/TAB3 or 
149 
 
IKK family members, respectively 86–88. TRIM23, which is essential for viral-induced 
NF-κB activation, enhances downstream antiviral signaling by modifying NEMO with 
ubiquitin 89. Although it remains unclear whether endogenous levels of TRIM22 can 
regulate NF-κB signaling, one recent study demonstrated that TRIM22 overexpression 
inhibited the TRAF6-stimulated NF-κB pathway by facilitating TAB2 degradation 69. 
However, TRIM22 overexpression has also been shown to activate NF-κB signaling 70.  
Since NF-κB activates the transcription of proinflammatory cytokines, and because the 
APR is induced by proinflammatory cytokines, TRIM22 expression may inadvertently 
alter the APR by regulating NF-κB signaling. In this scenario, nsSNP rs1063303:G>C 
would either: 1) disrupt TRIM22-mediated NF-κB activation, or 2) amplify TRIM22-
mediated NF-κB inhibition. Both possibilities would theoretically lead to a decrease in 
proinflammatory cytokine production and a less potent APR. Given the integral role 
played by TRIM proteins in the antiviral response, and the link between the immune 
system and the APR, other TRIM family members may have a similar effect on serum 
lipoproteins. Future studies are needed to address these possibilities and others and to 
determine the molecular details underlying TRIM22-mediated effects on serum TG and 
HDL levels.  
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Chapter 5 
5 Discussion 
 
5.1 Summary of results  
5.1.1 Ancient and recent adaptive evolution in the antiviral TRIM22 
gene: identification of a single nucleotide polymorphism that 
impacts TRIM22 function 
The evolution of TRIM22 in mammals was examined using 29 evolutionarily diverse 
mammalian TRIM22 sequences. These sequences were aligned using COBALT and a 
phylogenetic tree was generated using EvolView software. Site-specific evolutionary 
analysis of TRIM22 with the Selecton program identified multiple amino acid sites in 
TRIM22 that have evolved under strong positive selection. The majority of these sites 
were located in the PRY/SPRY (B30.2) domain; however, there was also evidence for 
positive selection in other TRIM22 domains. Many positively selected sites clustered 
around putative functional motifs in TRIM22, such as the zinc-finger motif in the BB2 
domain and the NLS in the SP2 domain. Moreover, a number of sites corresponded in 
location and spacing to sites that have evolved under positive selection in the closely-
related TRIM5α protein. For example, in both TRIM22 and TRIM5α, many positively 
selected sites are located in one of four variable regions (v1-v4) in the B30.2 domain.  
In addition to sites undergoing positive selection among mammals, nsSNPs in human 
TRIM22 were investigated. A total of 64 nsSNPs and 2 indels were obtained from the 
NCBI dbSNP database for the human TRIM22 gene, including 56 missense mutation-
inducing nsSNPs and 8 frameshift mutation-inducing nsSNPs. To identify nsSNPs in 
TRIM22 that may be functionally relevant, an in silico prediction program (SIFT) was 
used to analyze the 56 missense mutation-inducing nsSNPs. SIFT predicted that 23 of 
these nsSNPs were deleterious to TRIM22 function and 33 were tolerated. Notably, 2 
potentially deleterious nsSNPs were located at sites that evolved under strong positive 
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selection in mammals. One of these nsSNPs, rs1063303:G>C, was selected for further 
analysis because of its high prevalence in the human population.  
Large frequency differences were observed for nsSNP rs1063303:G>C among distinct 
ethnic populations, including AFR, AMR, ASN, and EUR 1000 Genomes cohorts. Of 
interest, an excess of intermediate frequency rs1063303 alleles was identified in AFR, 
AMR, and EUR populations, indicating a decrease in population size and/or balancing 
selection. To assess potential functional consequences of nsSNP rs1063303:G>C, its 
RNA and protein expression, sub-cellular localization pattern, and anti-HIV-1 activity 
were determined and compared to the wild type TRIM22 protein. Surprisingly, nsSNP 
rs1063303:G>C significantly increased both RNA and protein expression of TRIM22, 
but disrupted its anti-HIV-1 activity. nsSNP rs1063303:G>C also obstructed TRIM22 
sub-cellular localization (localized diffusely in both the cytoplasm and nucleus, not in 
punctate NBs). Taken together, these results describe multiple sites that have evolved 
under positive selection in TRIM22 and identify a highly prevalent functional nsSNP 
(rs1063303:G>C) with a complex evolutionary history.   
 
5.1.2 In silico analysis of functional single nucleotide 
polymorphisms in the human TRIM22 gene 
To identify additional nsSNPs that may alter TRIM22 function, and to examine amino 
acid sites in TRIM22 that may be subject to post-translational modification (PTM), an 
extensive in silico analysis was performed on the protein coding region of the TRIM22 
gene. All missense mutation-inducing nsSNPs (56) in TRIM22 were analyzed using 6 
different nsSNP prediction algorithms, including Polyphen-2, PhD-SNP, SIFT, nsSNP 
Analyzer, PMUT, and SNPs&GO. Since these algorithms use different parameters to 
evaluate and rank nsSNPs, multiple algorithms were used to increase the accuracy and 
power of prediction. A total of 14 nsSNPs were predicted to be deleterious to TRIM22 
function by ≥ 4 nsSNP prediction algorithms. These 14 nsSNPs (L68R, H73R, E135K, 
I234K, S244L, G346S, K364N, P403T, L432W, R442C, F456I, T460I, C494F) were 
classified as high-risk deleterious and selected for further in silico analysis.   
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Highly conserved amino acids tend to be required for important protein functions. As 
such, nsSNPs that are located at highly conserved sites are often deleterious to protein 
function 1. ConSurf analysis revealed that 13 of the 14 sites occupied by the high-risk 
nsSNPs were highly conserved (conservation score of 7-9). In addition, by combining 
evolutionary conservation data and solvent accessibility predictions, the ConSurf web 
server predicted that T460 was a key structural residue and that L68, K364, and P403 
were key functional residues. Structural analysis of the 9 high-risk deleterious nsSNPs 
located in the B30.2 domain, including K364N, P403T, and T460I, showed that all of 
these nsSNPs markedly altered the putative 3D structure of TRIM22’s B30.2 domain, 
particularly the surface-exposed v2 and v3 regions. These same regions are critical for 
HIV-1 restriction in the closely-related TRIM5α protein 2,3.  
A number of putative PTM sites were also identified in the TRIM22 protein, including 
multiple ubiquitylation (3), sumoylation (1), and phosphorylation (21) sites that were 
predicted to undergo PTM by two or more in silico programs. Moreover, 7 SIMs were 
identified in TRIM22, 2 of which are also present in TRIM5α (ILGV and VIGL) and 
were previously shown to be required for its antiviral activity 4,5. These 2 SIMs, plus 3 
additional SIMs (5/7), are highly conserved among TRIM22 orthologues. Of interest, 
several PTM sites coincide with the location of nsSNPs, including 2 high-risk nsSNPs 
(S244L and T460I, which are both predicted to undergo phosphorylation). This study 
comprises the first systematic in silico analysis of functional sites in the TRIM22 gene 
and will be a valuable resource for future studies.  
 
5.1.3 The TRIM22 nsSNP rs1063303:G>C is not evolving under 
balancing selection in the Inuit and is associated with low 
serum TG and high serum HDL levels in the Canadian Inuit 
To determine the frequency of TRIM22 nsSNP rs1063303:G>C in the Inuit and examine 
the selective forces acting on this site, we genotyped TRIM22 rs1063303:G>C in two 
different Inuit populations and one non-Inuit population (Canadian Inuit, Greenlandic 
Inuit, and Canadian population of European Caucasian descent). Interestingly, we found 
that the TRIM22 rs1063303:C allele is inordinately prevalent in both Inuit populations 
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and that unlike in the AFR, AMR, and EUR cohorts from the 1000 Genomes project, the 
Canadian and Greenlandic Inuit populations do not contain an excess of intermediate 
frequency TRIM22 rs1063303:G>C alleles. The latter indicates that in these two Inuit 
populations TRIM22 nsSNP rs1063303:G>C is not evolving under balancing selection. 
We also found an unexpected, but interesting association between the TRIM22 nsSNP 
rs1063303:G>C and serum lipoprotein levels. Specifically, the TRIM22 rs1063303:C 
allele was associated with significantly lower serum TG levels and significantly higher 
serum HDL levels in the Canadian Inuit population. The effect on TRIM22 on TG and 
HDL levels is unprecedented in the TRIM family and may represent an exiting new 
avenue of research for TRIM22 and other TRIM family members.  
 
5.2 Multiple sites in TRIM22 have evolved under positive 
and/or balancing selection  
5.2.1 Positive selection  
Genetic conflict between host and viral genomes often results in the accumulation of a 
large number of non-synonymous (dN) relative to synonymous (dS) mutations in host 
and/or viral genes. While the majority of host genes evolve under negative (purifying) 
selection, which removes deleterious nsSNPs from genes to preserve protein function, 
host restriction factors tend to evolve under positive (directional) selection (defined as 
dN/dS > 1) 6–8. This is largely due to the evolutionary ‘arms race’ that occurs between 
host restriction factors and viruses as they attempt to gain evolutionary superiority over 
each other. Host restriction factors, for example, are often targeted by viral antagonists 
and/or interact directly with viral proteins as part of their antiviral mechanism. For this 
reason, they tend to select for novel nsSNPs that allow them to evade viral antagonists 
and/or enhance their antiviral capacity (e.g. nsSNPs that increase viral protein binding 
affinity). However, since viruses mutate frequently and select for their own beneficial 
nsSNPs (e.g. nsSNPs that help circumvent the immune response and/or augment viral 
replication), both host restriction factors and viruses are under tremendous pressure to 
evolve new, more effective ways to counteract each other 9. As a result, multiple host 
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restriction factors contain genetic signatures of positive selection, particularly at amino 
acid sites that interact with viral antagonists. It follows that a number of recent studies 
have conducted evolutionary analyses on host restriction factors to pinpoint amino acid 
sites that are important for their antiviral activity 10–12.    
In this work, we used a similar approach to examine 29 evolutionarily diverse TRIM22 
sequences spanning >100 million years of evolution in mammals. While we identified 
codons evolving under positive selection in all TRIM22 protein domains, 11 of the 28 
codons were located in the B30.2 domain (Table 2.3). Moreover, 10 of these 11 codons 
were located within one of four variable loops (v1-v4) in the B30.2 (Fig 2.1d). v1-v4, 
which are also found in the closely-related TRIM5α protein, are required for TRIM5α-
mediated retroviral restriction 2,13. In the rhTRIM5α protein, v1-v4 form an extensive, 
highly flexible, HIV-1 capsid binding interface 3. The v1-v4 interface, which includes 
several positively selected codons in the v1 and v2 loops (324, 332, 385, and 389), are 
critical TRIM5α-mediated inhibition of HIV and/or SIV in hominoids 2,14–16. There are 
also two positively selected codons in the v3 loop of huTRIM5α (409 and 410) that are 
required for N-MLV restriction 17. We identified 6 positively selected codons (K324, 
R327, T330, K332, S334, and C337) in the v1 loop of TRIM22, 2 in the v2 loop (S377 
and S395), and 2 in the v4 loop (i.e. L488 and V489). Many of these codons mirrored 
both the location and spacing of positively selected codons in the TRIM5α protein (Fig 
2.1c). Similar to TRIM5α, TRIM22 has been shown to interact with the HIV-1 Gag or 
capsid protein; however, the binding site for capsid is unknown 18–20. It is possible that 
the v1-v4 loops also comprise an HIV-1 capsid binding interface in TRIM22 and that 
some of the positively selected codons in v1, v2, and/or v4 are important for TRIM22-
mediated HIV-1 restriction. Codons K324 and K332 are particularly interesting given 
their importance in TRIM5α-mediated retroviral restriction and because both sites have 
also evolved under positive selection in TRIM5α. Some of the codons evolving under 
positive selection in TRIM22’s v1-v4 loops may alternatively be required for TRIM22-
mediated inhibition of other viruses, such as HBV and/or IAV, or help form a binding 
site for interacting with viral proteins other than Gag. Previous studies have shown that 
TRIM22 interacts with the EMCV 3C protease and the IAV NP; however, the binding 
sites for these viral proteins are unknown 21,22. One interesting difference between the 
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TRIM22 and TRIM5α proteins is not there are no positively selected codons in the v3 
loop of TRIM22 (Fig 2.1d). In contrast, there are several positively selected codons in 
TRIM5α’s v3 loop, some of which are required for inhibition of N-MLV 17. Thus, it is 
possible that TRIM22, which does not inhibit N-MLV replication, does not contain any 
positively selected codons in its v3 loop because it has not been subject to evolutionary 
pressure from N-MLV 18. Future studies are needed to address these possibilities and to 
establish the functional implications of the positively selected sites found in TRIM22’s 
B30.2 domain.     
Outside of the B30.2 domain, we identified 5 positively selected codons in the RING 
domain (D2, F3, S4, S50, and S54), 3 in the SP1 domain (T61, N76, and V96), 2 in the 
BB2 domain (Q105, I106), 3 in the CC domain (A171, V192, and T220), and 4 in the 
SP2 domain (L241, R242, K257, R279) (Table 2.3). Of interest, many of these codons 
are located close to putative protein binding sites in the TRIM22 protein. For example, 
codons V96, Q105, and I106 cluster around the zinc finger motif in the BB2 domain. 
Codons L241, R242, K257, and R279 flank the bipartite NLS in the SP2 domain (Fig 
2.1b, Fig 2.2). Consistent with this, previous studies have shown that codons evolving 
under positive selection tend to be located near protein binding sites and are typically 
solvent-exposed 23. Although the zinc finger motif and bipartite NLS in TRIM22 have 
never explicitly been shown to function as protein binding sites, these motifs are often 
involved in protein-protein interactions in other proteins 24,25. Further, the presence of 
positively selected codons near these motifs suggests that they may indeed function as 
protein binding sites in TRIM22. Interestingly, our ConSurf results (Chapter 3) showed 
that 24 of the 28 positively selected codons are solvent-exposed (codons I106, V192, 
L241, and S395 are predicted to be buried) (Fig 3.1). 
Future studies should focus on determining the functional significance of the positively 
selected codons that we identified in TRIM22. For example, it will be important to test 
whether these codons are involved in TRIM22’s antiviral activity against HIV-1, HBV, 
IAV, and/or EMCV. In addition, examining whether specific codons affect TRIM22’s 
ability to interact with viral proteins, such as the HIV-1 Gag and/or capsid protein, the 
IAV NP, and the EMCV 3C protease, will be of great interest and may provide further 
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insight into TRIM22’s antiviral mechanism. Several codons within the B30.2 domain, 
such as K324 and K332, may be particularly relevant in this regard. Other codons may 
also be interesting to examine, including two codons (T61 and R242) that coincide in 
location with the TRIM22 nsSNPs rs192306924:C>A and rs1063303:G>C. Curiously, 
these nsSNPs were predicted to be deleterious by some of the prediction programs in 
Chapter 3; however, they are located at amino acid sites that have evolved under strong 
positive selection in mammals (Tables 2.3, 3.1). Due to its high prevalence in humans, 
we examined the TRIM22 nsSNP rs1063303:G>C in more detail in Chapters 2 and 4 
(discussed in sections below). Finally, some codons may be involved in protein-protein 
interactions. For example, codons V96, Q105, and I106 surround a zinc finger motif in 
the BB2 domain and are also located amongst 2 putative hydrophobic surface patches 
(also in the BB2). Zinc finger motifs are often involved in protein-protein interactions 
and the zinc finger motifs found in the BB2 domains of other TRIM proteins have been 
shown to facilitate homo- and/or heterodimerization 24,26–28. Notably, V96, Q105, and 
I106 are located amongst 2 putative hydrophobic surface patches in TRIM22. Similar 
patches were previously identified in the BB2 of TRIM5α and are required for proper 
TRIM5α self-association, capsid binding, and HIV-1 restriction 29. While TRIM22 has 
been shown to undergo trimerization, the residues responsible for self-association are 
unknown and it is unclear whether self-association is required for TRIM22 function or 
antiviral activity 30. For these reasons, it will be interesting to examine if V96, Q105, 
and/or I106 are involved in TRIM22 self-association and if self-association influences 
TRIM22 function and/or antiviral activity.  
 
5.2.2 Balancing selection 
In contrast to positive selection, which involves transient genetic diversity and drives 
advantageous alleles to fixation in a population, balancing selection actively maintains 
polymorphism (multiple alleles) at selected loci in a population 31,32. While it is rare in 
other host genes, balancing selection has been identified in a number of immune genes 
and may be beneficial in specific pathogenic environments 33. For example, one well-
known nsSNP in the β-globin gene induces sickle-cell disease in homozygotes (sickle-
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cell mutation), but affords protection from malaria in heterozygotes. Even though this 
mutation is deleterious in homozygous individuals, it is inordinately prevalent in high-
malaria environments because it lowers mortality in the overall population 34. In other 
words, balancing selection selects for heterozygosity in the population because in this 
environment it leads to fewer deaths. Heterozygosity may also be beneficial when, for 
example, different alleles are effective against different pathogens. In addition, having 
multiple alleles at specific loci in immune genes may make it harder for pathogens to 
evolve suitable escape mutants and evade immune surveillance 6. 
Several host restriction factors, including huTRIM5α and OAS1, have been shown to 
undergo balancing selection in primates 35–37. In Chapters 2 and 4, we found that there 
was an excess of intermediate frequency TRIM22 rs1063303:G>C alleles in the AFN, 
AMR, and EUR cohorts from the 1000 Genomes project, but not in the ASN cohort or 
two different Inuit populations (Tables 2.4, 4.3). An excess of intermediate frequency 
alleles is typically indicative of balancing selection. Interestingly, the frequency of the 
TRIM22 nsSNP rs1063303:G>C varied markedly among different ethnic groups. The 
Canadian and Greenlandic Inuit populations had the highest rs1063303:C frequencies, 
whereas the ASN population had the lowest (Fig 2.3, Table 4.2). While the reasons for 
these differences in frequency are currently unknown, it is possible that they are due to 
differential prevalence of specific diseases in distinct geographic locations. Indeed, we 
have shown in this work that the TRIM22 nsSNP rs1063303:G>C influences both the 
antiviral activity of TRIM22 and its novel effects on serum TG and HDL levels in the 
Canadian Inuit. Given the excess of intermediate frequency TRIM22 rs1063303:G>C 
alleles in AFR, AMR, and EUR cohorts, and its disease-related functional effects, it is 
possible that TRIM22 rs1063303:C confers some selective advantage in heterozygotes 
and that the nsSNP is being maintained by balancing selection in these populations. In 
contrast, the lack of balancing selection at the TRIM22 rs1063303:G>C site in the two 
Inuit populations (Canadian and Greenlandic Inuit), may be due to lack of exposure to 
certain pathogens. These populations have lived in isolation for many years with little 
exposure to modern infectious diseases 38. 
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In the future, it will be important to establish which pathogens (if any) are targeting the 
TRIM22 rs1063303:G>C site in AFN, AMR, and EUR populations and to investigate 
why these pathogenic pressures are not present in ASN and Inuit populations. This will 
likely provide insight into the antiviral mechanism of TRIM22 and help elucidate why 
the TRIM22 rs1063303:G>C site has been targeted by multiple evolutionary forces. Of 
interest, a recent genome-wide scan of two ethnic populations (African Americans and 
European Americans) identified TRIM22 as one of 60 ‘extreme’ genes evolving under 
balancing selection in humans 39. While we have identified one site in TRIM22 that is 
likely targeted by balancing selection, additional sites may also be targeted. As such, it 
would be interesting to perform a more thorough analysis of the entire TRIM22 gene 
(coding and non-coding regions) to search for additional sites that may be undergoing 
balancing selection.  
 
5.3 TRIM22 contains 14 high-risk deleterious nsSNPs and 
numerous putative PTM sites 
5.3.1 High-risk deleterious nsSNPs 
Studies have shown that genes that evolve under positive selection during interspecies 
evolution also tend to be highly polymorphic in humans 40. In Chapter 3, we found that 
the human TRIM22 gene is highly polymorphic and contains multiple nsSNPs that are 
likely deleterious to TRIM22 structure and/or function (Table 3.1). Using 6 different in 
silico prediction programs, we analyzed all of the missense mutation-inducing nsSNPs 
(56) in TRIM22 and identified 14 high-risk deleterious nsSNPs (L68R, H73R, E135K, 
I234K, S244L, G346S, K364N, P403T, L432W, R442C, F456I, T460I, C494F) (Table 
3.3). These nsSNPs were predicted to be deleterious by ≥ 4 of the prediction programs 
and were located at highly conserved amino acid sites (Fig 3.1). Conserved sites are often 
involved in important biological processes and thus, nsSNPs located at these sites are 
often deleterious 1,41.  
Of interest, our ConSurf analysis, which combines evolutionary conservation data with 
solvent accessibility predictions, identified codon T460 as a critical structural site and 
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codons L68, K364, and P403 as critical functional sites in the TRIM22 protein (Table 
4.3). These sites coincide in location with 4 high-risk deleterious nsSNPs (i.e. L68R, 
K364N, P403T, and T460I). While it is currently unknown why these sites are critical, 
one possibility is that they are involved in key protein-protein interactions. Sites K364 
and P403, for example, are located in the B30.2 domain just upstream of the v2 and v3 
loops, respectively. These loops are essential for the antiviral activity of the rhTRIM5α 
protein and help form an extensive HIV-1 capsid binding interface that is required for 
HIV-1 restriction 3,20. Since TRIM22 also interacts with the HIV-1 Gag and/or capsid 
protein, its v2 and v3 loops may help form a similar interface in the B30.2 domain for 
binding to capsid or other host and/or viral proteins 18. K364N and P403T may disrupt 
this interface and impair these interactions. Indeed, our molecular modeling results in 
Chapter 3 showed that K364N and P403T significantly altered the putative structure of 
the v1-v4 loops (Fig 3.2). Molecular modeling of the 7 additional high-risk deleterious 
nsSNPs located in the B30.2 domain also altered the putative structure of these loops, 
particularly within the v2 and v3 loops. Importantly, these 9 nsSNPs may decrease the 
flexibility of v2 and v3 (and/or v1 and v4 for some nsSNPs) by introducing more rigid 
secondary structures, such as alpha helices and/or beta strands, into these regions (Fig 
3.2). In rhTRIM5α, v1-v4 flexibility is thought to facilitate the restriction of divergent 
retroviruses and increase resistance to mutations in the HIV-1 capsid protein 3. nsSNPs 
that interfere with v1-v4 flexibility in TRIM22 may be equally important to restriction 
and may impair the antiviral activity and/or breath of TRIM22. Further studies, such as 
the resolution of TRIM22’s tertiary structure, will be critical for addressing these and 
other possibilities.   
In Chapter 3, we analyzed and prioritized all 56 missense mutation-inducing nsSNPs in 
TRIM22 and identified 14 high-risk deleterious nsSNPs that likely disrupt its structure 
and/or function. Future in-depth studies on these 14 nsSNPs are required to establish if 
they alter, for example, TRIM22 stability, localization, and/or antiviral activity. It will 
also be important to investigate the clinical implications (if any) of these nsSNPs. This 
will be essential for further prioritizing the 14 nsSNPs and elucidating their functional 
consequences.  
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5.3.2 Putative PTM sites 
Although TRIM22 is involved in a variety of important biological processes, very few 
studies have investigated the molecular determinants of its function. In Chapter 3, we 
performed an extensive in silico analysis of TRIM22 and identified numerous putative 
PTM sites (sites predicted to undergo ubiquitylation, sumoylation, or phosphorylation, 
and several SIMs) that likely influence its function. PTMs are involved in a number of 
biological processes, including many immune pathways, and are often essential for the 
regulation of protein structure and function 42–45. 
Previous studies have shown that TRIM22 can mediate both its own polyubiquitylation 
and monoubiquitylation. These modifications are dependent on its RING-mediated E3 
ligase activity; however, the specific sites within TRIM22 that undergo ubiquitylation 
have not been identified 21,46. One study demonstrated that a TRIM22 mutant lacking 
residues 201-498 (comprises approximately one-third of the CC domain and the entire 
B30.2 domain), but not a TRIM22 mutant lacking residues 1-200 (entire RING domain 
and BB2 domain plus approximately two-thirds of the CC domain), was susceptible to 
self-mediated TRIM22 polyubiquitylation 21. Our results in Chapter 3, which revealed 
that K93, K160, and K173 were the only TRIM22 lysine residues predicted to undergo 
ubiquitylation by both UbPred and BDM-PUB, are consistent with this finding (Table 
3.5). In addition, K173 was predicted to be an important functional residue by ConSurf 
(Fig 3.1). Further studies on K93, K160, and K173 are required to establish how they 
may influence TRIM22 turnover and/or function. 
Our work also identified a number of putative sumoylation sites in TRIM22, as well as 
several highly conserved SIM domains. K153 was the only lysine residue predicted to 
undergo sumoylation by both SUMOplot and SUMOsp 2.0 (Table 3.6). While TRIM22 
has been shown to function as a E3 sumo ligase for Mdm2, it has never been shown to 
undergo sumoylation itself 47. Notably, sumoylation is often associated with nuclear or 
sub-nuclear targeting. For example, TRIM19/PML contains 8 sumoylation sites plus 1 
SIM domain that are required for proper formation, maintenance, and function of sub-
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nuclear structures called PML nuclear bodies (NB). PML NBs recruit diverse proteins 
involved in many cellular processes, including transcriptional regulation, DNA damage 
repair, cell cycle control, apoptosis, and the host antiviral response. Thus, it is perhaps 
not surprising that these sumoylation and SIM sites are also required for TRIM19/PML 
stability and protein-protein interactions 48,49. Of interest, the number and size of PML 
NBs increases in response to IFN treatment and PML NBs contribute to innate defense 
against a number of viruses. It follows that following entry into host cells many viruses 
induce the modification and/or disassembly of PML NBs 50–52. 
Although TRIM22 does not co-localize with TRIM19/PML in PML NBs, it does form 
NBs and partially co-localizes with p80-coilin in Cajal bodies (CB) 53,54. Interestingly, 
several recent studies have implicated sumoylation in CB biogenesis and function. For 
example, survival motor neuron protein (SMN), one of the major components found in 
CBs, is targeted by sumoylation and contains a SIM-like domain that is integral to CB 
assembly and SMN’s interaction with p80-coilin 55. In addition, the sumo isopeptidase 
UPL1 co-localizes with p80-coilin in CBs and its depletion leads to striking p80-coilin 
mislocalization and defects in cell proliferation 56. Given these studies, and the critical 
role of sumoylation in PML NB assembly and function, it would be interesting to test 
whether K153 and the SIMs in TRIM22 are necessary for its co-localization with p80-
coilin in CBs. Indeed, previous studies have shown that the B30.2 domain of TRIM22, 
which contains 3 of the putative SIMs we identified in Chapter 3, is required for proper 
TRIM22 localization in NBs 53. Finally, because K153 is located in the CC domain of 
TRIM22, which is typically required for self-association, it is possible that SIMs in one 
TRIM22 monomer interact with sumoylated K153 in another TRIM22 monomer 57,58. 
This may help facilitate TRIM22 trimerization and/or its localization in CBs. It will be 
interesting to investigate these possibilities in future studies.   
Interestingly, 3 of the SIMs we identified in TRIM22 are also present in TRIM5α (Fig 
3.3). Previous studies have demonstrated that 2 of these 3 SIMs (i.e. ILGV and VIGL) 
are required TRIM5α-mediated antiviral activity. Mutating these SIMs in huTRIM5α 
abolished its ability to interact with the sumoylated N-MLV capsid protein. As a result, 
SIM mutation prevented N-MLV restriction 4. Similarly, SIM mutation in rhTRIM5α 
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abrogated its ability to inhibit HIV-1 replication 5. Although the role of these SIMs in 
TRIM22 is currently unknown, it is tempting to speculate that they are involved in its 
antiviral activities. Further studies are necessary to determine whether these 2 SIMs (or 
any of the other SIMs in TRIM22) are important for its antiviral activity against HIV-1 
and/or other viruses.  
Our in silico analyses in Chapter 3 also identified multiple phosphorylation sites in the 
TRIM22 protein (Table 3.6). A total of 21 sites were predicted to undergo serine (16), 
threonine (3), or tyrosine (2) phosphorylation by both GPS 2.1 and NetPhos 2.0. Many 
sites were also predicted to be important structural or functional residues by ConSurf 
(Table 3.6, Fig 3.1). TRIM22 phosphorylation has never been demonstrated; however, 
several other TRIM proteins have been shown to undergo phosphorylation, including 
TRIM19/PML and TRIM21 59–63. A few particularly interesting sites exist in TRIM22, 
such as S244, S259, S271, and T460. S259 and S271, both of which were identified as 
key functional sites by ConSurf, are located within the NLS in TRIM22’s SP2 domain 
(Table 3.6, Fig 3.1). Importantly, phosphorylation sites within or adjacent to NLSs are 
often found in key regulatory proteins (e.g. transcription factors) and typically regulate 
nuclear import, which directly affects gene expression 64,65. Sites S244 and T460 both 
coincide with the location of high-risk deleterious nsSNPs (S244L and T460I) (Tables 
3.2, 3.3). In the future, it will be important to determine whether S259 and/or S271 are 
required for the nuclear localization of TRIM22 and if the nsSNPs S244L and/or T460I 
disrupt functionally relevant phosphorylation sites.  
Collectively, this work comprises the first systematic in silico analysis of the TRIM22 
gene and will be a valuable resource for many future studies. Although we identified a 
number of putative PTM sites in TRIM22, these PTMs must be verified experimentally 
and it remains unknown how specific PTMs influence TRIM22 function. Future work 
using a panel of PTM mutants (clones of wild-type TRIM22 mutated at specific PTM 
sites) could be used to confirm our in silico results and to establish how (or if) verified 
PTMs affect TRIM22 stability, localization, and/or antiviral activity. Moreover, it may 
also be interesting to investigate if certain PTM sites in TRIM22 are required for the 
recruitment of specific E3 ligase target proteins. For example, sumo-targeted ubiquitin 
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ligases (STUb), a novel class of E3 ubiquitin ligases, only recognize sumoylated target 
proteins. STUbs that have been identified thus far are characterized by the presence of 
multiple SIMs (facilitate the recruitment of the sumoylated target protein) and a RING 
domain (mediates ubiquitylation of the sumoylated target protein) 66.  
 
5.4 The TRIM22 nsSNP rs1063303:G>C influences diverse 
TRIM22-mediated biological functions 
5.4.1 The TRIM22 nsSNP rs1063303:G>C increases TRIM22 
expression levels   
Several interesting functional consequences of the TRIM22 nsSNP rs1063303:C were 
identified in this work. In Chapter 2, we found that exogenous expression of TRIM22 
rs1063303:C significantly increased TRIM22 mRNA and protein levels in human cells 
(Fig 2.4a,b). nsSNPs often alter protein function, expression, conformation, or stability 
and there are multiple examples of this in the literature 67–71. Fewer studies have reported 
nsSNP-induced changes in mRNA expression; however, there are a number of notable 
examples 72–75. In these studies, the nsSNPs altered the secondary structure of the RNA 
transcript, which led to changes in mRNA expression. Changes in RNA structure have 
been shown to alter mRNA stability, splicing and/or the rate of translation 76,77. While 
TRIM22 rs1063303:C may alter the secondary structure of the RNA transcript, further 
studies are needed to determine whether this is the case. Since TRIM22 has previously 
been shown to inhibit gene expression from the HIV-1 and HBV promoters, it is also 
possible that TRIM22 targets the promoter controlling its own expression 78–80. In this 
scenario, the resultant TRIM22 rs1063303:C protein may exhibit reduced or enhanced 
activity, thereby increasing its own mRNA expression. It will be important to address 
these possibilities in future research.   
Given its effect on TRIM22 mRNA expression, it is likely that TRIM22 rs1063303:C 
increases TRIM22 protein expression by increasing TRIM22 mRNA levels. However, 
other possibilities for increased TRIM22 protein levels also exist. For example, since 
TRIM22 undergoes self-ubiquitylation and proteasomal degradation, it is possible that 
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TRIM22 rs1063303:C impairs TRIM22’s ability to regulate its own turnover 46. Other 
possible explanations include changes in TRIM22 protein stability and/or structure. Of 
interest, one recent study demonstrated that α-helices in the SP2 domain of rhTRIM5α 
govern cytoplasmic body formation and HIV-1 restriction. Specific residues in the SP2 
domain, including residues 240-242 (RLQ), were critical for the formation of these α-
helices 81. Notably, the study showed that rhTRIM5α forms antiparallel dimers that are 
stabilized by interactions between three α-helices (H1, H2, H3) found in the CC/SP2 
domains of each monomer. H1, which contains the CC domain and the N-terminus of 
SP2, makes contacts with H2 and together they form a hairpin structure that allows the 
monomer to double back along the dimer. Residues surrounding the hairpin structure, 
including residues 240-242, interact with each other and with other residues in the N-
terminus of H1' in the second monomer 81. Because TRIM22 and TRIM5α are closely-
related, it is tempting to speculate that TRIM22 also forms antiparallel dimers that are 
linked via the CC and SP2 domains. Since TRIM22 rs1063303:C induces a ‘R’ to ‘T’ 
amino acid change at site 242 in the TRIM22 protein, it is also possible that this nsSNP 
disrupts critical intra- and/or intermolecular interactions that are needed for antiparallel 
dimer formation. While the tertiary structure of TRIM22 has not been resolved, other 
TRIM proteins (e.g. TRIM25) have been shown to form antiparallel dimers and studies 
have noted that this structure may be a common feature among all TRIM proteins 82.  
 
5.3.2 The TRIM22 nsSNP rs1063303:G>C decreases TRIM22-
mediated antiviral activity against HIV-1 
In addition to its effects on mRNA and protein expression, TRIM22 rs1063303:C also 
altered the sub-cellular localization of TRIM22 and abrogated its anti-HIV-1 activity in 
human cells. Other host restriction factors, such as APOBEC3G and TRIM5α, contain 
nsSNPs that have been shown to decrease their ability to inhibit HIV-1. For example, 
several nsSNPs in TRIM5α, including H43Y, R136Q, and G249D are associated with 
marked changes in HIV-1 acquisition and disease progression in vivo 83,84. In addition, 
nsSNP H186R in APOBEC3G is strongly associated with reduced CD4+ T-cell counts 
and accelerated disease progression in African American individuals. Interestingly, this 
172 
 
effect is not present in European Caucasian individuals 85–87. In Chapter 2, we showed 
that a TRIM22 clone containing the ancestral allele rs1063303:G (wild-type TRIM22) 
potently inhibited HIV-1 replication, whereas a TRIM22 clone containing the derived 
allele rs1063303:C (nsSNP TRIM22) failed to restrict HIV-1 replication (Fig 2.4d). In 
contrast, a previous report by Ghezzi and colleagues 88 showed that a TRIM22 clone 
containing the derived allele rs1063303:C inhibited HIV-1 LTR-driven expression of a 
luciferase reporter gene. This discrepancy is likely due to differences between the two 
systems where we used full-length HIV-1 and they used a reporter construct controlled 
by the HIV-1 LTR. Of interest, these differences imply that other HIV-1 proteins (e.g. 
antagonists) may influence TRIM22’s antiviral activity. Ghezzi and colleagues 88 also 
found that TRIM22 rs1063303:C alone was not associated with disease progression in 
HIV-1 infected individuals; however, a TRIM22 haplotype including nsSNP alleles of 
rs1063303 and rs7935564 was found more often in advanced progressors compared to 
long-term non-progressors.  
It is interesting to note that two previous studies have shown that TRIM22 expression 
levels influence HIV-1 infection in vivo. One study examined the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA) study cohort and found that the 
expression of TRIM22 mRNA was positively correlated with CD4+ T-cell counts and 
negatively correlated with viral load 89. In contrast, the other study examined the Swiss 
HIV study cohort and found that TRIM22 mRNA expression was positively correlated 
with HIV-1 RNA levels at the viral set point 90. In Chapters 2 and 4, we found striking 
differences in TRIM22 rs1063303:G>C allele frequency among different ethnic groups 
(Fig 2.3b, Table 4.2). Along these lines, it is worth noting that the CAPRISA cohort is 
comprised entirely of African females, while the Swiss cohort is comprised entirely of 
Caucasian individuals. It is possible that the high prevalence of TRIM22 rs1063303:C 
found in Caucasian individuals is at least partially responsible for the increased HIV-1 
RNA levels in the Swiss cohort. More studies that include populations from different 
geographic regions are required to establish how TRIM22 rs1063303:C impacts HIV-1 
infection and if other nsSNPs are involved.  
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5.3.3 The TRIM22 nsSNP rs1063303:G>C is associated with low 
serum TG and high serum HDL levels in the Canadian Inuit 
In Chapter 4, we demonstrated that the TRIM22 rs1063303:C allele is associated with 
significantly lower serum TG levels and significantly higher serum HDL levels in the 
Canadian Inuit. Notably, these associations were not found in the Greenlandic Inuit or 
European Caucasian populations (Table 4.4). Our results showed that homozygotes for 
the TRIM22 rs1063303:C allele (Canadian Inuit population) had lower levels of serum 
TG and higher levels of serum HDL than heterozygotes, while the TRIM22 rs1063303:G 
allele homozygotes had higher serum TG levels and lower serum HDL levels (Table 4.5). 
It remains unclear how the TRIM22 nsSNP rs1063303:C alters serum lipoprotein levels; 
however, one possible explanation is that it alters them indirectly by regulating innate 
immune signaling pathways. Recent studies have identified many TRIM proteins that 
modulate key innate immune pathways, including NF-κB signaling, the IFN response, 
and cytokine production following PRR activation 91–93. Although TRIM22 has never 
been explicitly shown to regulate these pathways, there is some evidence that it affects 
NF-κB signaling. For example, one study showed that exogenous TRIM22 expression 
inhibited the TRAF6-stimulated NF-κB pathway by degrading TAB2 94. However, a 
serparte study showed that TRIM22 activated NF-κB signaling 70. Because activation of 
the NF-κB signaling pathway leads to proinflammatory cytokine production, and since 
proinflammatory cytokines induce the APR, it is possible that TRIM22 influences TG 
and HDL levels by modulating  NF-κB signaling. Future studies are needed to address 
these possibilities and others.  
 
5.5 Concluding remarks 
In this body of work, we have identified a number of pertinent sites in the TRIM22 
protein the likely contribute to its overall biological and/or antiviral functions. Further, 
we have shown that specific amino acid sites in TRIM22 have been subjected to strong 
positive and/or balancing selection. One particular site, which coincides in location with 
the TRIM22 nsSNP rs1063303:G>C, has evolved under positive selection during the 
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evolution of mammals and has a disparate evolutionary footprint among distinct ethnic 
populations. Moreover, TRIM22 nsSNP rs1063303:G>C increased TRIM22 expression 
levels, altered its subcellular localization, decreased its antiviral activity against HIV, and 
was associated with significantly lower serum TG levels and significantly higher serum 
HDL levels in the Canadian Inuit population. Collectively, this research has paved the 
way for multiple follow-up studies to further characterize highly relevant sites in the 
TRIM22 protein and help identify novel factors that may regulate TRIM22 expression, 
subcellular localization, and antiviral activity.  
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Appendix A 
 
A.1 Overview of serum lipoproteins 
A.1.1  Introduction to serum lipoproteins   
Serum lipoproteins are complex aggregates of lipids and proteins that are formed in the 
liver and intestine, secreted into the circulation, and then taken up by peripheral tissues 
for energy and storage 1. The formation of lipoproteins is necessary because it enables 
lipid transport in the aqueous plasma environment. There are 4 major groups of serum 
lipoproteins: 1) chylomicrons (CM), 2) very-low-density lipoproteins (VLDL), 3) low-
density lipoproteins (LDL), and 4) high-density lipoproteins (HDL). These groups each 
contain different ratios of specific lipid constituents, namely triacylglycerols (TG), free 
cholesterol, cholesterol esters, and phospholipids (Table A.1). The groups also contain 
several lipid-binding proteins called apolipoproteins that surround the lipids and create 
soluble lipoprotein particles (Fig A.1). All lipoproteins are involved in lipid transport; 
however, CM and VLDL function primarily to transport TG, whereas LDL and HDL 
function primarily to transport cholesterol 2.   
 
A.1.2  Triacylglycerol transport 
Serum TG levels are often measured clinically, in which case they are defined as all of 
the TGs present in one deciliter of plasma (mg/dL). This definition includes both CMs 
and VLDLs; however, because CMs are very short-lived (half-life of ~1 hour) most of 
the TGs transported in plasma are associated with VLDLs. CMs are synthesized in the 
small intestine after meals and function primarily to transport dietary (exogenous) TGs 
from the intestine to other tissues in the periphery 3. VLDLs, which are synthesized by 
the liver, transport endogenous TGs to peripheral tissues following their excretion into 
the bloodstream. VLDLs are carried into tissue capillaries via the bloodstream, where 
they encounter an enzyme called lipoprotein lipase (LpL). LpL hydrolyzes some of the  
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Table A.1 
Table A.1: Physical properties and lipid composition of serum lipoproteins 
 
 CM VLDL LDL HDL 
Density (g/ml) < 0.94 0.94-1.006 1.006-1.063 1.063-1.210 
Total lipids (wt. %) * 99 91 80 44 
Triacylglycerols  85 55 10 6 
Cholesterol esters 3 18 50 40 
Cholesterol  2 7 11 7 
Phospholipids  8 20 29 46 
* The remaining material is mainly composed of apolipoproteins  
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Figure A.1: General structure of serum lipoprotein. 
Schematic showing the general structure of serum lipoproteins (CM, VLDL, LDL, and 
HDL). Lipoproteins are spherical in shape with a hydrophobic core comprised of both 
triacylglycerols (TG) and cholesterol esters. This core is surrounded by a monolayer of 
phospholipids, free cholesterol, and apolipoproteins.  
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Figure A.1 
 
 
Figure A.1 General structure of serum lipoprotein. 
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TGs from VLDL into their core components (TGs consist of 1 glycerol molecule and 3 
fatty acid molecules) so that they can be taken up by adjacent cells. For example, they 
may be taken up by muscle cells for energy or fat cells for storage. VLDLs continue to 
lose TGs as they travel through the blood and decrease in size, eventually turning into 
intermediate density lipoproteins (IDL). Some IDLs are subjected to further lipolysis to 
become LDL particles; however, most are reabsorbed by the liver (Fig A.2) 4. 
 
A.1.3  Cholesterol transport 
As mentioned above, LDLs are formed from VLDLs as they lose TGs to surrounding 
tissues. As such, LDLs contain very few TGs compared to VLDLs, but have the same 
protein shell and amount of cholesterol (Table A.1). Cells internalize LDL particles via 
receptor-mediated endocytosis and hydrolyze LDL-bound cholesterol esters to release 
free cholesterol. Cholesterol can be used for a variety of cellular functions, such as in 
cellular membranes or for the synthesis of steroid hormones. Although LDL is integral 
for cholesterol transport and cholesterol is necessary for proper cellular functions, too 
much LDL can be harmful. Multiple studies have shown that higher levels of LDL are 
associated with an increased risk of cardiovascular disease 5,6.  
In contrast to LDLs, nascent HDL particles are formed in the liver and small intestine. 
HDLs interact with multiple apolipoproteins (Apo) to facilitate cholesterol efflux from 
cells; however, ApoA1 is particularly important in the initial stages of HDL assembly. 
ApoA1 forms the scaffold for HDL assembly and is also required for activation of the 
lecithin:cholesterol acyltransferase (LCAT) enzyme. LCAT, which is essential for the 
formation of cholesterol esters, allows HDL to extract free cholesterol from LDLs and 
IDLs. Cholesterol is also removed by HDL from cell surface membranes via a specific 
transporter molecule (ABCG1) and delivered back to the liver for excretion (Fig A.2). 
This process, whereby HDL extracts excess cellular cholesterol and transports it to the 
liver, is called reverse cholesterol transport 7.  A large number of epidemiological and 
clinical studies have demonstrated that low HDL levels are a major risk factor for the 
development of cardiovascular disease 8.  
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Figure A.2: Serum lipoprotein synthesis and transport.   
CMs are synthesized in the small intestine and enter the bloodstream to deliver dietary 
(exogenous) TGs to various peripheral tissues. VLDLs are synthesized in the liver and 
deliver endogenous TGs to the periphery. LpL hydrolyzes TGs from both VLDLs and 
CMs so they can be taken up by cells. IDLs are formed from VLDLs as they lose TGs. 
IDLs continue to lose TGs to peripheral tissues and are eventually either reabsorbed by 
the liver or turned into LDL particles. LDLs transport cholesterol to cells in peripheral 
tissues. In contrast, HDL, which is synthesized in the liver, removes excess cholesterol 
from cells in the periphery. This excess cholesterol is transported back to the liver to be 
excreted in a process called reverse cholesterol transport. The path for CM, VLDL, and 
IDL transport is outlined in red, LDL in blue, and HDL in green.   
 
 
188 
 
Figure A.2 
 
 
Figure A.2 Serum lipoprotein synthesis and transport.   
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A.2 Serum lipoproteins during the APR 
A.2.1 Overview of the APR  
The acute phase response (APR) is an early, complex host reaction that is generated by 
infection and inflammation. The APR in animals leads to significant changes in serum 
lipoprotein metabolism. For example, in primates, serum TG levels increase and serum 
HDL levels decrease during the APR 9. The increase in serum TGs is largely due to a 
concomitant increase in serum VLDL levels. Multiple proinflammatory cytokines (e.g. 
TNF, IL-1, IL-2, IL-6, and IFN) induce this increase in serum VLDL levels via one or 
more of the following metabolic changes: 1) increase in hepatic fatty acid synthesis, 2) 
decrease in hepatic fatty acid oxidation, 3) induction of adipose tissue lipolysis, and 4) 
decrease in hepatic VLDL clearance. Changes 1-3 increase the overall production and 
secretion of VLDL into the circulation by increasing the amount of fatty acid substrate 
available for TG re-esterification. Change 4, which often only occurs at higher doses of 
LPS, decreases TG catabolism by reducing the activity of the LpL enzyme.  
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